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Quantitative systems pharmacology (QSP) modelling, being an integral 
part of pharmacometrics, is attracting a great amount of attention in drug 
development and clinical therapy as QSP models are used to identify drug 
targets and biomarkers of response. The QSP model based approach was used 
to address the clinical challenges with azathioprine dosing in inflammatory 
bowel disease. The Overarching aim of the thesis was to understand unknown 
mechanism to toxicities associated with azathioprine metabolism using a QSP 
approach. However some unanticipated challenges resulted during 
development of the azathioprine QSP model which, ultimately, was found to not 
be able to describe the various clinical scenarios.  These challenges did, however, 
provide an opportunity to understand some issues that might arise during QSP 
model development and develop methods to solve them. 
A 30 state QSP model was developed for azathioprine metabolism based 
on known purine metabolic pathways supported by literature and expert 
opinion (Chapter 2). The model provided a good prediction of both extraceullar 
and intracellular metabolite formation after azathioprine dosing for the typical 
clinical scenario. The model was then used to test the existing hypotheses for 
abnormal enzyme activities for two atypical clinical scenarios. The results 
indicated that the model could not reflect the reference concentrations for either 
atypical scenario.  This raised the following questions: whether the hypothesised 
enzymes that were considered to be responsible for the atypical clinical scenarios 
were not responsible, whether the model was correct but the set of parameters 
for the whole system were incorrect or whether the structure was incorrect. 
The first two questions were addressed simultaneously by proposing a 
combined question, does a set of parameter values exist that could describe the 
typical and both atypical scenarios.  If a set existed then the model was described 
as being complete.  To address the model completeness issue in a QSP 
framework a global search algorithm was developed to optimise the model 





atypical scenarios (Chapter 3). No sets of parameter values were found that 
adequately described the reference data from both the typical and both atypical 
scenarios. The model was therefore deemed to be incomplete.  The conclusion 
from this evaluation was that the model structure was incorrect. 
Given the outcome from the search for model completeness, it was 
necessary to determine alternative structures that could solve for the reference 
data.  In the next work (Chapter 4) a search across potential model structures 
was implemented using simulated annealing.  A method was developed that 
used a combination of binary logic and continuous flux to search across model 
structures and parameter values, respectively. The search was found to be stable 
and was unaffected by dimensionality and identifiability issues (within the 
confines of the models evaluated). Four alternative model structures were 
identified by the search that when implemented in the azathioprine model 
yielded appropriate predictions of the reference data for all clinical scenarios. 
These structures suggested missing mechanisms in the pathway. Overall this 
work offered a method to provide alternative hypotheses where the 
underpinning knowledge for a developed model was incomplete.  
Lastly, a methodological concept called internal deterministic 
identifiability was introduced (Chapter 5) to address the precision of the 
parameter estimates under the optimal design setting. Internal deterministic 
identifiability was defined as a setting whether the parameter values were 
imprecisely estimated despite the model being structurally identifiable and the 
design being optimal.  The theory was explored using three commonly used PK 
and PKPD models. This methodology might be helpful to provide awareness 
about the situations where modelling results in poor precision of parameter 
estimates. 
In this work a systematic approach is used to explore weaknesses of QSP 
models using azathioprine model as a case example. Two mathematical 
approaches were proposed and explored to understand the nature of the issues. 




adjustments.  Ultimately, however, azathioprine dosing was not able to be 
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𝑅𝑖𝑛 Zero-order rate constant for the formation of 𝑟 
𝑘𝑜𝑢𝑡 First-order rate constant for the elimination of 𝑟 
ℝ+ Set of positive real numbers 
𝐾𝑀 Michaelis-Menten constant 
𝑉max Maximum possible velocity of the enzyme activity 
𝑀 Matrix of mass transfer rate constants 
𝐽𝑥𝑦 Flux transfer between 𝑥 and 𝑦 states 
⋀ Eigen value 
𝑃 Eigen vector 
𝐽𝑖  Flux matrix for various scenarios 





𝑆𝑏 Switch matrix for prior modes 
𝐾 Matrix of rate constants 
𝐹𝑖 Matrix of perturbing factors for various scenarios 
𝐽𝐼 Matrix of indicator variables 
𝐽𝐹 Matrix of values for always on /off 
𝐽𝑡 Matrix of values to be introduced to transient terminal states 
𝑝 Number of parameters 
𝜉 Design vector 
𝜓 Level of imprecision 
𝑇 Matrix transpose 
𝐼 Fisher information matrix 
𝐽 Jacobian matrix 
𝛴 Matrix variance of the residual effects 
𝛺 Matrix variance of the between subject effects 
Δ Indicates difference between corresponding elements 
𝜔𝑝 Between subject variance with respect to specific parameter 
𝐼max Inhibition maximum 
𝐼50 Concentration required to give 50% of 𝐼max 
mg Milligram 
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1.1. Introduction to thesis 
This thesis is concerned with the development of a quantitative systems 
pharmacology (QSP)-type model to describe the metabolic fate of azathioprine 
and 6-mercaptopurine, immunosuppressants used in the treatment of 
inflammatory bowel disease. Six-mercaptopurine is a metabolite in the 
azathioprine pathway so when the azathioprine metabolic pathway is discussed 
in the thesis, this automatically includes the drug 6-mercaptopurine. The 
development, evaluation, and application of the model were conducted using an 
adapted version of the 6-stage work flow proposed by Gadkar et al.1. The 
workflow was intended to include the following steps:  
1. define the objectives of the project,  
2. review the biochemical pathway of azathioprine metabolism and collate 
with the opinions obtained from experts in purine metabolism,  
3. develop the model structure representing the reviewed pathway,  
4. calibrate and test whether the model could capture the behaviour of the 
system under different scenarios,  
5. evaluate model performance: if the model performs well, simplify the 
model and perform an identifiability analysis; if the model does not 
perform well, explore knowledge gaps by conducting a model 
completeness analysis or if the model is found to be incomplete, search 
for alternative structure,  
6. once the structure of the model is reasonable and any identifiability 
issues resolved, use the model to predict clinically important outcome 
measures (e.g. active metabolite concentrations) and explore optimal 
dosing to achieve pre-defined targets in the clinical setting. 
All stages of the workflow are shown in a logical flow diagram in Figure 1.1. 
 




Review biochemical pathway and collate with expert s opinion
Define objectives of the project
Develop model structure representing reviewed pathway
Calibrate the model 
Test: Can the model predict 
different clinical scenarios?
Search for an alternative model structure
Simplify the model and perform identifiability analysis
Test: Is the model complete












Figure 1.1 Schematic of 6-stage work flow used in this thesis to develop 
a QSP model for azathioprine metabolism 
A number of unanticipated challenges arose during the model 
development process that limits the clinical utility of the final model. 
Importantly, it became clear that there were critical gaps in our understanding 
of the purine metabolic pathways which underpinned the model. This finding 
necessitated a shift in the research focus away from the ultimate goal of clinical 
application (see step 6 above) to the development of methods to solve the 
underpinning challenges encountered in steps 3–5 (above) during model 
development. This resulted in two methodology intensive projects outlined in 
Chapters 3 and 4, which were: (i) an evaluation of model completeness and (ii) a 
logical search for alternative model structures. The first project enquired 
whether there were a set of parameter values that could predict the observed 
outcomes of interest (azathioprine metabolite concentrations in this case) given 
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the current model structure. This work provided an evaluation of the 
appropriateness of the structure of the model. The second project questions 
whether there were alternative model structures, e.g. missing metabolic 
pathways, which allowed predictions of the observed outcomes of interest. 
Following these two lines of enquiries, the research focussed on developing a 
search method to revise and optimise the structure and parameters of the model. 
There have been a large number of publications concerned with best 
practice for QSP modelling. These include guidelines for model development, 
validation and model simplification as well as reviews about the importance of 
the QSP framework and its application in various disease areas2-17. The 
guidelines in the existing literature are based on high level overviews or from 
examples that worked as intended. Unarguably, they provide the groundwork 
for researchers either to make use of the information or to develop models in 
new therapeutic areas (or both). However, there is a paucity of literature 
pertaining to negative results that illustrates how to interpret them, as well as 
information to guide researchers on alternate ways in case such issues are 
encountered. It appears that researchers are empowered up to and until the point 
that their model does not work. Therefore, a systematic reporting of the negative 
results can shed light on the existence of the issues during model development 
and can also stimulate novel ideas to resolve them. Such an approach has the 
potential to enrich the area of QSP modelling. 
Given this introduction, this thesis is divided into 3 parts that align with 
the 6-stage work flow for the development of QSP models (mentioned above). 
Part I, relating to stages 1-4, works on (i) gathering and collating information on 
azathioprine metabolism, and (ii) developing a QSP-type of model. Part II, 
pertaining to stage-5, deals with issues that arose with the application of the 
model and presents some methodologies for evaluating the implications of these 
issues. Part III, relates to stage-6, and introduces some new concepts in 
identifiability of systems models that have been simplified, although this part 
has relevance to any data driven model approach. 
 




The chapters organised into 3 parts are as below: 
Part-I Model Development 
Chapter-2: Development of a systems based model for azathioprine 
metabolism 
Part-II Methods to account for model deficiencies 
Chapter-3: Model completeness  
Chapter-4: Searching for alternative QSP model structures 
Part-III Considerations for application of models 
Chapter-5: Deterministic identifiability of population 
pharmacokinetic and pharmacokinetic-pharmacodynamic models 
1.2. Background and rationale 
This section introduces the important aspects of the QSP framework and its 
relationship with pharmacometrics. 
Pharmacometrics also termed Quantitative Pharmacology, is an established 
field in the discipline of clinical pharmacology. The field has gained significant 
attention in the area of drug development and pharmacotherapy due to its ability 
to quantify the interactions between drugs and a biological system, using either 
empirical or mechanistic approaches. Since the publication of the first citation in 
197118, pharmacometrics has been growing continuously and expanding its 
scope (and approach) by integrating several scientific disciplines including 
physiology, systems biology, mathematics, statistics and computational sciences. 
In this process the field has embraced two distinct modelling approaches (1) top-
down, typically pharmacokinetics (PK) and pharmacodynamics (PD), and (2) 
bottom-up, typically physiologically based pharmacokinetics (PBPK) and QSP. 
It has been suggested that pharmacometrics is restricted to data driven top-down 
approaches19. However, considering its description 20 and its original definition 
(quantitative pharmacology) it would not seem appropriate to restrict the use of 
the term to just data driven approaches. Therefore, as pharmacometrics grows 
and embraces new approaches, e.g. QSP, these become, over time, an integral 
part of pharmacometrics. This philosophy is represented schematically in Figure 
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1.2. Here it is shown that pharmacometrics uses the concepts of mathematics, 
statistics and computational sciences to integrate the knowledge from systems 
biology and physiology, with pharmacokinetics and pharmacodynamics. 
Depending on the combination of the specialities different sets of modelling 
formalisms (pharmacokinetic-pharmacodynamic [PKPD], physiologically based 
pharmacokinetic [PBPK], pharmacology and QSP) have evolved to understand 
the interactions between drugs and the system. In this schematic QSP takes the 







Figure 1.2 Philosophy of pharmacometrics that embraces all 
components that enable quantification of pharmacology 
1.2.1. An introduction to quantitative systems pharmacology models 
QSP models utilise knowledge and concepts obtained from systems 
biology and integrates this with PKPD models to quantify the biological 




responses under the influence of drug effect. QSP modelling is relatively new in 
the pharmacometric framework and this approach has been increasingly 
popular to identify potential drug targets or biomarkers in the drug industry for 
new drug development and in clinical practice for optimal drug therapy.21 
When moving from the cellular to whole organism we see 
pharmacodynamic models as the essential tool to determine drug-target 
interactions which via an understanding of the system leads to a change in a 
physiological response and ultimately the outcome.  
To summarise 
 pharmacokinetics define the time course of concentrations, 
 pharmacodynamics relate drug effects against the their concentrations,  
 PKPD models determine the time course of drug effects,  
 QSP models capture behaviours of the systems and  
 survival analysis focuses on the time of appearance of a clinical event.  
All of these approaches are interconnected in such a way that the output 
variable of one component is essentially input for another approach (see Figure 
1.3). These aspects are further discussed in detail in the next sections while 
keeping the main emphasis on QSP modelling. Note that patient centred 
behaviours (e.g. adherence) are not depicted in the dose through outcome flow 
but are nevertheless important for predicting drug outcomes. 
Chapter 1: Introduction 
9  
 




























𝐶(𝑡)   
𝐹 𝐷    𝑘𝑎
𝑉 (𝑘𝑎 − 𝑘)






































































































Figure 1.3 Flow diagram for the importance of different pharmacometrics 
approaches to improve therapeutic outcome. 
1.2.1.1. Pharmacokinetic models  
Pharmacokinetics (PK) describes the movement of drugs in the body and is 
a function of dose and time. In general it is described as what the body does to the 
drug. The time course of drug concentrations is determined quantitatively from 
the processes of its absorption (in the case of extravascular drug administration), 
distribution, metabolism and excretion (known as ADME). Typically a 
compartmental (e.g. 1 or 2 or 3) formalism is used to visualise the disposition 
(DME) process to which an input process A (absorption) is added. For instance, 
the PK of many orally administered drugs can be described using a 1-
compartment disposition model (see Figure 1.4). Note that, by convention, 
compartments are numbered based on disposition compartments only.  
  












Figure 1.4 Schematic for 1-compartment model for oral administration 
without absorption delay. The solid arrows represent mass balance and the 
line with a circle (“lollipop”) the compartment that is being sampled 
Mathematically the model can be represented in the form of either algebraic 
(Equation 1.1) or ordinary differential equations (ODEs) form (Equation 1.2). 
An algebraic equation for the model for the concentration in the disposition 
compartment in Figure 1.4 is 
𝐶(𝑡)  
𝐹 ∙ 𝐷𝑜𝑠 ∙ 𝑘𝑎
𝑉 ∙ (𝑘𝑎 − 𝑘)
(   ∙𝑡 −     ∙𝑡)  
Equation 1.1 Algebraic equation for 1-compartment model for oral 
administration without absorption delay with respect to the observation 
compartment (See Figure 1.4) 
Where, 𝐶 is the drug concentration, 𝐹 denotes the bioavailable fraction, 𝑉 
the apparent volume of distribution, 𝐶𝐿 clearance (see 𝑘 in Figure 1.4), and 𝑘𝑎 
and 𝑘 are the first-order rate constants for absorption of the drug from the dosing 
compartment and elimination from the sampling compartment, respectively. 
ODE for the model in Equation 1.1 is shown by Equation 1.2. 
𝑑𝐴1 
𝑑𝑡
 − 𝐴1 ∙ 𝑘𝑎;  
𝑑𝐴2
𝑑𝑡
  𝐴1 ∙ 𝑘𝑎 − 𝑘 ∙ 𝐴2; 
𝑨(∅)  [







Equation 1.2 ODEs for a 1-compartment model for oral administration 
without absorption delay. 𝑨𝟏 and 𝑨𝟐 are the amount of the drug in gut and 
central compartments, and 𝑨(∅) is the vector of initial values for the 
respective compartments 
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1.2.1.2. Pharmacodynamics and its link with drug-receptor kinetics 
Pharmacodynamics (PD) is concerned with quantification of drug action22, 
and relate drug effects or biological responses to concentration. In other words 
PD is what the drug does to the body. Mostly these models focus on pharmacological 
response based on drug exposure.  
Pharmacodynamic models assume that pharmacological response is based 
on the amount of the drug bound to the target or receptor. The model for drug-










Equation 1.3 Drug-receptor kinetic model 
Here, 𝐷  is the molar drug concentration, 𝑅  is the molar receptor 
concentration, 𝐷𝑅  the receptor-drug bound concentration, 𝑘𝑜𝑛  denotes the 
second-order rate constant for binding, 𝑘𝑜𝑓𝑓  the first-order rate constant for 
dissociation, and 𝐾𝐷 the equilibrium dissociation constant (inverse of affinity).  
1.2.1.3. Pharmacokinetic pharmacodynamic (PKPD) models 
These models link pharmacodynamic response with drug concentrations. 
They are classified into two types based on the presence of a time delay between 
PK and PD.  The absence of an apparent time delay can be described using an 
immediate effect model whereas in the presence of a time delay may be 
described by a turnover model or other forms that allow for a delay. 
(1) Immediate effect models: 
Immediate effect models assume no delay between plasma drug 
concentrations and appearance of the PD response. In other words the maximum 
effect (𝐸𝑚 𝑥) of the drug occurs at the same time as the maximum concentration. 




The mathematical form of the model shown in Equation 1.4. Note this model 
may be expanded to accommodate sigmoidicity and other relationships. 
𝐸(𝑡)  
𝐸𝑚 𝑥 ∙ 𝐶(𝑡)
𝐸𝐶50 + 𝐶(𝑡)
 
Equation 1.4 Mathematical form of immediate effect PKPD model 
(2) Turnover models: 
These models consider that the pharmacological response is due to a 
change in the natural homeostasis of the biomarker of the biological response. 
The biological response is deemed to be at its baseline as long as there is an 
equilibrium between the rate of synthesis and elimination of the biomarker. 
When this equilibrium is perturbed by a drug, either by altering the synthesis or 
elimination, then this will lead to the generation of a response with some delay 
related to the turn-over rate of the biomarker. Table 1.1 summarises four 
different types of turnover models1 where the baseline response in all the 4 cases 
















                                                 
1 Dayneka et al. J. Pharmacokinet. Biopharm 21 (4) 457-78 (1993). 
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Table 1.1 Four basic drug effects on biological response and their 
turnover models. 𝒓 is the biological response, 𝑹𝒊𝒏 and 𝒌𝒐𝒖𝒕 represent the zero-
order rate constant for the formation and first-order rate constant for the 
elimination of biological response, 𝑬𝒎𝒂𝒙 and 𝑰𝒎𝒂𝒙 refer to the maximum extent 
of stimulation and inhibition of synthesis or elimination of the biological 
response (respectively), 𝑪(𝒕) is the concentration of the drug at time 𝒕, and 
𝑬𝑪𝟓𝟎 the concentration of drug at which stimulation or inhibition would be 
50% of 𝑬𝒎𝒂𝒙 or 𝑰𝒎𝒂𝒙. 
Type of perturbation Model 
Stimulation of the response production 
𝑑𝑟
𝑑𝑡
 𝑅𝑖𝑛 ∙ (1 +
𝐸𝑚 𝑥 ∙ 𝐶(𝑡)
𝐸𝐶50 + 𝐶(𝑡)
) − 𝑘𝑜𝑢𝑡 ∙ 𝑟 
Inhibition of the response production 
𝑑𝑟
𝑑𝑡
 𝑅𝑖𝑛 ∙ (1 −
𝐼𝑚 𝑥 ∙ 𝐶(𝑡)
𝐼𝐶50 + 𝐶(𝑡)
) − 𝑘𝑜𝑢𝑡 ∙ 𝑟 
Stimulation of the response elimination 
𝑑𝑟
𝑑𝑡
 𝑅𝑖𝑛 − 𝑘𝑜𝑢𝑡 ∙ 𝑟 ∙ (1 +
𝐸𝑚 𝑥 ∙ 𝐶(𝑡)
𝐸𝐶50 + 𝐶(𝑡)
) 
Inhibition of the response elimination 
𝑑𝑟
𝑑𝑡
 𝑅𝑖𝑛 − 𝑘𝑜𝑢𝑡 ∙ 𝑟 ∙ (1 −




An early example was described by Jusko et al. who modelled a data for 
the control of prolactin secretion by cimetidine using a turnover model (see 
Figure 1.5).23 Here, pharmacological response to cimetidine was considered to be 
the alteration of the biological response, i.e. secretion of prolactin (𝑟𝑝𝑟𝑜𝑙 𝑐𝑡𝑖𝑛), via 
stimulation of the production rate of prolactin. 








Figure 1.5 Schematic for the cimetidine mediated stimulation of prolactin 
secretion 
In this setting a stimulatory turnover model (see Equation 1.5) was used to 
reflect the mechanism of the drug to control the secretion of prolactin.  
𝑑𝑟𝑝𝑟𝑜𝑙 𝑐𝑡𝑖𝑛
𝑑𝑡
 𝑅𝑖𝑛 ∙ (1 +
𝐸𝑚 𝑥 ∙ 𝐶(𝑡)
𝐸𝐶50 + 𝐶(𝑡)
) − 𝑘𝑜𝑢𝑡 ∙ 𝑟𝑝𝑟𝑜𝑙 𝑐𝑡𝑖𝑛 
Equation 1.5 Turnover model for the control of prolactin concentrations 




This model is an example to quantify time course of response based on 
exposure of the drug.  
1.2.1.4. Combining PK and PKPD within a biological system 
1. Physiologically based pharmacokinetic models 
Incorporating PK within the concept of physiological and biological 
processes as well as considering the drug’s physicochemical properties forms the 
basis of PBPK models.  These models have found use in scaling dosing between 
species and incorporate compartments that represent organs and tissues 
arranged on an anatomical schema. Drug transfer between different 
compartments is considered to take place by blood flow or blood to tissue 
permeability or both. Therefore they use parameters representing blood and 
tissue volumes, fractions of cardiac output (or organ perfusion), partition co-
efficients for blood to plasma ratio and clearance (systemic or intrinsic). 
Depending on the requirements, these models are often simplified to 
reduce the number of compartments and therefore reduce multidimensionality 
and subsequent issues with parameter estimation. Such (reduced) models are 
termed minimal PBPK models. 
There is an extensive body of literature on development and application of 
PBPK models.24-38 However it is out of scope of this thesis to consider describing 
the modelling formalism of PBPK models.  
2. Quantitative systems pharmacology models 
Quantitative systems pharmacology (QSP) has no formal definition, 
however as per Van der Graaf et al. it is described as the “quantitative analysis of 
the dynamic interactions between drug(s) and a biological system that aims to 
understand the behaviour of the system as a whole.”17 QSP models combine 
knowledge and approaches from systems biology with exogenous molecules 
and their effects. These models help to (a) understand regulation and 
deregulation of the system in healthy and diseased conditions, and (b) quantify 
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perturbations in biological processes, such as cell signalling and/or biochemical 
pathways, under the influence of diseases and administered drugs.  
The important goals of QSP models are: 
(i) to understand the underlying mechanism for therapeutic benefits and 
toxicities of new and existing drugs 
(ii) to identify the use of an existing drug in a new disease area 
(iii) to identify new drug targets in new and existing therapeutic areas 
1.2.2. Development of QSP models 
In the process of developing QSP models, information on the knowledge of 
the system is collated from the literature and expert opinion. This information is 
then typically visualised using schematics based on which a mathematical model 
of the system is constructed. 
1.2.2.1. Graphical representation of QSP models 
Graphics in the form of model schematics provide a summary of the 
dynamic properties of the systems in the form of mass action (example: an effect 
of a drug at a target) and mass balance (example: movement of a drug between 
different locations). This helps to (i) communicate mechanistic aspects of the 
system between different disciplines, (ii) generate hypotheses on plausible drug 
targets and (iii) construct and track modifications of the structural components 
of the mathematical models. 
There are several tools to draw schematics of the QSP models. Some of them 
can be used as graphic user interphases to perform simulations (such as 
Cytoscape, JDesigner, CellDesigner, and SBML’s Qualitative Models Package 
and MATLAB SimBiology package) and some are used for illustration only (for 
example Microsoft Visio). At this point there is no industry standard 
visualisation tool. 
  




1.2.2.2. Mathematical representation of QSP models 
The interactions between different components of the system are modelled 
using mathematical equations. Depending on the availability of the kinetic data 
with respect to the mass transfer of the system these models can be discrete or 
continuous in nature. The three most commonly used modelling formalisms of 
QSP models are: 1. Logic models, 2. Fuzzy logic models and 3. Flux equations. 
Each approach has its own advantages and disadvantages where the first two 
are applied to determine information on the status of a node whereas the third 
can provide continuous information over time (or provide spatial resolution or 
both). 
In all formalisms it is common that components in a system are defined by 
nodes and edges. Nodes represent the compartments (or states) and edges 
represent connections between the compartments. The formalisms differ with 
respect to how the edges are defined. An example 3-node model with two 





Figure 1.6 A 3-node model. Nodes are represented by circles and edges 
by arrows. 
1. Logic models 
Logic models allow the behaviours of the system to be tested using quantal 
connections. They apply binary interpretation (0 or 1) to nodes in the system in 
order to reflect their status, off or on. In a QSP framework, logic models are 
mostly used for cellular regulatory networks, which may include thousands of 
nodes and edges. This type of formalism helps to explore knowledge gaps with 
respect to the interaction between the components, i.e. activation or inhibition, 
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in the network. Logic modelling comprises two layers, (i) determination of the 
status of a node and (ii) determining the outcome of multiple interactions 
between nodes. The former is achieved by assigning binary logic to the node and 
the latter by combining the nodes using Boolean functions (e.g. AND, OR, NOT). 
For instance if two nodes represent two different proteins in a network (one 
might be an activator and one might be an inhibitor), the net activity or 
regulation of the target protein can be determined by the type of interaction 
between the proteins. The set of interactions between the two proteins can be 
tested using Boolean functions. Figure 1.7 shows different possibilities of the 
interactions. In terms of application logic models can be useful to (i) identify the 
drug targets and (ii) provide a starting point for kinetic modelling in future. 










Ct+1=At AND NOT Bt Ct+1=At OR NOT Bt 
 
At Bt Ct+1 
0 0 0 
1 0 1 
0 1 0 
1 1 0 
 
At Bt Ct+1 
0 0 1 
1 0 1 
0 1 0 
1 1 1 
Figure 1.7 A Boolean logic applied to a simple three-node model for the 
net activation of one node by other two nodes. A and B refer to activator and 
inhibitor proteins. When these are combined by (i) AND function where 
inhibitory protein Bt (t stands for the time) is off, while At is on the overall 
activation of Ct+1 is determined or (ii) OR function where activator protein At 
is off while Bt is on the overall inactivation of Ct+1 is determined. This figure 
is adapted from the paper by Wynne et al.39 after taking permission from 
Copyright clearance centre (Licence number: 4535100240210) 
There have been several publications on the use of logic models in the QSP 
framework (see Table 1.2). 




Table 1.2 Logic based QSP models developed in various therapeutic areas 
and their application 




To identify therapeutic targets40 
2 Lupus erythematosus 
To identify immune response to 
autoantigens41 
3 Cancer 
To describe carcinogenesis and treatment 
outcomes42 
4 Multiple myeloma To identify drug targets43 
 
One advantage of using this approach to QSP model development is the 
lack of need to define parameter values. This is often an advantage since kinetic 
information of many intracellular biological networks are poorly understood. 
Nevertheless, it is important to note that these models describe a simplification 
of the biological system and might not capture the complexity.44 
2. Fuzzy logic modelling 
Fuzzy logic models are an extension of logic models where a node is 
initiated with any real value on the interval of 0 to 1, rather than only taking the 
values of 0 or 1. This allows a variable status to be assigned to a node rather than 
a discrete on or off state. 
These models use any typical sigmoid function to obtain the output within 
constrained boundaries. For instance the constrained fuzzy logic function 
reported by Morris et al. was constructed using a normalised Hill function (see 
Equation 1.6) for the activation of target node-C (𝑐 𝑐𝑡) by a precursor node-A45. 
For inhibition (𝑐𝑖𝑛ℎ), the function for activation is subtracted from 1 (Equation 
1.7).  





Equation 1.6 A normalised Hill function for the activation of the target 
node (𝒄𝒂𝒄𝒕) 
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Equation 1.7 A normalised Hill function for the inhibition of the target 
node (𝒄𝒊𝒏𝒉) 
Here the value of 𝑎  should be between 0-1 to constrain the value of 
𝑐 𝑐𝑡 𝑜𝑟 𝑐𝑖𝑛ℎ  between 0-1, 𝑘 (∈ ℝ
+)  is the sensitivity parameter obtained from 
𝐸𝐶50 (i.e. 𝑘  1 − 𝐸𝐶50), 𝑛 is the Hill coefficient. Figure 1.8 shows the profile for 
activated and inhibited status of node-C. 
 
 
Figure 1.8 Profiles of node-C as activated (left) inactivated (right) by the 
node-A in continuous domain 
 
If A and B are two nodes that combined, either by (i) AND or (ii) OR, act 
on node-C the equation are 
(i) AND 



























Here, 𝑎 and 𝑏 are the values of nodes A and B (0 < 𝑎&𝑏 < 1).  
Fuzzy logic was used by Morris et al. who applied a constrained version to 
address the effect of combinations of drugs in hepatocellular carcinoma under 
the influence of growth factors and inflammatory cytokines46. Similarly, 
Aldridge et al. applied fuzzy logic analysis to simulate and generate predictions 
of kinase pathway crosstalk under the influence of the large molecule treatment 
choices47.  
In this thesis logic modelling is used to switch on and off the edges (see 
Chapter 4).  Fuzzy logic is not strictly used in this work although there are some 
similarities with the method of using flux equations in Chapter 4. 
2. Flux equations  
Flux equations remains the most common approach for expressing QSP 
systems. These equations are usually described by a set of ODEs. This approach 
uses mass or molar transfer or conversion (such as metabolic reactions) and mass 
or molar action (such as drug effects at the target in the system). For instance, the 
mass flux for the schematic shown in Figure 1.9 can be mathematically shown 
using ODEs as shown below. 
𝑑𝐴
𝑑𝑡
 −𝑘 𝑐 ∙ 𝐴 
𝑑𝐵
𝑑𝑡
 −𝑘𝑏𝑐 ∙ 𝐵 
𝑑𝐶
𝑑𝑡
 𝑘 𝑐 ∙ 𝐴 + 𝑘𝑏𝑐 ∙ 𝐵 
Equation 1.8 Set of flux equations for the molar conversions (shown in 
Figure 1.9) 







Figure 1.9 Schematic showing molar conversion of nodes A and B to C 
The simulations of the profiles (shown in Figure 1.10) for the schematic in 
Figure 1.9. It can be seen from this plot that, flux equations provided quantitative 
understanding of the molecular flux over time.  
 
Figure 1.10 A plot showing flux equations based simulations for the 
molar conversion of nodes A & B to node C.  
Numerous QSP models have been published using ODEs and the  majority 
of these models represent mass balance and mass action; some examples include 




cell proliferation and apoptosis48, coagulation network4, bone mineral density49 
and eosinophil dynamics50 
In comparison to logic and fuzzy logic models, ODE based models provide 
more physiological meaning and mechanistic understanding as they determine 
the kinetics of the pathways using parameters that have real world corollaries, 
such as zero-order, first-order or mixed-order processes. The parameters for 
these processes are conventionally obtained from in vitro or in vivo studies. In 
this work, the QSP model for azathioprine metabolism was developed based on 
a biochemical pathway that is represented by a set of 30 ODEs (see Chapter 2). 
On the other hand, these models are prone to suffer from limited or missing 
information on parameter values. Some parameter values are may be 
determined empirically during model calibration.  
1.2.2.3. Calibration of QSP models 
The term calibration in a QSP framework refers to the process of aligning 
model predictions with reference data by optimisation of the parameter values. 
This evaluates whether the QSP model can capture the behaviour of the system. 
The calibration process is generally informally applied and typically involves 
two steps: (1) sensitivity analysis and (2) optimisation (often heuristic).  
(1) Sensitivity analysis: Since most QSP models contain large sets of 
parameters, optimisation methods suffer from issues of multidimensionality. 
Therefore, usually a sensitivity analysis is performed to identify those 
parameters that make the largest differences in the predictions for a small change 
in their values. By eliminating the insensitive parameters, the optimisation space 
can be reduced. Depending on the relationship (e.g. linear or non-linear) 
between output and model parameters either local or global sensitivity analysis 
is applied for a given model.51  
(2) Optimisation: The sensitive parameters are optimised using either a 
heuristic approach or optimisation algorithms (that uses local or global or hybrid 
approaches1) to find parameter values that can align model predictions with the 
reference data. 
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There are no specific guiding rules for performing calibration and therefore 
methods tend to depend on the project requirements. For instance Peterson et al. 
studied bone mineral density (BMD) changes with denosumab dosing where the 
model was calibrated for the target BMD using literature data. Parameter 
optimisation was performed using local simplex search algorithm.49 Since this 
model is an extension to an existing model, sensitivity analysis was skipped, and 
was calibrated using a heuristic approach which is a similar approach that 
Wajima et al. adapted for their coagulation network model.4 In contrast, Zhu et 
al. performed calibration of a model using Sobol global sensitivity analysis 
followed by a local optimisation tool.48  
In this thesis the calibration process was performed heuristically (more in 
Chapter 2).  
1.2.3. Evaluation of QSP models 
Model evaluation aims to examine whether the developed QSP model 
meets the goals for which it was developed. It is to be noted that some 
researchers use the terms model validation and qualification interchangeably 
with evaluation.7, 12 While some use these terms interchangeably it is arguable 
that a systems model cannot be validated per se but rather is able to perform 
acceptably across a range of circumstances. In this work the term model 
evaluation is preferred. Important questions that evaluation of a QSP model 
address is that, can the model facilitate exploring drug mechanism with respect 
to desired and undesired effects. This determines the ability of the model to 
reflect the known relationships of the system. Apart from this, there are some 
other concepts connected to QSP model evaluation, such as understanding 
variability of the drug response and biological uncertainty. These are well 
defined with respect to cellular signalling network models and need more 
attention and exploration in enzyme-substrate related systems. 
  




1.2.3.1. Prediction of desired and undesired drug responses 
The ultimate aim of pharmacometrics, as mentioned above, is to improve 
safety and efficacy of drugs and drug use. In conventional PKPD modelling this 
is performed by relating drug concentrations to the observed response and 
making use of this information to predict appropriate doses for future studies 
(aka learn and confirm). But this glosses over the complexity of the interaction 
of the drug with its target in the system. In QSP modelling, safety and efficacy is 
determined by two aspects, (i) identifying the specific system(s) that the drug 
acts upon and (ii) identifying the specific component(s) of the system that are 
perturbed by the drug. The knowledge on these aspects helps to understand 
potential mechanisms of new or existing drugs. While in standard (empirical) 
PKPD analysis these two layers (i.e. system and drug target) are combined in a 
single statistical model, in a QSP setting they are separated as a drug-target 
model and a target-system model. Hence the QSP approach allows an 
understanding of the target-system interaction which is otherwise lost in PKPD 
modelling framework.  
In this work, model evaluation was performed by testing the ability of the 
model to predict different clinical scenarios by perturbing the hypothesised 
enzymatic pathways (see Chapter 2). This was done with an aim to explore the 
unknown mechanism for the toxicities. 
1.2.3.2. Quantification of the variability in response and biological uncertainty 
In conventional pharmacostatistical (or nonlinear mixed effects) modelling 
approaches, importance is given to parameter uncertainty, which is obtained 
using asymptotic standard errors of the parameter estimates, and variability in 
response that is reflected in the between subject variance in the parameters. But 
these concepts are not widely addressed in QSP models.  
In cellular network systems, biological uncertainty and biological 
variability represent different constructs and are determined separately.12, 48, 52, 53 
Here, biological uncertainty is used to refer the setting where there is insufficient 
knowledge of some components of a biological network, which may lead to, for 
Chapter 1: Introduction 
25  
 
instance, missing nodes in a developed QSP model. Whereas variability in the 
system results in variability in the physiological function or pharmacological 
response. In the case of biological uncertainty an alternative (but reasonable) 
model structure is considered, and in case of response variability alternative 
parameter values are considered.1, 5, 7, 12, 52-57 
Most publications that consider knowledge gaps restrict their description 
to biological uncertainty.12, 48, 52, 53 But due to the nature of the research question 
in this work, the term ‘knowledge gaps’ referred to biological uncertainty (i.e. 
under representation of the system) and poor understanding in drug’s 
mechanism for some undesired clinical outcomes. 
1.2.4. Applications of QSP models 
1.2.4.1. Identification and evaluation of disease markers and drug targets 
The importance of QSP models lies in their ability to help modellers to 
explore and understand the dynamics of the system under the influence of 
internal or external perturbations (due to disease or drug action). Since biological 
systems are very complex and involve recursive processes, interpretation of 
outcomes from any perturbation may not be intuitive.12  
In this regard, QSP models provide a platform to evaluate existing 
hypotheses on dysregulated pathways in the system and determine whether the 
observed outcome can be predicted. In addition, these models help to identify 
and test plausible drug targets in a complex pathway. This might form the basis 
of in silico testing prior to testing in vivo. There have been several publications 
that reported this advantage of applying systems based approach (see Table 1.3 
for some case examples).




Table 1.3 Various published QSP models showing their application in different therapeutic areas 
# Therapeutic area QSP model used Reference 
1 Proof of mechanism for clotting time test to 
monitor enoxaparin  
Coagulation network4 Gulati et al.58 
2 A novel drug target for pain management Nerve growth pathway Benson et al.59 
3 Absorption of ketones QSP model for  gastrointestinal absorption of the ketone 
monoester and its systemic catabolism 
Shivva et al.60 
4 Biomarkers for rheumatoid arthritis Systems model for rheumatic joint Meeuwisse et al.61 
5 Role of p53 mutations in diminished 
gemcitabine effect 
Systems model for cell proliferation and apoptosis. Zhu et al.48 
6 Drug targets in the treatment of 
inflammatory bowel disease. 




Chapter 1: Introduction 
27  
 
In this work several existing hypotheses for azathioprine dosing related 
toxicity were tested using a QSP model developed in Chapter 2. 
1.2.4.2. Identifiability issues with parameter estimation  
This section provides an outline about estimation issues related to 
parameter identifiability that may arise with a developed QSP model. 
Systems models often have vast numbers of parameters to describe a 
biological mechanism. Estimation of all these parameters when applying the 
model to data is generally not practical since data from many nodes may not be 
available. In this case, estimation of the model parameters may need to occur 
with observations available from some (perhaps few) nodes and hence in these 
cases the estimation process may not find a unique solution to all parameters. 
Therefore, in the majority of cases, QSP models are not amenable to an estimation 
process directly. To overcome this issue, parameters that are not informed by the 
available input-output data (in other words, insensitive parameters) are often 
aggregated into composite parameters3, 62 or eliminated63  using scale reduction 
(aka model simplification) techniques. These reduced models with fewer states 
and parameters can be applied to a particular input-output relationship while 
retaining important mechanisms. 
A scale reduced systems model may still either have more parameters than 
available data or have parameters that do not directly and independently 
influence the predictive quality of the model in terms of describing a specific set 
of data. Such models might be a priori (structural) or a posteriori (deterministic) 
unidentifiable. In these cases parameters are often fixed. 
i. Structural identifiability 
Structural identifiability is defined by the uniqueness of the solutions for 
parameters in a given model in a perfect input-output scenario. 
A model is considered to be 
a. globally structurally identifiable if there is a unique set of solutions 
for the model parameters for any given input-output relationship 




b. locally structurally identifiable, if there are a finite set of solutions for 
the model parameters for any given input-output relationship 
c. structurally unidentifiable, if there are an infinite set of solutions for 
the model parameters for any given input-output relationship 
ii. Deterministic identifiability 
Deterministic identifiability is concerned with the precision of the 
parameter estimates for a structurally (at least locally) identifiable model given 
imperfect input-output data. The work in Chapter 5 introduced two 
subcategories of deterministic identifiability  
a. External deterministic identifiability: where the identifiability of a model 
is a result of the study design. The term ‘external’ refers to identifiability 
that is external to the model and relates to the design, i.e. factors 
controlled by the investigator (e.g. the number and timing of blood 
samples). 
b. Internal deterministic identifiability: refers to the identifiability of a 
model given an optimal design which is governed by internal aspects of 
the model, for instance for a given set of model parameter values.   
This methodological work provides an introduction to the concept that, for 
a globally structurally identifiable model for which the experimental design is 
optimal, some of its parameters may still be imprecisely estimated. 
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1.2.5. Azathioprine in the treatment of inflammatory bowel disease 
Azathioprine is an immunomodulatory agent which has been in clinical 
practice for over 60 years and remains amongst the most widely used drugs for 
the treatment of inflammatory bowel disease (IBD). The drug is as effective as 
the newer biologics for maintaining remission but poses more challenges to get 








Figure 1.11 Chemical structures of azathioprine (A), 6-mercaptopurine 
(B) and purine (C) 
1.2.5.1. Mechanism of action 
Azathioprine is a prodrug of 6-mercaptopurine with an additional methyl 
nitro imidazole group. Both contain a purine derivative (see Figure 1.11). After 
oral administration, azathioprine gets metabolised in the cytosol of liver cells by 
glutathione transferase to 6-mercaptopurine. 6-Mercaptopurine is transported to 
several types of cells, including erythrocytes, T and B lymphocytes, where it 
undergoes metabolism by a complex purine metabolic pathway to form several 
intermediate and final metabolites. Out of all these metabolites the 6-thioguanine 
nucleotides (6-TGN), a composite of phosphate derivatives of 6-thioguanosine 
nucleotide, are responsible for the therapeutic benefit of azathioprine. 6-TGN 
competes with endogenous guanine nucleotides and interferes with DNA and 
RNA synthesis in rapidly dividing cells such as T and B cells thus causing 
immunosuppression. It is worth noting that excessive concentrations of 6-TGN 
may result in severe immunosuppression. Also, another metabolite in the 
pathway, 6-methyl mercaptopurine (6-MMP, a composite of phosphate 
derivatives of methyl inosine), upon over production, can cause hepatotoxicity. 
Details of the metabolic fate and pathways are provided in the next sections. 




1.2.5.2. Issues with dosing and their relationship with the metabolic pathway 
Azathioprine recommended doses are 2-3 mg/kg/day.64 Ideally, in clinical 
practice, these doses are adjusted to achieve 6-TGN concentrations within 235 – 
450 pmol/8×108 RBCs.65 However, 30% of patients need to stop therapy after the 
initiation due to serious toxicities, and up to 40% of patients fail to respond to 
the treatment.66 These clinical issues can be understood by knowing the details 
of the azathioprine metabolic pathway (shown in Figure 1.12, reproduced with 
permission from Elsevier-license Number: 4442870903008).  
 










Figure 1.12 A simple schematic of azathioprine metabolism67.  
It can be seen from the schematic (Figure 1.12) that 6-mercaptopurine is 
further metabolised by three different enzymes that lead to three different 
pathways. The first pathway mediated by thiopurine methyl transferase (TPMT), 
forms methylated products (example, 6-methyl mercaptopurine or 6-meMP). 
The second pathway, mediated by hypoxanthine guanine phosphoribosyl 
transferase (HGPRT), produces 6-thioinosine monophosphate (6-TIMP). 6-TIMP 
will further undergo a series of metabolic steps that lead to formation of a group 
of metabolites called 6-TGN, where TPMT is also involved in some locations of 
the pathway. In the third pathway, xanthine oxidase (XO) forms water soluble 
6-thiouric acid (6-TUA). Out of these three pathways, the first two (TPMT and 
HGPRT) are more clinically important. 
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1. Elevated 6-TGN concentrations and myelotoxicity 
The metabolites collectively termed, 6-TGN (which includes mono, di and 
tri phosphates of 6-thioguanine and 6-thiodeoxy guanine) are responsible for 
modulation of the immune system.  In excess, these metabolites may lead to bone 
marrow (myelo) toxicity.  
Genetic polymorphism in TPMT activity has been shown to lead to 
differential metabolic profiles of 6-TGN production.68 Three major genetic 
variant alleles of the enzyme have been found, that follow a tri-modal 
distribution among the observed population. In normal cases, patients with 
wild-type alleles for the enzyme activity (i.e. TPMT*1/*1) will produce therapeutic 
6-TGN with the recommended dosing. But in abnormal cases, where TPMT 
activity is either intermediate (i.e. TPMT*1/*3) or deficient (i.e. TPMT*3/*3), patients 
produce excessive 6-TGN. The issue of bone marrow toxicity related to TPMT 
poor metabolism is well understood, and there are guidelines by CPIC (clinical 
pharmacogenetics implementation consortium) for dose adjustments based on 
TPMT activity.64 
In addition to TPMT, another enzyme in the pathway called nucleoside 
diphosphate-linked moiety X-type motif 15 (NUDT15) has more recently been 
found to be responsible for elevated 6-TGN concentrations in some Asian 
populations.69-74 NUDT15 dephosphorylates the derivatives of triphosphates to 
monophosphates. In the azathioprine metabolic pathway, 6-thioguanine 
triphosphate (6-TGTP) and 6-thio deoxyguanine triphosphate directly interferes 
with DNA and RNA synthesis. NUDT15 controls this by converting 6-TGTP 
back to 6-TGMP, and 6-TdGTP to 6-TdGMP (see Figure 1.13). Deficient NUDT15 
activity leads to excessive concentrations of 6-TGTP and 6-TdGTP. Since both of 
these metabolites are important components of 6-TGN to interfere with DNA 
synthesis, deficiency of NUDT15 will increase the risk of bone marrow toxicity. 














Figure 1.13 Role of NUDT15 (shown in purple) in the azathioprine 
metabolic pathway. Formation of the active components of 6-TGN 
(specifically 6-TGTP and 6-TdGTP, that shown in orange boxes) are 
controlled by NUDT15 by converting them back to 6-TGMP and 6-TdGMP 
respectively. 
In addition, some have suggested a role of inositol triphosphatase (ITPase) 
in bone marrow toxicity. This is not shown in the simple schematic of 
azathioprine (Figure 1.12) but as per Figure 1.14, 6-TIMP (6-thioinosine 
monophosphate) is further phosphorylated to 6-thioinosine diphosphate (6-
TIDP) then to 6-thioinosine triphosphate (6-TITP). ITPase converts 6-TITP back 
to 6-TIMP (see Figure 1.14). In this regard, Zelinkova et al. reported that some 
genotypes of TPMT and ITPase are associated with leucopaenia.75 Therefore it is 
worth testing the role of abnormal ITPase activity in bone marrow toxicity. 




































Figure 1.14 ITPase (in red) activity in azathioprine metabolism 




2. Non-responders, metabolite shunting and hepatotoxicity 
Some patients do not respond to the usual starting dose of azathioprine, 
due to sub-therapeutic 6-TGN concentrations. Increasing doses in some of these 
cases does not appear to appreciably increase 6-TGN but potentially leads to 
hepatotoxicity due to accumulation of 6-MMP. Several studies have found a 
strong association between dose-dependent hepatotoxicity and excessive 6-
methyl mercaptopurine (6-meMP or 6-MMP) concentrations.76-79. This 
phenomena has been termed shunting as the fate of azathioprine seems to be 
channelled towards 6-MMP in preference to 6-TGN. It has been consistently 
reported that in most of these cases the concentration of 6-MMP are above 5700 
pmol/8×108 RBCs or the ratio between 6-MMP and 6-TGN is greater than 20.78, 
80 Therefore it is required to measure both 6-TGN and 6-MMP concentrations to 
determine the potential for therapeutic failure or hepatotoxicity. The mechanism 
for the shunting is not known. There are some conflicting hypotheses about the 
mechanism (see Section 1.2.5.3).  
3. Allopurinol to rescue shunting 
Shunting is controlled in the clinical setting by adding small doses of 
allopurinol to reduced doses of azathioprine, with improved response to 
azathioprine.81 This has been shown to result in a decrease in 6-MMP 
concentrations while increasing 6-TGN. Although this add-on therapy has been 
proved to be effective, the exact mechanism by which allopurinol avoids 
shunting is still in debate. Several different hypotheses, based on experience or 
experiments, have been postulated. For instance (i) Sparrow et al. hypothesised 
that allopurinol modifies TPMT activity to reduce 6-MMP81, (ii) Sienen et al. 
purports that the combination therapy enhances HGPRT activity and therefore 
increases the concentrations of 6-TGN82, and (iii) Blaker et al. reported that 
allopurinol indirectly enhances the levels of 6-thioxanthine that inhibits TPMT 
in in vitro experiments.83 
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1.2.5.3. Hypotheses on biomarkers for metabolite shunting 
There have been different hypotheses on possible biomarkers to identify 
azathioprine metabolic shunting. This section briefly outlines the pathways for 
consideration for pharmacometric testing in this thesis. 
1. TPMT pathway 
As per the metabolic pathway (Figure 1.12) it seems plausible that TPMT 
should play a role in the metabolite shunting. To this end some researchers have 
hypothesised that hyperactivity of TPMT might cause an elevation of 6-MMP 
and subsequent depletion of 6-TGN.65, 84, 85 However, others cast doubt on the 
role of TPMT activity as the primary reason for the preferential 6-MMP 
production.80, 86, 87 
2. HGPRT or IMPDH or GMPS pathways 
Other enzymes in the metabolic pathway towards the production of 6-TGN 
include HGPRT, inosine monophosphate dehydrogenase (IMPDH) and 
guanosine monophosphate synthetase (GMPS). Impaired activity of these 
enzymes, either individually or in combination, has also been hypothesised or 
reported (from genotyping studies) to increase the ratio of 6-MMP/6-TGN.88-90  
3. ITPase 
In the process of azathioprine metabolism, 6-TIMP (6-thioinosine 
monophosphate) is further phosphorylated to 6-thioinosine diphosphate (6-
TIDP) then to 6-thioinosine triphosphate (6-TITP), where ITPase converts 6-TITP 
to 6-TIMP (see Figure 1.14). 
In this regard Beaumais et al. noted high 6-MMP concentrations in patients 
with wild type TPMT and variant ITPase genotypes91, and concluded that this 
information could be used to predict hepatotoxicity. 
However, wild-type TPMT and variant ITPase may favour high 
concentrations of 6-TIMP since this metabolite is equally available for TPMT and 
HGPRT and therefore the high 6-MMP/6-TGN ratio would not result unless the 




activities of other enzymes are also varied. In support of this logical argument, 
Zelinkova et al. reported that genotypes of neither TPMT nor ITPase predicted 
hepatotoxicity.75 Although, as per these publications, the impact of altered 
ITPase activity on shunting seems unlikely, it is still tested in this thesis. 
1.2.5.4. Need for a QSP model to understand the mechanism of shunting 
It has been known that use of azathioprine can produce three therapeutic 
outcomes, i.e. (i) therapeutic benefit, (ii) bone marrow toxicity and (iii) 
therapeutic failure due to (a) dosing too low and (b) metabolite shunting that 
may potentially lead to hepatotoxicity upon dose escalation. Azathioprine 
metabolism with respect to metabolite shunting is at this stage unpredictable. 
Therefore, it is important to identify the target enzyme(s) and understand 
the impact of enzyme variability on the concentrations of 6-TGN and 6-MMP. In 
this context, some of the important questions that could be handled by 
pharmacometrics are: 
- Can a mathematical model of azathioprine metabolism accurately 
predict metabolite concentrations, and therefore efficacy and toxicity? 
- Can the model inform which of the enzymes in the pathway would be 
the most helpful to investigate in the various atypical patient scenarios? 
- Can the modelled pathway be used to help optimise dosing of 
azathioprine? 
As per the discussion in section 1.2.1, a systems based model is anticipated 
to be helpful in this regard.  
1.2.5.5. A QSP model for azathioprine 
In this setting the QSP model for azathioprine represents PK only.  
The next chapter discusses the development of a systems based 
mathematical model for azathioprine metabolism. This approach is intended to 
test what-if scenarios generated from the hypotheses on metabolite shunting that 
















































































Azathioprine is an immunomodulatory purine analogue widely used to 
treat patients with inflammatory bowel disease (IBD). The parent drug is inactive 
but undergoes a series of metabolic reactions to form two primary active 
metabolites; 6-thioguanine nucleotides (6-TGN) and 6-methyl mercaptopurine 
(6-MMP).92 93 The metabolism of azathioprine is predominantly intracellular and 
involves a complex series of metabolic reactions and a number of different 
pathways. Many of the enzymatic reactions involved in the intracellular 
metabolism of azathioprine are shared with the endogenous purine salvage 
pathway. 
The active metabolite of azathioprine, 6-TGN, is primarily associated with 
clinical response in IBD patients. A target concentration range for 6-TGN of 250 
– 450 pmol/8x108 in red blood cells (RBCs) is generally accepted to increase the 
probability of treatment success while minimising the risk of toxicity.64 
Concentrations of 6-MMP >5700 pmol/8×108 RBCs are associated with liver 
toxicity.65  
The optimal dose of azathioprine for each patient is difficult to predict at 
the initiation of therapy. About 30% of patients produce excessive 6-TGN 
concentrations that will lead to bone marrow toxicity. An inherited genetic 
variability in the enzyme thiopurine methyl transferase (TPMT) has been found 
to predict 6-TGN concentrations and influence dose requirements in these 
patients. Other patients (approximately 40%) have been found to produce sub-
therapeutic 6-TGN concentrations under normal dosing that does not improve 
with dose escalation. Some of these patients also produce excessive 
concentrations of 6-MMP and are at increased risk the hepatotoxicity. These 
patients are often referred to as ‘shunters’.  
Azathioprine metabolism is complex, involving several enzyme systems 
and multiple pathways. This means that the mechanisms responsible for the 
observed atypical clinical scenarios, such as ‘shunters’, can be difficult to predict 
and are not intuitive. In this setting, in vitro experiments to explore the impact of 
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altered enzyme activity or expression on 6-TGN and 6-MMP concentrations 
would be a slow trial and error process Therefore a QSP type modelling 
framework was adapted which will enable the exploration of different 
mechanisms that might explain the clinical observations and generate 
hypothesis about how to predict these altered phenotypes in clinical practice. 
Ultimately this might allow to predict efficacy or toxicity (and dosing). It is to be 
noted that, although the model does not include any interaction with biology, or 
does not represent pharmacological mechanisms, an approach similar to a QSP 
model development was used. Therefore the terms QSP and ‘systems-based 
model’ will be used interchangeably. 
The present chapter describes the development of a mathematical model 
for azathioprine metabolism by drawing on current knowledge about the 
salvage pathways for purine metabolism. The model will be used to simulate 6-
TGN and 6-MMP concentrations observed in practice as a means of optimising 
the dose of azathioprine. 
2.2. Model scope, aims and objectives 
Model scope: The systems-based model developed in this work is intended 
to understand the metabolic fate of azathioprine. The model will include all 
known azathioprine metabolic pathways, in both the extra- and intra-cellular 
space. There will be a particular focus on two active metabolites, 6-TGN and 6-
MMP.  
Aims and objective: The overarching aim is to predict azathioprine response 
across different clinical scenarios to predict dose requirements and improve 
outcomes for patients with inflammatory bowel disease.  
The specific objectives of this chapter are: 
1. to collate and archive known pathways involved in the metabolic fate 
of  azathioprine  
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2. to develop a systems-based model for the kinetics of azathioprine 
metabolism, including all known extra-cellular and intra-cellular 
metabolic pathways  
3. to assess the ability of the model to predict the concentrations of 6-TGN 
and 6-MMP, under three  scenarios encountered in the clinic, including: 
i) typical (normal) azathioprine metabolism, ii) patients with reduced 
enzyme function, specifically TPMT, and, iii) so-called “shunters” who 
produce an unusual metabolite profile characterised by elevated 
concentrations of 6-MMP relative to 6-TGN.  
2.3. Methods 
2.3.1. Collating the biochemical pathways involved in azathioprine 
metabolism 
The metabolic fate of azathioprine occurs in both the extra- and intra-
cellular space. While the extracellular metabolism will be explored the focus of 
this chapter will be the intra-cellular pathways since both 6-TGN and 6-MMP are 
measured intra-cellularly in the clinic (in red blood cells (RBCs)).  
2.3.1.1. Assumptions 
The assumptions underpinning this work are that: 
1. the intracellular pathway reflects a generic blood cell where the 
metabolites interfere with DNA synthesis, 
2. the extracellular pathways include metabolism at any site outside of a 
blood cell including the intestinal lumen, enterocytes, plasma, and 
hepatocytes, 
3. the published experimental reports that describe thiopurine and purine 
metabolic pathways are sufficient to summarise the metabolic fate of 
azathioprine. 
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2.3.1.2. Literature search 
A literature search was conducted in:  
(i) MEDLINE (Ovid MEDLINE(R) 1946-May 2017) using  
a. keywords, such as “azathioprine metabolism”, “purine salvage 
pathway”, “glutathione transferase”, “thiopurine methyl 
transferase”, “hepatotoxicity in azathioprine therapy”, 
“quantitative analysis of azathioprine metabolites”, etc., and  
b. based on the results from keywords search, MeSH terms, such as 
“xanthine oxidase”, “aldehyde dehydrogenase”, “xanthine 
dehydrogenase”, “hypoxanthine guanosine phosphoribosyl 
transferase”, “nucleotidase”, “nucleoside kinase”, “purine 
nucleotide phosphorylase”, “nucleoside monophosphate 
kinase”, “nucleoside diphosphate kinase”, “inosine tri 
phosphatase”, “inosine mono phosphate dehydrogenase”, 
“guanosine mono phosphate synthetase”, “guanosine 
monophosphate reductase”, “NUDT15”, “guanase” “solute 
carrier proteins”, “ATP Binding Cassette Transporters”, “6-
thioxanthine”, “6-thioinosine triphosphate”, “6-methyl 
thioinosine triphosphate”, “6-methyl mercaptopurine riboside” 
“6-TdGTP”, ”6-thioguanosine triphosphate”, “6-TGR” and“6-
TG” were used to get the literature for more details. 
(ii) Google Scholar (1947-May 2017) with the text words that were used 
in MEDLINE search.  
The search focused on papers concerned with purine and azathioprine 
metabolism, many of which are published in the biochemical and physiological 
literature. Therefore, a formal systematic search, such as that recommended by 
the PRISMA guidelines94) was not conducted. A citation search was also 
conducted using seminal papers on azathioprine metabolism, including 92, 95-101. 
Finally, key review papers, clinical summaries, and biochemical research reports 
were mined for additional studies.  
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Inclusion/ exclusion criteria:  
Published literature concerned with purine and thiopurine metabolism 
were included (this included research publications, text books, thesis archives 
and conference abstracts). Any items published in a language other than English 
were excluded.  
2.3.1.3. Searching on-line repositories 
There are several on-line repositories of biochemical, pharmacological and 
pharmacogenetic data. They provide publicly accessible information on 
metabolic pathways, cell signalling pathways and gene regulatory networks. 
The following on-line repositories were accessed and mined for relevant data on 
azathioprine and purine metabolism: 
(i) PharmGKB - https://www.pharmgkb.org/pathway/PA2040.102 




2.3.1.4. Canvassing expert opinion 
Expert opinion was sought in cases where the information available in the 
published literature or from on-line repositories was unclear or contradictory. In 
addition, expert opinion provided reassurance that the information collected 
was complete with respect to current knowledge. 
Opinions were sought from the following established researchers in purine 
metabolism: 
1. Dr Caroline Thorn, Scientific Curator, Stanford University School of 
Medicine104  
2. Professor Matthias Shwab, Chair of Clinical Pharmacology, Head of 
the Dr Margarete Fischer-Bosch Institute of Clinical Pharmacology, 
University Hospital, Tübingen, Germany105 
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3. Professor Lizbeth Hedstrom, Departments of Biology and Chemistry, 
Brandeis University, Waltham, MA, USA106 
4. Dr William Parker, Founding Scientist, PNP Therapeutics, 
Birmingham, Alabama, USA107 
5. Dr John Duley, Senior Research Fellow, School of Pharmacy, The 
University of Queensland, Australia108  
2.3.1.5. Data collection and extraction 
The following types of data were extracted from the information sources: 
1. azathioprine extracellular and intracellular metabolic products  
2. purine metabolic products in the purine salvage pathway (see 
justification below) 
3. enzymes involved in the formation of azathioprine or purine metabolic 
products 
4. mass transfer information for azathioprine, including absorption from 
the gut, and transport into and out of cells.  
5. enzyme and transporter kinetic data (e.g. 𝑉𝑚 𝑥  and 𝐾𝑀  values that 
reported in the in vitro experiments)  
The data collection followed an iterative and pragmatic search strategy 
including the following steps for extracellular and intracellular pathways. 
a. Extracellular pathway 
Collection of the data for the extracellular pathway was done in two stages: 
(i) Azathioprine extracellular mass transfer and metabolism:  
The search focused on information about the absorption kinetics of 
azathioprine, its conversion to 6-mercaptopurine, and other metabolic 
products in the extra-cellular space following the oral administration.  
(ii) Azathioprine extracellular enzyme and transporter kinetics:  
Chapter 2: Development of a QSP model for azathioprine metabolism 
47  
 
Based on the search results of stage (i) above, a second search was 
performed to gather information on the enzymes (e.g. glutathione 
transferase and xanthine oxidase), transporters (e.g. SLC (SoLute Carrier) 
and ABC (ATP binding carrier)), genetic  variants, and kinetic parameter 
values (i.e. 𝑉𝑚 𝑥 and 𝐾𝑀)  in the pathway. 
b. Intracellular pathway: 
Information gathered for the intracellular pathway was done in three 
stages: 
(i) Identification of endogenous purine metabolic products: 
 While the QSP model developed here is not intended to describe 
endogenous purine metabolism, azathioprine and its metabolite 6-MP are 
both purine analogues and therefore expected to share many enzymatic 
reactions with endogenous purines. Hence the information on purine 
metabolism was collected. 
(ii) Endogenous purine metabolising enzymes and their kinetics: 
Endogenous purines undergo a complex series of metabolic 
conversions to form nucleotides via a salvage pathway. A detailed search 
was performed to find studies that authenticate and describe the enzymes 
involved in the purine salvage pathway. This was intend to link any 
missing information in azathioprine metabolism. 
(iii) Pathways that are specific for azathioprine metabolism : 
A search was conducted to identify the mechanisms believed to be 
involved in the elimination of azathioprine metabolites from the 
intracellular pathway. This also included studies or reports of analytical 
methods109, 110 that confirmed the presence of azathioprine’s metabolites 
in patients, where no other in vitro studies have reported them.  
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Evidence to support the correctness of the pathways: 
Before extracting relevant data, the correctness of the information about the 
pathways was evaluated against three types of evidence: 
I. Direct evidence supporting the enzyme kinetics:  
This would include experimental evidence, such as in vitro data that 
supports the existence of various components in the azathioprine metabolic 
pathway. For example, reports based on in vitro data confirming the role of 
TPMT and its activity in the conversion of 6-thioinosine monophosphate 
(6-TIMP) to 6-methyl thioinosine monophosphate (6-MeTIMP) in 
intracellular pathway. 
II. Indirect evidence supporting the enzyme kinetics:  
This would include experimental evidence that indirectly supports 
the existence of various components in azathioprine metabolic pathway. 
For instance, there is no experimental data to support the role of guanosine 
monophosphate synthetase (GMPS) in the conversion of 6-thioxanthine 
monophosphate (6-TXMP) to 6-thioguanine monophosphate (6-TGMP). 
However, there are some quantification assays that reported the formation 
of 6-TGMP109, 111-113, and in vitro experiments that informed the role of 
GMPS in the conversion of xanthine monophosphate, a structurally similar 
molecule to TXMP, to guanosine monophosphate, a structural analogue of 
TGMP (i.e. XMP
𝐺𝑀𝑃𝑆
→   GMP) 114. This information was considered to be 
indirect evidence of the metabolic step (i.e. 6-TXMP
𝐺𝑀𝑃𝑆
→   6-TGMP) in the 
azathioprine pathway. 
III. Refinement of the model structure based on biological plausibility:  
Some published reports included steps in the pathway which raised 
concerns about biological or biochemical plausibility. Such steps were 
excluded based on the supporting evidences.  
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2.3.1.6. Archiving the metabolic pathways 
 All extracted data was stored and archived in a spreadsheet including: 
1. Enzymatic biochemical reactions 
2. Elimination steps  
3. Transporters 
a. Efflux 
b. Carrier mediated  
4. Additional information related to  
a. Mass transfer 
b. PK parameter values for enzyme and transporter activities 
5. Relevant references/citations  
This database was reviewed by Dr John Duley, an expert in purine 
biochemistry. 
2.3.2. Development of systems-based model for azathioprine metabolism 
2.3.2.1. Visualisation of the azathioprine metabolism  
The structure of the model was represented using a flow diagram based on 
the information extracted from the literature and relevant on-line resources. Each 
box corresponded to a state (also called node) in the systems model, in all cases 
a metabolic product. The lines connecting the states (also called edges) 
represented either mass transfer or metabolic conversion by an enzyme.   
A previously published simple schematic that showed the three major 
metabolic pathways (mediated by TPMT, Xanthine oxidase and HGPRT) of 
azathioprine67 was taken as a skeleton (see Figure 2.1) and expanded with the 
additional components of the database. The schematic (Figure 2.3) was drawn in 
Microsoft Visio®2016.  
Chapter 2: Development of a QSP model for azathioprine metabolism 
 50 
 










Figure 2.1 A simple schematic of azathioprine metabolism.67 (6-MP: 6-
mercaptopurine, 6-meMP: 6-methyl mercaptopurine, 6-TIMP: 6-thioinosine 
monophosphate, 6-TUA: 6-thiouric acid, 6-meTIMP: 6-methyl thioinosine 
monophosphate, 6-TXMP: 6-thioxanthine monophosphate, 6-TGMP: 6-
thiguanine monophosphate, 6-meTGMP: 6-methyl thioguanine 
monophosphate, 6-TGN: 6-thioguanine nucleotides, TPMT: thiopurine 
methyl transferase, HGPRT: hypoxanthine guanine phosphoribosyl 
transferase, IMPDH: inosine monophosphate dehydrogenase, GMPS: 
guanosine monophosphate synthetase) 
2.3.2.2. The mathematical components of the model 
A mathematical model representing mass transfer was written as a series 
of ordinary differential equations (ODEs) in MATLAB (R2017a, Math Works 
Inc). A Runge-Kutta stiff ODE solving method (ODE15s) was used to solve the 
differential equations. The equations are based on the data for mass balance (for 
the extracellular pathway) and metabolic conversion (for the intracellular 
pathway). It was noted that little is known about mass balance inside of the cells. 
The model was written in terms of equilibrium dynamics where it was assumed 
that the rates of the metabolic reactions were more rapid than the half-lives of 
the various species, which means that the enzymatic processes themselves were 
not rate limiting.  
Since this work is concerned with the metabolic fate of azathioprine and 6-
mercaptopurine, initial concentrations of the metabolites were set at zero. The 
rate processes across the ODEs were specified by three types of 
parameterisations, as follows (note that selection of the values for these 
parameter is mentioned in the next section): 
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(i) Absorption of azathioprine, its metabolism to 6-mercaptopurine, 
transportation of 6-mercaptoprine into the blood cell and elimination of 
some metabolites were specified with time invariant first order rate 
constants (𝑘).  
(ii) Elimination of azathioprine and 6-mercpatopurine was 
parameterised using a rate constant 𝑘 calculated from 𝐶𝐿 and 𝑉. 
(iii) In other cases, for enzyme kinetics and efflux transport, time 
varying reaction rate constants ( 𝑘(𝑡) ) based on the Michaelis-Menten 





where 𝑉𝑚 𝑥 denotes the maximum activity of the enzyme which is a 
function of the amount of enzyme, 𝐾𝑀 is the equilibrium constant, which is 
equivalent to the concentration of substrate that provides a rate that is 50% 
of maximal velocity and 𝐴 is the quantity of the substrate.  
The matrix form of ODEs describing production and loss of the substrates 
is therefore denoted as, 
𝑑𝐴
𝑑𝑡
 𝑀 · 𝐴;   𝐴(𝑡0)  𝐴0 
Where, 𝐴 is the column matrix of quantities of all the metabolites, 𝑀 is the 
matrix of mass transfer rate constants, for instance in case of 𝑁 metabolites  









































Here, the diagonal elements represent the sum of output (or elimination) 
rate constants and the off diagonal elements represent the input rate constants 
of the respective row. Note that 𝑘𝑥𝑦 (𝑥  𝑦 𝑜𝑟 𝑥 ≠ 𝑦) is either time invariant or 
variant rate constant. 
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2.3.2.3. Model scaling and refinement 
Many first order rate constants were not available in the literature, so they 
were assigned to either multiples of 1, or a value computed based on the known 
half-life (𝑡1/2) of the metabolite. Here, it is to be noted that ‘the multiples of 1’ 
means the factors that obtained by multiplying the default number 1 by factors 
from positive real numbers (ℝ+). The values of 𝐶𝐿 and 𝑉 for both azathioprine 
and 6-mercaptopurine were obtained as weighted averages of the values pooled 
from published studies. In the case of enzyme kinetics, even though the 
Michaelis-Menten parameters (maximum velocities (𝑉𝑚 𝑥 ) and the Michaelis-
Menten constants (𝐾𝑀)) for some enzyme activities were available in published 
reports, they were not in suitable units (e.g. the unit quantity of the respective 
enzyme). Therefore, the values of 𝑉𝑚 𝑥 and 𝐾𝑀 were scaled to multiples of 1 and 
5 respectively.  
Setting the mass balance values for extracellular metabolism: 
The oral absorption and metabolic conversion of azathioprine and 6-
mercaptopurine in plasma have been well documented. These are presented 
schematically in Figure 2.2. In the QSP model, the extracellular mass balance for 
azathioprine, 6-mercaptopurine and their metabolites was based on literature 
values for the metabolic fate of azathioprine. It is to be noted that the dotted red 
lines are just to show mass transfer across different components of the body. 
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Figure 2.2 Mass balance for azathioprine (AZA) absorption and its 
conversion to 6-mercaptopurine (6-MP) 
Intracellular pathway: 
It was not possible to determine mass-balance for the intracellular 
pathways associated with azathioprine metabolism since the fraction of 6-MP in 
plasma that is transported into RBCs by the solute carrier (SLC) is not known. 
The model included the clinically important 6-MMP and 6-TGN along with the 
intermediate metabolites that lead to these two metabolites, and 6-TUA. 
Originally 6-MMP and 6-TGN are composites of several compounds. 
Conventionally these composites are reported in the clinic, instead of individual 
metabolites. This is because the established analytical methods hydrolyse the 
target nucleotide analogues of the corresponding metabolites. In the schematic 
of azathioprine QSP model, the individual metabolites rather than the 
composites were included in order to reflect the complete biochemical pathway. 
Therefore the QSP model simulates the individual components in the pathway, 
and these are collated post-hoc to create the composite entities for comparison 
with clinical measurements. 
2.3.2.4. Calibration of the model predictions to reference targets 
The calibration of the model prediction was done in 2 steps:  
(1) Adjusting the parameter values for intracellular components: 
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The parameter values were calibrated by comparing the model predictions 
for 6-TGN and 6-MMP concentrations in typical clinical scenarios collected as 
part of usual treatment for inflammatory bowel disease in 51 patients in 
Christchurch, New Zealand. Model predictions for 4 weeks were simulated with 
100 mg doses and compared with observations that normalised to azathioprine 
dose of 100mg.  
(2) Calibration of the model using intra and extracellular components: 
The model was then further calibrated by comparing the predicted 
concentrations of azathioprine, 6-MP and 6-thiouric acid (for extracellular 
pathway), and 6-TGN and 6-MMP to published data.115-122 and 123 Concentration 
data were digitally extracted from graphs in instances where the data was not 
provided in the papers. 
For the calibration, a heuristic sensitivity analysis was conducted. When 
the model predictions of the moiety of interest (e.g. 6-TGN or 6-MMP) were 
unaffected by the value of a particular parameter then the parameter was set to 
unity. Otherwise, if the model predictions were sensitive to the choice of 
parameter values then the parameters were set to the values where the model 
predictions for extracellular and intracellular concentrations agreed with the 
available data.  
Finally, simulations from the full model were conducted to illustrate the 
concentration-time profiles for azathioprine, 6-MP, and their extracellular and 
intracellular metabolites after a single dose and for multiple dosing over 8 weeks 
of therapy. Simulations were performed for a typical subject weighing 70 kg 
following to once a day azathioprine given at an oral dose of 2.68 mg/kg. Note 
that reference concentrations of 6-TGN and 6-MMP for some of the clinical 
scenarios used in this work are reported from 6-MP dosing studies. In such 
instances azathioprine doses are computed using a conversion factor (i.e. 1 mg 
of 6-MP is equivalent to 2.08 mg of azathioprine).113, 124 All extracellular 
concentrations are predicted in units of mg/mL. Considering the number of 
RBCs per unit volume of blood (i.e. 0.2ml of blood contains 8x108 RBCs), 
intracellular concentrations were converted to pmols/8x108 RBCs. 
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2.3.3. Evaluation of the model predictive performance  
The model was used to simulate values of metabolite concentrations in red 
blood cells (RBC) (units: pmols/8x108 RBCs) under three different clinical 
scenarios.  
1. Typical scenario: represents patients who produce concentrations of 6-
TGN and 6-MMP within the expected concentration ranges under usual 
dosing (2.68 mg/kg once daily).  
2. Atypical1 scenario:  represents patients who produce excessive 6-TGN 
concentrations. 
3. Atypical2 scenario: represents patients who produce sub therapeutic 
concentrations of 6-TGN and excessive 6-MMP. Also called ‘shunters’.  
Simulation of typical scenario: 
For the typical scenario concentrations for 6-TGN and 6-MMP were 
simulated using the calibrated model parameters and compared to the mean 
concentrations of 6-TGN and 6-MMP in RBCs reported in the literature. 
Simulation of atypical1 scenario: 
The mechanism underpinning atypical1 scenario is well established. 
Increased 6-TGN concentrations have been shown to be associated with reduced 
TPMT activity caused by genetic variants. Therefore the excessive 6-TGN 
concentrations were obtained by down-regulation of TPMT activity, i.e. 
reducing 𝑉𝑚 𝑥 values to a third of the activity in typical scenario.  
Simulation of atypical2 scenario (‘shunters’): 
The mechanism responsible for atypical2 scenario is not well understood.  It 
was therefore assumed that:  
i. the unknown mechanism for excessive 6-methyl mercaptopurine (6-
MMP) (the factor that has been reported to be responsible for 
azathioprine mediated hepatotoxicity) is due to abnormal activity of the 
enzymes in the pathway,  
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ii. the abnormal activities can be simulated by upregulating or down 
regulating enzyme(s) involved the metabolic pathway and 
iii. the knowledge underpinning azathioprine metabolic pathway is 
sufficient to test the hypotheses on abnormal activity of the enzymes for 
metabolite shunting.  
Atypical2 scenario patients (shunters) were simulated by down or up-
regulation of hypoxanthine guanosine phosphoribosyl transferase (HGPRT) or 
inosine mono phosphate dehydrogenase (IMPDH) and/or guanosine mono 
phosphate synthase activities (GMPS). The down or up-regulation of the activity 
of the proposed enzymes was done by multiplying the 𝑉𝑚 𝑥 values of typical 
scenario by a factor ranging from 0.01 to 1 (for down-regulation) or 5-50 times 
(for up-regulation). It was expected that this approach would provide 
suggestions for the underlying mechanism in metabolite shunting.  
2.4. Results 
2.4.1. Collating the biochemical pathways involved in azathioprine 
metabolism 
A total of 55 articles were found to be informative for data extraction. 
Extracted data from these papers were archived in a database (presented in 
Appendix 2). It is hoped that the archive will be a useful resource for future 
researchers who may want to replicate or expand the final model. Note that the 
numbers assigned in the archive (as unique ID) identifies unique metabolism, 
transport or elimination mechanism but does not indicate the sequence of the 
steps in the pathway.   
While collating the pathways it was noted that some of the literature has 
provided implausible metabolic reactions. Existence of these reactions was ruled 
out considering experimental evidence and/or expert opinion on the enzyme 
kinetics that deemed to involve. For instance, information on two following 
pathways in the metabolism of azathioprine was contradictory.  
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(i) Bostrom et al.125 published a schematic that showed the conversion 
of 6-MMP to 6-methyl mercaptopurine monophosphate (6-
MeMPMP) mediated by hypoxanthine guanine phosphoribosyl 
transferase (HGPRT) (i.e. 6-MMP
𝐻𝐺𝑃𝑅𝑇
→    6-MeMMP). But Krenitsky et 
al. suggested that 6-MeTIMP binds poorly to HGPRT, with a high 𝐾𝑖 
value, and the existence of a methyl group on 6-MeTIMP that will 
hinder the binding97. and 
(ii) Bostrom et al.125 also reported the metabolic conversion of 6-
MeMPMP to 6-methyl thioguanine monophosphate (6-MeTGMP) 
by purine nucleoside phosphorylase (PNP) (6-MeMPMP
𝑃𝑁𝑃
→  6-
MeTGMP). Ignoring the biological plausibility, according to the 
endogenous pathway this step should ideally involve two steps, i.e. 
6-methyl thioinosine monophosphate (6-MeTIMP)
𝐼𝑀𝑃𝐷𝐻
→    6-methyl 
thioxanthine monophosphate (6-MeTXMP) and 6-MeTXMP
𝐺𝑀𝑃𝑆
→   6-
MeTGMP. But these enzymatic reactions are considered to be 
implausible in the pathway. As per Hedstrom,126 the thiomethyl 
group (-S-CH3) on 6-MeTIMP would not allow it to bind with 
IMPDH. Therefore, it was deemed to be unlikely that these steps 
were important for azathioprine metabolism. 
Therefore, in the mechanism perspective, these pathways are not included, 
and will not be considered for any modifications, in the model building process.  
2.4.1.1. Results for archiving the metabolic pathway 
The pathway was identified to have 30 compartments (i.e. nodes) that 
connected by 60 edges, where 42 edges are for enzymatic metabolism, 12 edges 
are for elimination, 5 edges are for transportation (3 efflux and 2 carrier 
mediated), and one edge is for absorption of azathioprine. There are 18 enzymes 
that found to involve in the 42 metabolic reactions.  
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2.4.2. Development of systems-based model for azathioprine metabolism 
2.4.2.1. Visualisation of the azathioprine metabolism  
The schematic for the metabolic pathway included 30 states reflecting the 
substrates and metabolites, and these states are connected by 60 unidirectional 
arrows indicating the respective enzymes or transporters (see Figure 2.3). The 
entire pathway was divided between intracellular and extracellular pathways 
(separated by a dotted red line). Overall, there are two sets of sampling 
compartments inside the cell that include the composite of 6-MMP 








































































































































































Figure 2.3 Schematic for azathioprine metabolism drawn based on the 
archived data 
2.4.2.2. Mathematical components of the model 
The mathematical model comprised of 30 ODEs each describing the 
formation of a metabolic product, or mass transfer between locations. 
Extracellular concentrations depicted metabolites in plasma whereas 
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intracellular concentrations represent a generic blood cell. Michaelis-Menten 
type equations with maximum kinetic velocities are used for enzymatic 
reactions. A full set of equations and parameter values are provided in 
Appendix-2.  
The bioavailability of azathioprine is reported to range from 27%—83%.127, 
128 Therefore a mean value of azathioprine bioavailability of 54% was used. This 
value is close to the reported value from a radio-labelled study.100 Once 
azathioprine is absorbed it is rapidly converted to 6-MP and S-methyl-4-nitro-5-
thioimidazole. It is reported that 12% of the oral dose of azathioprine is excreted 
in the form of S-methyl-4-nitro-5-thioimidazole.98 It is also reported that nearly 
80% of the azathioprine in plasma is converted to MP.100, 127  
The initial metabolism of 6-mercaptopurine is catalysed by xanthine 
oxidase (XO).93 XO is the enzyme responsible for the catabolism of 6-MP through 
6-thioxanthine (6-TX) to 6-thiouric acid (6-TUA). According to Elion100, 10%-20% 
of an azathioprine dose is converted to 6-TUA and 8.7% of the dose is excreted 
as 6-TUA in the 24 hour urine samples of patients treated with oral 
azathioprine.98 The value of mass transfer rate constants for 6-MP for 
extracellular to intracellular transportation and vice versa was heuristically 
adjusted in such a way that the model simulations for 6-MMP:6-TGN ratio was 
matched to that of the patient data under typical clinical scenario. In this setting 
the transport rate from intra to extracellular be 0.01% of the rate from extra to 
intracellular components. 
2.4.2.3. Calibration of the model predictions to reference targets 
The model was calibrated in such a way that predictions for the clinical 
data (Figure 2.4), and the published profiles are matched (see Figure 2.5 and 
Figure 2.6). It is noted from Figure 2.5 that the profiles of azathioprine (A) and 6-
TUA (C) concentrations were not well described by the overlay plot of the model 
on the data (no parameter estimation was performed). This is likely to be due to 
limitations on the availability of the data. However, since they relate to 
Chapter 2: Development of a QSP model for azathioprine metabolism 
 60 
 
extracellular components they have limited significance with respect to 
predicting the clinical scenarios relating to intracellular components. 
 
Figure 2.4 Model predictions for 6-TGN and 6-MMP for 100 mg of 
azathioprine dosing before and after the adjustment of parameter values 
  









Figure 2.5 Model predictions (red lines) for the extracellular 
pathway overlaid on the published profiles (dashed lines with 
observations in open circles). A. azathioprine, B. 6-mercaptopurine 




Figure 2.6 Plot showing model predictions overlaid on the median 
profiles of 6-TGN and 6-MMP from the published data 
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Model-predictions of 6-TGN and 6-MMP after 8 weeks of azathioprine once 
daily showed that the extracellular and intracellular metabolites reached the 
steady state concentrations after six weeks (see Figure 2.7 and Figure 2.8). 
 
Figure 2.7 Simulated concentration time profiles of azathioprine and its 
metabolites in the extracellular pathway




Figure 2.8 Simulated concentration (in pmol/8x108 RBCs) time profiles for intracellular pathway of azathioprine 
metabolism 
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Table 2.1 Model predictions (in pmol/8x108 RBCs) for azathioprine daily doses in different clinical scenarios 
 
                                                 
2 2.68 mg/kg/day  
3 2.5 mg/kg/day 
4 SE is not available 
5 2.5 mg/kg/day 
 
6-MMP 
(mean ± SE) 
6-TGN 
(mean ± SE) 
Typical scenario2 
Published value129 2973 ± 899 325 ± 73 
Predicted 2465 335 
 
Atypical1  scenario3 
Published value65 2683 (± ?4) 490 (± ?) 
Predicted 1235 485 
 
Atypical2 scenario5 
Published value81 10380 ± 1235 185 ± 17.7 
Predicted 3965 15 
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2.4.3. Evaluation of the model predictive performance  
For the typical scenario, the model was able to predict the central tendency 
of the observed values from publication (see Table 2.1). 
For the atypical1 scenario, when 𝑉𝑚 𝑥 values of TPMT were reduced by 3.5 
times, the model could predict 6-TGN concentrations that aligned with the 
published values but not for 6-MMP (see Table 2.1). 
In case of atypical2 scenario, the modifications of the enzymes HGPRT, 
IMPDH and GMPS did not produce model-predictions for 6-TGN and 6-MMP 
concentrations that aligned with published values (Table 2.1). The results shown 
in Table 2.1 were obtained by reducing the activity of IMPDH by a factor of 50 
times. 
Table 2.2 shows the factor change to achieve these results. 




Typical Atypical1 Atypical2 
TPMT 1 3.5 fold reduction NA 
IMPDH 1 NA 50 fold reduction 
2.5. Discussion 
In this work, a quantitative systems pharmacology model for azathioprine 
metabolism was developed. All known biochemical pathways involved in 
azathioprine metabolism were explored and archived using information from 
the published literature, on-line resources and expert opinion. The model 
included 30 ODEs representing the mass transfer and metabolism of 
azathioprine. The final model was calibrated using concentrations of the 
intracellular, 6-TGN and 6-MMP, and extracellular, i.e. azathioprine, 6-MP and 
6-TUA, metabolites. The model was used to predict three clinical scenarios 
commonly encountered in practice: typical scenario, atypical1 scenario and 
atypical2 scenario. The first scenario represented patients who produce target 
metabolites within the expected concentration ranges, the second scenario 
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represented patients who produce excessive 6-TGN concentrations, and the 
third scenario represented patients who produce sub therapeutic concentrations 
of 6-TGN and excessive 6-MMP. As per the model evaluation the model 
predicted typical scenario, but did not predict atypical scenarios (see Table 2.1). 
Since the model was developed from the current knowledge it was expected to 
reflect system’s behaviour.  
It appears that the model failed to capture the behaviour of the system 
under all scenarios tested, suggesting a deficiency in the model. Deficiency in 
this context questions the completeness of the knowledge underpinning the 
model, in other words the developed QSP model is not reflecting the clinical data 
as some components in the metabolic pathway may be missing. This provides 
the basis for work conducted in subsequent chapters.  The problem has two 
layers: knowledge gaps could be due to incorrectness of the set of parameter 
values, or the model structure could be incomplete. Therefore, the next steps in 
this work can be divided into two projects. (1) Development of a global search 
algorithm to search for a plausible set of parameter values that predict the clinical 
scenarios, given the model structure is correct. (2) Development of a logic search 
algorithm to search for an alternative model structure, given the current mode 
structure is incorrect. Chapter 3 is dedicated for the former project the results of 
which will decide the existence of the latter project. 
There are other published models for azathioprine and 6-MP intended to 
predict the clinical data. Panetta et al. developed a model to assess the effect of 
thiopurine doses on the cell cycle.130 This model was intended to identify causes 
of drug resistance to 6- mercaptopurine based on the alterations in the cell cycle 
dynamics. Jayachandran et al. reported a semi mechanistic model to determine 
effect of 6-mercaptopurine metabolism on leucopenia131. The same authors also 
developed a Bayesian population modelling approach for dose individualisation 
of the drug.132 Lavrova et al. compared Boolean  and ordinary differential 
equation approaches to assess the effect of adenosine triphosphate on switching 
between different pathways for azathioprine metabolism.133 Ogungbenro et al. 
developed a PBPK model to explore drug interactions and understand the role 
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of genetic polymorphism in the enzymatic pathway for 6-mercaptopurine 
metabolism.134-136 Overall these publications reported either empirical or semi 
mechanistic models to understand the formation of 6-TGN with respect to 
thiopurine doses. By contrast, the QSP model developed in this work included 
all known metabolic pathways for azathioprine, and aimed to explore the altered 
enzyme activity in the biochemical pathway in order to predict 6-TGN and 6-
MMP in all clinical scenarios and investigate unknown mechanisms for 
metabolite shunting. 
The work conducted here had some important limitations.  
While the true site of action for azathioprine is being white blood cells, since 
concentrations of the metabolites cannot be measured due to analytical 
limitations, RBCs are considered as surrogate site for the measurement. An 
underpinning assumption considered here is that the concentrations of the 
metabolites between all types of blood cells is in equilibrium. This assumption 
was based on Dr Duley’s suggestion that IMPDH activity in RBCs is quite low 
(almost 1000 fold) compared to other enzymes in the pathway (i.e. HGPRT and 
GMPS) which makes it difficult to rely on RBCs to produce excessive 6-TGN 
concentrations.137, 138 As per his theory, there might be a separate input of 6-TGN 
into RBCs from other cells in which IMPDH is fully functional (for example 
neutrophils). Considering this theory, despite the data used to calibrate and 
evaluate the model was collected from RBCs the model developed here is 
assumed to represent a generic blood cells. 
The extracellular and intracellular metabolic steps and transportations is 
modelled by time varying rate constant except for the GST based metabolism of 
azathioprine to 6-mercaptopurine. As per the reports 80% of azathioprine is 
converted to 6-mercaptorine in about 5 minutes of time.113, 139-141 Therefore this 
reaction is provided by a first order time invariant rate process in the model. 
Model evaluation did not consider all the hypotheses on the role of the 
enzymes that are suspected to be responsible for atypical clinical scenarios (see 
sections 1.2.5.2 and 1.2.5.3 of chapter 1). Since heuristic evaluation of all 
hypotheses was not feasible only the plausible hypotheses were tested. 
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Considering the negative results in this chapter, all the hypotheses were tested 
in the next steps. 
This work showed a case example of how to build a QSP model utilising 
the knowledge from various sources. Further to this, as per the 6 stages described 
in chapter 1, the model was expected to address unknown mechanism for 
metabolite shunting, and advise optimum doses to achieve pre-defined 
metabolite concentrations in clinical setting. The unanticipated issues posed 
challenges that limited the clinical utility of the model. This has motivated to 
address the issues in the next stage of the work.  
2.6. Conclusions 
In this work a QSP model was constructed based the data that supports the 
metabolic pathway for azathioprine metabolism. The model was found to 
predict the typical clinical scenarios for azathioprine recommended doses. 
However, the same set of parameter values with perturbation of the enzyme 
activities could not provide atypical clinical scenarios. This suggested model 
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A QSP model for azathioprine was developed based on a meta-analysis of 
the literature and incorporation of expert opinion presented in Chapter 2. The 
model parameters were calibrated for the typical scenario based on the 
concentration vs time profiles for the components of the extracellular 
(azathioprine, 6-mercaptopurine and 6-TUA) and intracellular (6-TGN and 6-
MMP) pathways. The calibration was based on a heuristic search of the 
parameter values for the activities of enzymes that were otherwise considered 
not known. Further adjustment of some enzyme pathways was conducted to 
attempt to describe two atypical scenarios. It was expected that the model, with 
30 states, would be capable of describing the metabolite concentrations for all 
three clinical scenarios within the perturbations of parameter values of some of 
the enzyme activities based on existing hypotheses. 
The results from chapter-2 noted, however, that while the developed QSP 
model for azathioprine metabolism was able to predict the typical concentrations 
of both 6-TGN and 6-MMP it was not able to predict the profiles for the atypical 
scenarios (see Table 3.1). Atypical1 shows significant accumulation of the 
metabolite 6-TGN and atypical2 shows a shunting towards 6-MMP production. 
As per the stage-4 of the six-stage work flow of the QSP model 
development framework described in chapter-1 the model should be able to 
capture the behaviours of the system under different scenarios. In this context, 
since the model is deficient, it appears that knowledge underpinning the model 
misses some essential information. Exploration of the knowledge gaps over the 
metabolic pathways is an essential next step to achieve the remaining goals, i.e. 
to produce a model that describes all clinical scenarios that could then be 
reduced and used to aid clinical care. In the azathioprine case a deficient model 
could arise because (i) the structure is correct but possesses incorrect parameter 
values or (ii) the structure is incorrect. Therefore a method to assess model 
completeness under the current structure is warranted.
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6-MMP 6-TGN  
Published 
(mean ± SE) 
Predicted 
Published 
(mean ± SE) 
Predicted 
Typical scenario129 2973 ± 899 2465 325 ± 73 335 
 
Atypical1 scenario65 2683 (± ?*) 1235 490 (± ?*) 485 
 
Atypical2 scenario81 10380 ± 1235 3965 185 ± 17.7 15 
*SE is not available    
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In this thesis, model deficiency due to knowledge gaps is considered part 
of an overarching concept termed model completeness.  Here a model is considered 
complete if there exists a set of parameter values for a specific model structure 
that provides a desired output for a given set of inputs. The current azathioprine 
model appears to be deficient on the basis that it is not able to replicate the input-
output relationships across the three desired clinical settings. However it 
remains unknown whether the replicability issue is due to the set of parameter 
values considered or the structure of the model. If it is the former then the model 
is complete just not correctly specified if it is the latter then this would signify 
that the model is incomplete.  
To address model completeness a typical model is defined based on structure 
and flux. The structure is a schematic representation of a mathematical model 
that is defined by nodes and edges, and flux represents rate of mass transfer 
along edges in the system. The latter is defined by the rate of movement of a 
molecule from one state to another. For instance in Figure 3.1 a 5-compartment 
model is depicted. It has 5 nodes and each node is connected with every other 
node by an edge (note this hypothetical model is further explored in Chapter 4). 
The flux from node 1 to 2 is represented by 𝐽12 which given it is a first-order 
process is mathematically provided by the product of the rate constant (𝑘12) and 
the amount in state-1 (𝐴1) (see Equation 3.1). 
  





























Figure 3.1 Schematic of a 5-state model. Each state is a node and the 
arrows connecting the nodes are edges. 𝑱𝒙𝒚 stands for the flux that represents 
the rate of mass transfer, from node 𝒙 to 𝒚, which is the product of rate 
constant 𝒌𝒙𝒚 and the amount in state 𝒙 (𝑨𝒙). 
𝐽12  𝑘12 · 𝐴1 
Equation 3.1 Flux from node 1 to 2 given by the product of rate constant 
and the amount in state-1. 
Under this definition it is apparent that an extremum complete model 
would have an infinite number of nodes and edges in order to define a set of flux 
values that solve for (any) input-output relationships. The above 5-state model, 
if the number of nodes is sufficient, is by definition complete on edges since 
every node is connected to every other node.  In this circumstance it is a matter 
of defining the parameter set. In circumstances where every node is not 
connected to every other node (as in the azathioprine example) then it is 
necessary to first evaluate the model for completeness based on defining the 
existence of a set of fluxes that solve for the desired input-output relationships. 
If this fails then the structure (i.e. number of edges or nodes) must be considered. 
In this work the nodes represent substrates and products in the system. The 
number and types of nodes are therefore physical quantities that can be defined 
or measured biochemically. It is assumed, for this current work, that the number 
of nodes is a complete description of the quantities of interest and consideration 
for the presence of additional nodes is not considered here.  
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Considering the concept of model completeness it is required to determine 
whether the model is complete but the fluxes are incorrect (i.e. that  a set of fluxes 
that solve for the system exist) or that the model is incomplete (i.e. a set of fluxes 
that solve for the system do not exist). This setting provides the hypothesis that 
the model could predict the target metabolite concentrations for all three clinical 
scenarios by revising the values of the rate constants and their perturbations.  
It is important to note that model completeness in this work has no 
relationship to the term model complete theory which is a domain of mathematical 
logic.  
This chapter focusses on completeness of the developed azathioprine 
model using a global search algorithm to find the possible parameter values of 
activities of enzymes, and their perturbations, and transporters that can predict 
all three (typical and atypical) clinical scenarios. Since this work considers only 
the existence of a set of parameter values, and their perturbations, to replicate 
the three scenarios then the issue of identifiability is not relevant. The parameter 
solutions are expected to provide an understanding over the missing knowledge 
of enzymes and their abnormal activity responsible for the atypical scenarios that 
would allow further investigation of these atypical enzyme targets.  
3.2. Aims 
The overarching aim of this work was to assess completeness of the current 
structure of the systems model for azathioprine metabolism. 
The specific aims were  
1. to implement a global search algorithm to search across 
multidimensional parameter space and 
2. to assess for the existence of a set of parameter values that can predict 
typical and atypical clinical scenarios. 
  




All algorithms were developed using MATLAB (R2017a, Math Works 
Inc.).6  
3.3.1. Defining the model in node and edge format: 
The developed azathioprine model consists of 30 nodes and 60 edges 
(representing absorption, metabolism, transportation and elimination steps). 
The rates of mass transfers are provided by flux (for example 𝐽12  represents 
metabolic conversion of node-1 to 2). The states shown in red are summed to 
produce the 6-MMP concentration and the states in green are summed to 



































































































Figure 3.2 Schematic for the 30-state model for azathioprine metabolism in 
the node and edge format 
                                                 
6 Electronic version of the code can be provided on request. 




The underlying assumption in this work on model completeness is that the 
current structure of the model is correct (and therefore complete), and the 
parameter values, and therefore the fluxes, are not correctly determined for all 
clinical circumstances. If this assumption holds true then a set of parameter 
values and perturbations for the typical and atypical scenarios should exist, 
respectively.  
Inherent in this work are the following specific assumptions 
1. Parameter values corresponding to intracellular enzyme activities and 
transporters were assumed to be incorrectly specified, therefore need to 
be revised. 
2. For the atypical scenarios, the scenarios could be accommodated by: (1) 
up to three enzyme activities were allowed to be down regulated and 
(2) up to five enzyme activities were allowed to be changed 
(upregulated or down regulated). These scenarios were based on 
existing hypotheses of enzyme activities. 
3. In atypical1 scenario the activities (i.e. 𝑉𝑚 𝑥 values) of TMPT, NUDT15 
and ITPase were changed (shown in red for TPMT and orange for the 
remaining in Figure 3.3). In atypical2 scenario changes were allowed in 
the activities (𝑉𝑚 𝑥  values) of TPMT, HGPRT, IMPDH, GMPS and 
ITPase (shown in red for TPMT and green for the remaining in Figure 
3.3). 
4. Enzyme function was assumed to exist within 3 orders of magnitude 
higher or lower than the current value in the model. 
3.3.3. Determining fluxes to be searched for typical and atypical scenarios 
The activities of the intracellular enzymes and transporters, and the 
enzyme perturbations that would change based on the search are shown 
schematically in Figure 3.3. 
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It was considered unlikely that the extracellular pathways, for instance 
glutathione transferase (GST), would differentially affect 6-TGN and 6-MMP and 



































































































































Figure 3.3 Schematic showing the enzymes activities and transporters 
that were searched where all the enzymes or fluxes other than in black colour 
were evaluated. The components that are shown in (i) orange are down 
regulated for the atypical1 scenario, (ii) green are up or down regulated for 
the atypical2 scenario and (iii) red are down regulated for the atypical1 
scenario and up or down regulated for atypical2 scenario. 
3.3.4. Implementation of a global search algorithm 
The parameter sets that were optimised were considered in two parts 
simultaneously, part 1 for the normal clinical setting and part 2 for the atypical 
settings. 
In part 1, a total of 44 sets of parameter values that control the activities of 
all enzymes and ABCC based efflux transporters were optimised, except for (i) 
the conversion of azathioprine to 6-mercaptopurine, and its extracellular 
conversion to 6-TUA and (ii) SLC based transporters. This represented 82 
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enzyme associated parameter values (i.e. 41 𝑉𝑚 𝑥 and 𝐾𝑀  values) and 6 
transporter associated parameter values (3 𝑉𝑚 𝑥 and 𝐾𝑀 values) to yield a total 
set of 88 parameters. 
In part 2, a total of 8 sets of parameter values that further modify activities 
of the typical clinical scenario values of the enzymes corresponding to atypical 
scenarios were optimised. This included three 𝑉𝑚 𝑥 values for atypical1 scenario 
and five 𝑉𝑚 𝑥 values for atypical2 scenario. 
The total search space was 96 parameter values. Both parts 1 and 2 were 
optimised simultaneously to assess for existence of a set of parameter values. An 
adaptive random search method was used. 
3.3.4.1. Generating possible sets of parameter values for evaluation of part 1 
(typical scenario) 
The vector of parameter values (𝜃) for 𝑉𝑚 𝑥 and 𝐾𝑀 for 44 enzyme activities 
were sampled from a left truncated normal distribution with 𝜎𝑐  1000 (at 1st 
cycle) and a mean set to 1 (i.e. 𝜇𝑐,𝑡𝑦𝑝𝑖𝑐 𝑙  1). 
𝜃 ~ 𝑁(𝜇𝑐,𝑡𝑦𝑝𝑖𝑐 𝑙, 𝜎𝑐,𝑡𝑦𝑝𝑖𝑐 𝑙) 𝐼(0, ) 
Where, 𝜃 is a 88 × 1 vector of parameter values, 𝜇𝑐,𝑡𝑦𝑝𝑖𝑐 𝑙 is a 88 × 1 vector 
of current best values of the parameters, 𝜎𝑐,𝑡𝑦𝑝𝑖𝑐 𝑙 is a 88 ×  1 vector of standard 
deviations set to the value of 𝜎𝑐 and assuming independence of the parameters. 
The subscript c indicates the value associated with the cth cycle of the search and 
𝐼(0, )  signifies a lower bound of truncation at zero and no upper bound 
truncation. The model was simulated, as mentioned in chapter-2, using a 
reference dose of 2.68 mg/kg/day for 8 weeks129. 
3.3.4.2. Evaluation of part 2 for atypical scenario 
In case of part 2, for atypical1 clinical scenario, the 3 down regulated factors 
(corresponding to 𝑉𝑚 𝑥 of the enzymes perturbed in this scenario) were sampled 
from a normal distribution with the initial values (at cycle 1) 𝜎𝑐=1000 and a mean 
(𝜇𝑐,𝐴𝑡𝑦𝑝𝑖𝑐 𝑙 1  1 for each of the 3 factors) representing no change to the typical 
parameter value. Each factor was transformed to a value between 0 and 1 using 
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an expit function, and these values were used as multipliers to generate enzyme 
activities (𝑉𝑚 𝑥) for atypical1 scenario. 
𝑓𝐴𝑡𝑦𝑝𝑖𝑐 𝑙 1 ~ 𝑁(𝜇𝑐,𝐴𝑡𝑦𝑝𝑖𝑐 𝑙 1, 𝜎𝑐,𝐴𝑡𝑦𝑝𝑖𝑐 𝑙 1) 
𝑀𝐴𝑡𝑦𝑝𝑖𝑐 𝑙 1  
1
1 +   𝑓𝐴𝑡𝑦𝑝𝑖𝑐𝑎𝑙−1
 
Where, 𝑓𝐴𝑡𝑦𝑝𝑖𝑐 𝑙 1  is a 3 × 1  vector of factors (in the logit domain), 
𝜇𝑐,𝐴𝑡𝑦𝑝𝑖𝑐 𝑙 1 is a 3 × 1 vector of current best factors, 𝑀𝐴𝑡𝑦𝑝𝑖𝑐 𝑙 1 is a 3 × 1 vector 
of the multiplier for atypical1 scenario and 𝜎𝑐,𝐴𝑡𝑦𝑝𝑖𝑐 𝑙 1  is a 3 ×  1  vector of 
standard deviations set to the value of 𝜎𝑐. 
Therefore, as an example, 𝑉𝑚 𝑥 of the mth enzyme (𝑉𝑚 𝑥𝑚,𝐴𝑡𝑦𝑝𝑖𝑐 𝑙 1) would 
be given by the product of the corresponding multiplier (𝑀𝑚,𝐴𝑡𝑦𝑝𝑖𝑐 𝑙 1) and 
parameter value for 𝑉𝑚 𝑥 of mth enzyme obtained in part-1 (𝜃𝑉𝑚𝑎𝑥𝑚). 
𝑉𝑚 𝑥𝑚,𝐴𝑡𝑦𝑝𝑖𝑐 𝑙 1  𝑀𝑚,𝐴𝑡𝑦𝑝𝑖𝑐 𝑙 1 · 𝜃𝑉𝑚𝑎𝑥𝑚. 
These 𝑉𝑚 𝑥𝑚,𝐴𝑡𝑝𝑦𝑐 𝑙 1  values correspond to the activities of the enzymes 
TPMT (which predominantly affects Caucasian population (~10%) than Asian 
population (3%)69), NUDT15 (which affects 90% of the Asian population vs 0.4% 
of the Caucasian population who are risked by bone marrow toxicity69) and 
ITPase for atypical1 scenario (see Figure 3.3). A dose of 1.25 mg/kg/day, as per 
the reference65, was used for these simulations. 
For atypical2 scenario, 5 sets of factors (𝑓𝐴𝑡𝑦𝑝𝑖𝑐 𝑙 2) (corresponding to the 
𝑉𝑚 𝑥 of the enzymes perturbed in this scenario) were sampled from a normal 
distribution with the initial values (at cycle 1) 𝜎𝑐=1000 and a mean (𝜇𝑐,𝐴𝑡𝑦𝑝𝑖𝑐 𝑙 2  
1 for each of the 5 factors) representing no change to the typical parameter value. 
Each factor was used as a multiplier, and multiplied against the normal value to 
create the up or down regulated enzyme activity. 
𝑓𝐴𝑡𝑦𝑝𝑖𝑐 𝑙 2 ~ 𝑁(𝜇𝑐,𝐴𝑡𝑦𝑝𝑖𝑐 𝑙 2, 𝜎𝑐,𝐴𝑡𝑦𝑝𝑖𝑐 𝑙 2)𝐼(0, ), 
𝑀𝐴𝑡𝑦𝑝𝑖𝑐 𝑙 2  𝑓𝐴𝑡𝑦𝑝𝑖𝑐 𝑙 2, 
𝑉𝑚 𝑥𝑛,𝐴𝑡𝑦𝑝𝑖𝑐 𝑙 2  𝑀𝑛,𝐴𝑡𝑦𝑝𝑖𝑐 𝑙 2 · 𝜃𝑉𝑚𝑎𝑥𝑛. 
Where, 𝑓𝐴𝑡𝑦𝑝𝑖𝑐 𝑙 2 is a 5 × 1 vector of factors, 𝜇𝑐,𝐴𝑡𝑦𝑝𝑖𝑐 𝑙 2 is a 5 × 1 vector 
of current best parameters values and 𝑀𝑛,𝐴𝑡𝑦𝑝𝑖𝑐 𝑙 2 is multiplier to generate 𝑉𝑚 𝑥 
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value for the activity of the nth enzyme (𝜃𝑉𝑚𝑎𝑥𝑛 ) for atypical2 scenario, and 
𝜎𝑐,𝐴𝑡𝑦𝑝𝑖𝑐 𝑙 2 is a 5 ×  1 vector of standard deviations set to the value of 𝜎𝑐. Note 
there is no transformation of the multiplier (𝑀𝐴𝑡𝑦𝑝𝑖𝑐 𝑙 2) for atypical2. 
These 𝑉𝑚 𝑥𝐴𝑡𝑦𝑝𝑖𝑐 𝑙 2 values correspond to the activities of the enzymes 
TPMT, HGPRT, IMPDH, GMPS and ITPase for atypical2 scenario (see Figure 
3.3). A dose of 1.25 mg/kg/day, as per the reference81, was used for these 
simulations. 
3.3.4.3. The iterative search 
At each iteration the objective function (OBJ) was computed (Section 
3.3.4.4). The current set of parameter values from both typical and atypical 
scenarios were kept as the current best set if the associated OBJ was lower. At 
each cycle of the search the value of 𝜎𝑐 was reduced by multiplying by a factor 
of 0.1 and the mean was re-centred on the current best set of parameters for all 
scenarios, i.e. 𝜇𝑐, 𝜇𝑐,𝐴𝑡𝑦𝑝𝑖𝑐 𝑙 1 and 𝜇𝑐,𝐴𝑡𝑦𝑝𝑖𝑐 𝑙 2 for typical, atypical1 and atypical2 
scenarios respectively. 
The initial value of 𝜎𝑐 was 1000, the same for all scenarios. A cycle consisted 
of 1000 iterations. The search was continued for 10 cycles (i.e. until the value of 
𝜎𝑐 was 10-7). 
Over all the search yields the optimal values of the parameters for the 
typical scenario and the factors that down regulate and/or upregulate for the 
atypical scenarios. 
3.3.4.4. Computation of objective function value7 
The objective function value (OBJ) was calculated as the sum of the absolute 
relative differences of each scenario (see Equation 3.2). 
                                                 
7  Different objective functions: (i) Sum of absolute relative difference with respect to 
reference values, (ii) Sum of absolute relative difference with respect to predicted values (iii) Sum 
of squared relative difference with respect to reference values (iv) Sum of squared differences 
were evaluated. Results are provided in section A3.3 of Appendix-3 
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𝑂𝐵𝐽  ∑∑𝑎𝑏𝑠 (
𝑟 𝑓 𝑟 𝑛𝑐  𝑣𝑎𝑙𝑢 𝑖𝑗 − 𝑝𝑟 𝑑𝑖𝑐𝑡 𝑑 𝑣𝑎𝑙𝑢  𝑖𝑗







Equation 3.2 Sum of relative differences: 𝒊  = 1, 2 (represents the 
concentrations of 6-TGN and 6-MMP respectively) and 𝒋 = 1, 2 & 3 (represent 
three clinical scenarios) and abs the absolute value. 
3.3.4.5. Criteria for model completeness 
At the end of the search if the resultant set of the parameter vectors yielded 
simulation values within 10% of the reference metabolite concentrations, then 
the model is considered to be complete. Otherwise the model was considered 
incomplete which suggests the original model from Chapter 2 is structurally 
inaccurate. 
Figure 3.4 shows the flow chart for the process of model completeness 
evaluation using global search algorithm. 
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Best OBJ = 1099; Best µc,typical = 1; Best µc,Atypical-1 = 1; Best µc,Atypical-2 = 1; i = 1; j = 1; σc = 1000
Let cycle = i
Generate θ , fAtypical-1 & fAtypical-2
Simulate typical and atypical (1&2) scenarios
Compute OBJ
Is OBJ < Best OBJ
Best OBJ =  OBJ; Best µc,typical = θ; 
Best µc,Atypical-1 = fAtypical-1; Best µc,Atypical-2 = fAtypical-2
Is iteration = 1000?
Test cycle = 10?
Are all predictions < 10% 
of observations ?
j = j + 1
i = i+1
j = 1
σc = 0.1  σc  








µc,typical = Best µc,typical ; 
 µc,Atypical-1 = Best µc,Atypical-1; µc,Atypical-2 = Best µc,Atypical-2
Let iteration = j
 
Figure 3.4 A logic flow chart for the global search algorithm used for 
model completeness analysis 
Additional set of reference concentrations: 
It is a limitation that the reference concentrations for the three scenarios 
were obtained from different studies. Therefore additional set of concentrations 
for the 3 scenarios were obtained from Canterbury hospital (shown in section 
A3.1 of Appendix-3). Nevertheless, when the search algorithm was implemented 
to this data the results were similar to that shown in Table 3.2. The results are 
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provided in section A3.2 of Appendix-3. This set of reference concentrations will 
be used for the subsequent work in the next chapter 
3.4. Results 
3.4.1. Implementation of global search algorithm 
The global search algorithm generated positive real values for the 96 sets of 
parameters (i.e. 44 𝑉𝑚 𝑥 and 𝐾𝑀 values – for typical scenarios, and 8 multipliers 
for 𝑉𝑚 𝑥 values - for atypical scenarios) in every iteration. Each set of parameter 
values were used to simulate typical and atypical scenarios simultaneously. The 
objective function value was computed (see Equation 3.2) by comparing model 
predictions for three scenarios with the reference values (see Table 3.2). In this 
process, if the current OBJ is found lower than the best OBJ, best OBJ along with 
the best mean parameter values for all three scenarios were updated. For every 
1000th iteration of a cycle the standard error was reduced by a factor of 10, and 
this was continued for 10 cycles. Overall the OBJ was tested for 10000 times with 
different sets of parameter values. 
3.4.2. Model completeness results 
At the end of all iterations, the global search algorithm could not find single 
set of parameter values that could predict the reference concentrations for all 
three clinical scenarios simultaneously. Table 3.2 shows the best possible 
predictions provided by the search process. As shown in the table the model was 
able to predict both 6-TGN and 6-MMP for typical and atypical2 scenarios. 
However model predictions could not provide the excessive 6-TGN for atypical1 
scenario where the concentrations of 6-TGN were the same as in the typical 
scenario and hence deviated significantly from the reference values. These 
results were obtained by the factor changes shown in Table 3.3.









(mean ± SE) 
6-TGN 
(mean ± SE) 
Typical scenario 
Published value129 2973 ± 899 325 ± 73 
Predicted 2936 325 
 
Atypical1 scenario 
Published value65 2683 (± ?*) 490 (± ?) 
Predicted 2856 313 
 
Atypical2 scenario 
Published value81 10380 ± 1235 185 ± 17.7 
Predicted 10380 185 
OBJ 0.43815 
*SE is not available    
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Table 3.3 Factor change for the enzyme activities that achieved by 
global search algorithm 
Enzymes 
Factor change 
Typical Atypical1 Atypical2 
TPMT 1 1 104.11 
NUDT15 1 0 NA 
ITPase 1 0.73 3.74 
HGPRT 1 NA 42.14 
IMPDH 1 NA 224.32 
GMPS 1 NA 58.37 
3.5. Discussion 
A global search algorithm has been developed to search across different 
sets of parameter values for the developed QSP model in chapter 2. This work 
introduced a new methodological concept called ‘model completeness’. Model 
completeness analysis explores an element of model deficiency in the QSP 
modelling framework. A structural model is considered to be complete if there 
exists a set of parameter values that provides input-output relationship for the 
given clinical data. The best parameter sets out of the existing ones are 
anticipated to provide knowledge of the biological process (such as enzymes 
activities in the azathioprine model) metabolic pathway in a correctly defined 
system. 
This work assumes that the model structure is correct, therefore the 
parameter values need to be specified correctly. These alternative parameter 
values are assumed to be the activities of the intracellular enzymes and 
transporters. The reasons to consider only intracellular enzyme activities in the 
search of alternative parameters is that the metabolic fate of azathioprine is 
underpinned by the intracellular enzymes that take crucial role in purine 
metabolism. Whereas most of the extracellular parameter values are obtained 
from in vivo or in vitro studies, hence there are ample data to support their values. 
Atypical scenarios are based on the existing hypotheses where 8 𝑉𝑚 𝑥  (3 for 




atypical1 and 5 for atypical2) values for the activities of the suspected enzymes 
were altered by 3 orders. The main difference between work in this and chapter-
2 is that, perturbation in current chapter is implemented for all the enzymes as 
per the existing hypotheses whereas the work in chapter-2 considered only the 
plausible enzymes and was limited to a heuristic search. 
There have been some virtual population analysis methods that search 
across parameter values.52, 56, 57 However, the aim of these methods is to generate 
a pool of sets of parameter values that can generate the distribution of the 
observations. For instance, Allen et al. generated a set of parameter values 
randomly from a uniform distribution, and optimised them to achieve a range 
of observations using simulated annealing, and further scaled to a probability 
distribution of the observations (see Figure 3.5, reused from the publication52). 
Whereas, the work presented in this chapter optimise the search for the 
parameter values that can predict mean of the observations (which were 
continuous data). 
 
Figure 3.5 Generation of virtual population recommended by Allen et 
al.52 (asper non-commercial license CC BY-NC, no permission was required 
at the time of reprint) 
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The search method used in this work is not affected by identifiability issues 
as, even if there are many sets of parameter values, the aim is to find whether 
any set of parameter values exist. This work does not purport that if a set was 
found that this would be the correct set of parameter values. Additionally, since 
this method uses an adaptive random sampling method, the search is unlikely 
to get lost in a local minima.  
As per the results, the search could not find any set of parameter values to 
support typical and atypical data. This provided sufficient evidence to suggest 
that the model is incomplete. Therefore an alternative structure is that shows 
model completeness is warranted. The next chapter will focus on developing an 
algorithm that can search across the model structures and the parameter values.  
3.6. Conclusion 
An adaptive search algorithm was developed to search across the sets of 
parameter values for the current structure of QSP model for azathioprine 
metabolism. The algorithm was capable of searching across the parameter values 
for enzyme activities and factors for the abnormality in suspected enzyme 
activities. The search provided a set of parameter values to accurately predict 6-
TGN and 6-MMP concentrations for typical and atypical2 scenarios but the 
predictions for 6-TGN for atypical1 scenario were substantially different from the 
reference values. This work provides a method for evaluation of QSP models 
that are not performing as intended. 
Further work is needed to search for an alternative structure of the model 
for azathioprine to predict the various clinical scenarios. 
 


































This work follows from the work described in the previous chapter. The 
optimisation study in Chapter 3 was set up under the belief that the current 
knowledge of the structure was correct (i.e. complete) but the flux was 
incorrectly specified.  However the results from this search indicated that there 
was no set of parameter values that solved for the system which lead to the 
conclusion that the model structure was incorrect and hence the underpinning 
science of the system was incomplete. This finding provided the motivation to 
devise a method to determine plausible structures of the QSP model for 
azathioprine that included new components but keep the body of the current 
model. The work entailed here uses azathioprine as a case example. The final 
inferences, while not necessarily directly applicable to solving the azathioprine 
dose individualisation, will help illustrate model deficiencies which can then be 
the source of further study. 
In this work, the model structure was defined in a way that facilitates 
graphical and mathematical manipulation. The number of model compartments 
is determined as the number of states, and therefore the number of differential 
equations. The states are defined graphically by nodes (or vertices) and the 
movement between nodes (i.e. fluxes) are defined by edges (visually as arrows). 
A typical 𝑛  state model can have 𝑛2  possible edges in which every node is 
connected uni-directionally with every other node and a flux representing 
permanent loss from each node. For instance in Figure 4.1 a 5-state model has 5 
nodes, and 25 edges. A mathematical representation can be expressed as a matrix 
of fluxes in which the row and column position, for the off diagonal elements, in 
the matrix determines the flux from one node (indexed by the row) to another 
node (indexed by the column). The diagonal elements represent elimination flux 
of the respective node (indexed by the row). For instance if a much simpler 
example is used for illustrative purposes (Figure 4.1) the flux from node 1 to 2 
would be presented in the matrix with a flux shown in position 1, 2 (i.e. J12). This 
is discussed in more detail in the following sections (see definitions in section 
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4.3.1.3). It is noted that this notation is used for all descriptions of flux.  We will 



























Figure 4.1 Schematic for a 5-compartment model comprising of 5 nodes, 
and all possible edges (𝑱𝒙𝒚) 









































The model shown in Figure 4.1 has the highest number of connecting 
fluxes. This can be compared with a model that has the fewest number of 
interconnecting fluxes (while maintaining at least 1 connection between each 
state) as shown in Figure 4.2. Addition or elimination of edges between the nodes 
(such as in the direction of node 2 to node 1) allows the minimal flux model and 
maximal flux model to be formed. 
















Figure 4.2 Schematic for the minimum structure for the 5-compartment 
model 









































Similar to this example, it is postulated that, if the azathioprine model 
structure is considered incomplete then, there are missing edge(s) from the 
schematic. This necessitates testing the hypothesis that a complete model (not 
necessarily a maximal flux model as shown for the 5-state model in Figure 4.1) 
could be formed by considering additional edges. This can be addressed by 
either turning on or off the edges and assigning flux values. A note here is that, 
since the existing edges are based on the current knowledge, removal of the 
edges from the model is not a plausible option. Therefore only additional edges 
suggested by the search will be considered for the alternative structure. 
A search across the edge space might generate cases where the removal of 
some edges could result in nodes becoming islands (a node disconnected from 
all other nodes) which is allowable. In this search the occurrence of island nodes 
does not require the node to be removed as it might be connected at some later 
part of the search.  
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This chapter outlines the development of a method to search across 
potential model structures using a combination of binary logic and continuous 
fluxes. 
Conventional binary logic approaches have been used to explore 
knowledge gaps in complex regulatory networks such as biochemical or intra 
cellular signalling pathways39, 142, 143. This approach approximates two discrete 
states of either the nodes or the edges (active/on or inactive/off) in a network 
using switch operators, i.e. 0 or 1. The interaction between two nodes, either 
active or inactive, is modelled using Boolean functions (‘AND’, ‘OR’ and ‘NOT’) 
that determine overall consequence of the signal, i.e. activation or inactivation.144 
The application of the logic approach for edges has been used to explore 
mechanistic insights where the knowledge of the biological network is not 
clear.60 In this work the binary on and off for edges was combined with a flux (as 
a continuous process) rather than use the Boolean operators.  
There are two main processes in this search. Process (1): A switch matrix of 
0s and 1s was created to turn off or on edges.  Process (2): a set of fluxes, were 
created for the edges assigned a switch value of 1. This concept has some 
similarity to a zero-inflated Poisson model in which the first stage the probability 
of a 0 is estimated then for non-0 probabilities a parameter (𝜆) is estimated as the 
count variable. The search was conducted across both processes simultaneously 
(see methods [section 4.3.1.4]). 
The global search algorithm, simulated annealing, was chosen because of 
the following optimisation characteristics of the algorithm: 
1) Simulated annealing, unlike many other search algorithms, is not 
affected by model identifiability (which contrasts with gradient based 
methods). 
2) The performance of simulated annealing is not affected when the 
dimensionality of the search space changes during the search. For 
example as may occur during the search that a parameter to be 
optimised is turned off (or on) during the optimisation step thus 
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reducing (or increasing) the dimensionality. This contrasts with some 
MCMC type methods which require fixed dimensionality. 
3) Simulated annealing has been used and studied in situations where the 
search space is in high dimensionality (e.g. 62 parameters to be 
optimised [145]). 
4) Simulated annealing has some properties that help it avoid local 
minima due to inclusion of a Metropolis step 146.  
All of these issues will be present in the proposed search and the 
performance of simulated annealing (which is not without issues) will be 
considered. The work shown in this chapter is underpinned by the assumption 
that within the reported number of states in the azathioprine model there exists 
a structure that predicts the reference values.  
An important note.  The three reference concentrations for the clinical 
scenarios that were used in chapter-2 and chapter-3 were based on three separate 
publications. Additional data from Canterbury hospital was used to compute the 
mean concentrations and their standard errors for the three clinical scenarios (see 
section A3.1 in Appendix-3). These references were also not achieved by the 
global search algorithm for the alternative parameter values (see section A3.2 in 
Appendix-3), which re-confirmed the existence of model incompleteness with 
the model. These new set of concentrations are used as references for the 5-state 
model (as arbitrary values) and for the azathioprine model.  
For most of the exploratory work here a much simpler 5-state model was 
used to evaluate the approach. This is later followed up by optimisation of the 
azathioprine model. 
Overarching goal of this work is to explore knowledge gaps of a biological 
system within the QSP modelling framework using azathioprine as an example 
system. 
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4.2. Aims and objectives 
The aim of this project was to determine a set of possible model structures 
that solve for the set of three clinical scenarios.  
The specific objectives were: 
1. Development of a search method (applied to a simple 5-state 
model). 
2. Application of the search method to the azathioprine system. 
4.3. Methods 
The work shown in this chapter was conducted using MATLAB (R2017a). 
The simulated annealing algorithm was adapted from a previous version written 
by Waterhouse (a previous lab member of the Otago Pharmacometrics Group) 
and is used in preference to the standard tool available in MATLAB. 
4.3.1. Development of a search method (applied to a simple 5-state model) 
The methods relating to aim 1 were applied to a simpler 5-state model in 
order to better understand its characteristics. 
All cases considered in this work assume steady-state conditions under a 
zero-order continuous input. The process of developing and implementing the 
search method was divided into five parts:  
1. Defining a node and edge model for a simple 5 state model,  
2. Deriving a steady state solution for the system from an arbitrary set of 
flux parameter values, 
3. Defining the flux parameters using logic and continuous variables, 
4. Setting up simulated annealing for the search, and defining the 
objective function,  
5. Evaluating the stability of the search process. 
Following sections describe each of the 5-stages. 
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4.3.1.1. Defining a node and edge model for a simple 5 state model  
A 5-state model, with 5 nodes and 9 unidirectional edges (out of a possible 
25 unidirectional edges), was chosen arbitrarily for exploration (see Figure 4.3). 
The model was constructed using a system of linear ordinary differential 
equations (ODEs) with a constant unit dose input given (as if) by a continuous 
intravenous infusion (1 mass unit/unit time). The parameter values for the rate 
constants (𝑘𝑥𝑦) were selected arbitrarily. Sampling is shown for measurement of 
















Figure 4.3 A 5-state model solved using steady state approach 
4.3.1.2. Deriving a steady state solution for the system from an arbitrary set of 
flux parameter values 
Since the system of differential equations are both linear and stationary 
then the system could be solved using an eigenvalue decomposition method 
(similar to and sometimes called matrix exponentials) rather than using standard 
time-stepping solvers (such as the Runge-Kutta methods). It will be seen that 
interest lies in the steady state solutions which greatly simplifies the problem.  
Solving linear ODEs using eigenvalue decomposition approach:  
Eigenvalue decomposition gives a general form of the solution for linear 
time-constant coefficient ODEs for (a) first-order input and (b) zero-order input 
PK models (see the tutorial147).  
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 𝑀 · 𝐴;   𝐴(𝑡0)  𝐴0 
Equation 4.1 A general form of first-order input linear ODE 
This can be solved to Equation 4.2  
𝐴(𝑡)    𝑡M · 𝐴0, 
Equation 4.2 Solution for first-order input linear ODE 
If 𝑀 is a vector or a matrix,  𝑡M can be solved by Taylor series. However, 
this can be difficult to solve and it is usually simpler to solve the system using 
eigenvalue decomposition, such as:  
   𝑡M   𝑃 ·  𝑡Λ · 𝑃 1  
For an 𝑛 state model, 𝐴(𝑡) and 𝐴0 are 𝑛 × 1 column vectors of the amount 
of the drug in each state at time 𝑡 and  0 respectively, 𝑀  represents the 𝑛 × 𝑛 
mass transfer rate constant matrix that can be computed from an 𝑛 × 𝑛  flux 
matrix (𝐽). Λ is an 𝑛 × 𝑛 diagonal matrix of eigenvalues of 𝑀, and 𝑃 is an 𝑛 ×
𝑛 matrix whose columns are the corresponding eigenvectors (see for example 
148). 
In this work a continuous intravenous input is implied which can be 
defined by a linear ODE function with a zero-order input (see Equation 4.3). 
𝑑𝐴
𝑑𝑡
 𝑀 · 𝐴 + 𝑓;   𝐴(𝑡0)  𝐴0 
Equation 4.3 A general form of zero-order input linear ODE 
In a PK setting it is usual for the initial values for each (non-input) state to 
be zero and the input function f to be on or off depending on the time of the 
infusion. 
Similar to the first-order input ODEs, Equation 4.3 can be written. 
𝐴(𝑡)   𝑡 𝑀 · (𝐴0 +𝑀
 1 · 𝑓) − 𝑀 1 · 𝑓 
Equation 4.4 Solution for zero-order input linear ODE 
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Equation 4.4 can then be expressed as the eigenvalue decomposition 
solution. 
 
     𝐴(𝑡)  𝑃 ·  𝑡 Λ · 𝑃 1 · (𝐴0 +𝑀
 1 · 𝑓) − 𝑀 1 · 𝑓  
Equation 4.5 Eigenvalue decomposition solution for zero-order input 
linear ODE 
Here, f is the 𝑛 × 1 column vector where the first element represents the 
dose and the remaining elements are just placeholders (with value 0). 
















































































































In this notation 𝐽 (a flux matrix) contains individual fluxes of the 𝑛 states, 
and 𝑀 (a mass transfer rate constant matrix) is constructed from the individual 
fluxes, where both 𝐽 and 𝑀 are rank 𝑛 matrices. 
- For a flux matrix, the diagonal elements (ex: 𝐽𝑥0) represent elimination 
out of the system from respective (𝑥𝑡ℎ ) node, and the off-diagonal 
element (𝐽𝑥𝑦) represents out flow from the node 𝑥 to y. 
- For an element 𝑀𝑖𝑗  in a mass transfer rate constant matrix, if 𝑖  𝑗  it 
represents the flux outfow from 𝑖𝑡ℎ node as a sum of elimination out of 
the system and transfer to other node, or if 𝑖 ≠ 𝑗 it represents flux inflow 
to node 𝑖 from 𝑗. 149 Note the M matrix has a different flux subscripting 
to the J matrix. 
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These matrices and vectors for the 5-state model (from Figure 4.3) can be 
















































































































Redefining the eigenvalue decomposition solution for a zero-order input 
linear ODE in an equilibrium setting: 
Under equilibrium dynamics (i.e. input = output), the system reaches 
steady state, and that can be defined at 𝑡 →  ∞ . Therefore the solution for 
Equation 4.5 can be rearranged and redefined to Equation 4.6 in order to 
calculate the steady state solution (𝐴𝑆𝑆):  
𝐴𝑆𝑆  −𝑀
 1 · 𝑓. 
Equation 4.6 A steady state solution for zero-order input linear ODE 
4.3.1.3. Defining the flux parameters using logic and continuous variables 
The search presented here was based on defining a set of edges and their 
flux values for a given set of fixed nodes. Hence it is a matter of defining the 
presence of an edge and then assigning a flux value to the edge. The presence or 
absence of an edge is akin to a logic search and the value of the edge corresponds 
(approximately) to a bounded continuous component where in this search the 
fluxes are constrained on the interval 0.1, 1. In this work both the presence (or 
absence) of an edge and the value of the flux for the edge were searched 
simultaneously. This was implemented by defining the fluxes using switches 
(𝑆𝑥𝑦) (for presence or absence of an edge) and rate constants (𝑘𝑥𝑦) (as the driver 
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for flux). The former determines the status of the connection (on or off) between 
two nodes and the latter determines the rate. In this notation, as with other 
notation in this thesis, the direction of the flow is given by the indices in the 
matrix, for instance 𝑆𝑥𝑦  denotes the switch that turns on or off flow between 
nodes 𝑥 and 𝑦, and similarly for rate constant (𝑘𝑥𝑦). 
Anomalies during the search: 
During a search three types of anomalies were identified: formation of (1) 
“island” state(s) or isolated group of states, (2) “transient terminal” state(s) or 
transient terminal groups of states and (3) “trivial solutions for the observing 
states”. 
Island states are defined as nodes that do not have any input fluxes 
irrespective of whether an output exists. Hence their steady state value is zero. 
The presence of these types of states may rarely yield implausible structures (see 
1a, 1b, 1c & 1d in Figure 4.4).  
Transient terminal states are nodes that have input but no output, i.e. 
during the search an output edge has been switched off and hence these states 
are now (transiently) terminal.  Steady state will never occur in these states. 
These transient terminal states always affect the structure and the search process 
(see 2a, 2b, 2c & 2d in Figure 4.4).  
Trivial solutions may arise when the input state is directly connected to the 
observation states (and no other states) and hence can yield an exact solution for 
reference value (see 2a in Figure 4.5).  Essentially this can arise in cases where 
the biology is entirely omitted from the structure. 
These anomalies may occur during the search for (on/off) switches. They 
were solved by considering two additional components in the search: 
introducing (a) always on or always off or (b) transient outputs. 



















































































































































































Figure 4.4 Different possibilities of anomalies that could appear during 
the exploration of different structures in a 5-state model. In the left panel the 
orange dashed boxes indicate the formation of island states (1a) and of 
isolated groups of island states (1b, 1c& 1d). In the right panel the orange 
nodes indicate the appearance of a transient terminal state (2a) and a group 
of transient terminal states (2b, 2c& 2d). 
a. Introducing always-on or always-off edges 
Some edges were determined a priori to be always-on or always-off. For 
example it was determined that (1) there would always be flux from the input 
state to another model state so that the drug enters the system (this is an example 
of an always-on setting), (2) there would never be flow from any state back to 
the input state (this is an example of an always-off setting). Therefore drug that 
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enters the system was eliminated by the system rather than back to the depot site 
for recycling.  
Turning an edge always-on prevents the appearance of island states while 
always-off avoids any trivial solutions. For example in Figure 4.5 𝐽12  should 
always be on to avoid island states (panel 1A vs 1B) and 𝐽13  and 𝐽15  should 












































1B. Turning J12 always on to avoid the formation of







































2A. Possibility of trivial solution 2B. Turning J13 and J15 always off to avoid trivial solutions 
 
Figure 4.5 Cases of formation of (1A) island states, where no state in the 
5-state model has an input from the 1st state, and (2A) trivial solution in five 
state model, where the sampled states (i.e. state-3 & 5) have inputs from the 
1st state. These anomalies were avoided by turning J12 always on (1B), and J13 
& J15 always off (2B). 
b. Introduction of transient output 
Transient terminal states can only be determined a posteriori to the search 
as they are the result from turning off edges associated with certain nodes so that 
there is no output from the node. For example in Figure 4.6 𝐽40 is always off as 
long as state-4 is a non-terminal state (in other words, the node that has out flow). 
During the search process the node can become a transient terminal state if all 
outward flow edges are turned off. In such a case an outflow is introduced 
transiently to the node by using the value from the flux matrix (𝐾) that would 
have been used at the switch (𝑆) not been set to zero, i.e. for node 4 (𝐽40  𝐾40) 
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that shown in purple in Figure 4.6. This solution allows the node to reach steady 



























Figure 4.6 A 5-state model with edges that are searched or always on/off 
or on transiently. Here, 𝑱𝒙𝒚 indicated in red, green, orange and purple are the 
flows that always off, always on, searched by simulated annealing 
and conditionally turned on for transient terminal states otherwise off, 
respectively.  
Setting up perturbation for atypical scenarios: 
Each atypical scenario was created by changing some of the fluxes present 
in the typical scenario. This was done by multiplying the currently selected 
fluxes by factors that modify the flux to provide an atypical flux. The number of 
fluxes to be perturbed in this setting was determined heuristically by starting 
with 1 flux, and increasing the number of perturbed fluxes until the reference 
values were obtained.  
Construction of flux matrices for different scenarios: 
Considering all elements mentioned above, the flux matrix for three 
scenarios was constructed using Equation 4.8. Note, in this notation {  }  is used 
to represent a set of values and (  ) a range of values. 
A search over edges that always includes the prior model as a base model 
is shown conceptually in Equation 4.7. 
𝐽𝑖  𝑔(𝑆 + 𝑆𝑏) ∘  𝐾 ∘  𝐹; 
Equation 4.7 Flux that determines the base model 
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In this notation, 𝑆  is the switch matrix, 𝑆𝑏  is a fixed switch matrix 
corresponding to the existing edges in the prior model, 𝐾 the flux matrix and 𝐹 
the factor matrix for atypical scenarios. The function 𝑔(𝑆 + 𝑆𝑏)   
 𝑚𝑖𝑛(𝑜𝑛 𝑠(𝑛, 𝑛), 𝑆 + 𝑆𝑏) (in MATLAB script) ensures the minimum logic states 
are the same as the base model (see Figure 4.2). The choice of 𝑆𝑏 solves the island, 
trivial and transient state issues.  In this work rather than pre-specifying 𝑆𝑏, a 
series of always on and always off and transient conditions were created in order 
to provide a fully generic solution to any problem (in cases where it may not be 
appropriate to define 𝑆𝑏 a priori). Here their function also accounts for the prior 
structure. 
The overall notation that includes the switch, flux, factors affecting the flux 
and the always on and always off components are shown in Equation 4.8.  
𝐽𝑖  𝑆 ∘ 𝐾 ∘ 𝐹𝑖 ∘ 𝐽𝐼 + 𝐽𝐹 + 𝐽𝑡 
Equation 4.8 Equation showing the computation of 𝑱 matrix 
In this notation ∘ is used to denote the Hadamard element wise product. 
For the 𝑛  state model, 𝐽𝑖  (𝑖 ∈ {1, 2 𝑎𝑛𝑑 3} that represents 3 scenarios), 𝑆, 𝐾, 𝐹𝑖,
𝐽𝑖 , 𝐽𝐹 , 𝑎𝑛𝑑 𝐽𝑡  are all  𝑛 × 𝑛 matrices. The order of the components shown in this 
equation is in the order that they involve in the structure modification. This 
notation is used to achieve the six model qualities (1) an optimised logic state, (2) 
an optimised flux state (together with 1 provide the model structure), (3) a 
perturbation of the system for the atypical scenarios (optimised by simulated 
annealing), (4) an always off state (flux fixed to zero), (5) an always on state (flux 
fixed to 1), and (6) an introduction of outflow fluxes transiently during the search 
(optimised by simulated annealing). 
This matrix was then used to construct 𝑀𝑖, the mass transfer rate constant 
matrix. 
Definitions: 
𝐽𝑖  is a flux matrix where 𝑖=1, 2 and 3 for typical, atypical1 scenario and 
atypical2 scenario. This matrix is used to develop the 𝑀  matrix for 
computation of steady-state state values. 
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𝑆  is a switch matrix, 𝑆 ∈ {0,1} , that determines the presence of edges 
between nodes (i.e. an edge in the of direction 𝑥 → 𝑦  is present when 
𝑆𝑥𝑦  1). This parameter is optimised by simulated annealing. 
𝐾  is a matrix of rate constants, ∈ (0 1, 1), that provides the quantitative 
value of flux between nodes.  This parameter is optimised by simulated 
annealing. 
𝐹𝑖  represents the matrix of the perturbing factors for the 3 different 
scenarios, where 𝑖  1 for typical, 2 for atypical1  and 3 for atypical2. When 
𝑖  1, all the elements of 𝐹1  1, and when 𝑖  2 or 3, depending on which 
fluxes to be perturbed the respective elements in 𝐹2 or 𝐹3 will be equal to 
a value between 0.001 and 1000 (that optimised by simulated annealing) 
and the remaining elements will remain as 1’s. 
 𝐽𝐼 is an indicator variable that is used to represent an always on or always off 
versus a variable state of fluxes. The value is predefined and not altered 
by the search. Each element is pre-set to a value of 0 when always on or 
always off is true otherwise to a value of 1.  
𝐽𝐹  represents the value of the flux for always on (1) and always off (0), 
(𝐽𝐹 ∈ {0,1}). This value is also predefined and not altered by the search. 
For example, for an always on state (where  𝐽𝐼,𝑥𝑦  0 which switches off 
the standard variable search), 𝐽𝐹,𝑥𝑦 is assigned to a pre-defined value of 1. 
For an always off scenario both 𝐽𝐼,𝑥𝑦 & 𝐽𝐹,𝑥𝑦 assigned to 0 which ensures 
the variable search is turned off and the flux is zero. For those fluxes that 
are subjected to parameter optimisation by simulated annealing, 
𝐽𝐼,𝑥𝑦 assigned to 1 and 𝐽𝐹,𝑥𝑦 to 0. Similar to 𝐽𝐼 , the elements of 𝐽𝐹  matrix 
also (i.e. both 0s and 1s) were fixed a priori. 
𝐽𝑡  represents the value of a flux (for the elimination) which would be 
introduced to transient terminal states that arise during the search 𝐽𝑡 ∈
 (0 1, 1). In this work, instances where these states arise were identified by 
rank deficiency of 𝑀𝑖, and the state that requires the introduction of the 
flux was known by the row index of null space vector of 𝑀𝑖  who’s 
absolute value is greater than 0.1 (i.e. 𝑎𝑏𝑠(∅(𝑀𝑖))>0.1). For an xth transient 
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terminal state outflow is replaced by 𝐽𝑡,𝑥𝑥  𝑘𝑥𝑥, and for the non-terminal 
states the rest of the matrix is 0’s (i.e. 𝐽𝑡,𝑥𝑦&𝑥𝑥  0). 
4.3.1.4. Setting up simulated annealing for the search, and defining the 
objective function 
This stage focused on implementation of simulated annealing as a tool to 
search for possible structural solutions, and to assess whether the up or down 
regulation of a pathway (i.e. an edge or set of edges) can accommodate the three 
scenarios (typical, atypical1 & atypical2). Note here that the same three scenarios 
were applied to the simple 5-state model as per the azathioprine model - even 
though it is anticipated that the simple model would not be able to support the 
three scenarios. During the runs of simulated annealing the follow settings were 
chosen (default values are given in [ ]): 
- Initial temperature: fixed to 1e+10 [default: variable temperature] 
- Temperature cooling: set to geometric cooling (0.1) [default: 0.9]. 
- Maximum number of iterations:  increased to 1e+8 [default: 1e+7]. 
- Vmin (the lower threshold of stepsize, equivalent to significant digits in 
NONMEM $EST, as the convergence criteria): set to the default value 
[default: 1e-4]. 
- Number of cycles between step: set to 50 [default: 20].  
- Number of step changes between temp change: set to 100 [default: 50]. 
The input for simulated annealing was provided as a hyper-set of matrices 
that comprise six different matrices (𝑆, 𝐾, 𝐽𝐼, 𝐽𝐹 , 𝐽𝑡  and 𝐹). Where 𝑆, 𝐾, 𝐽𝑡  and 𝐹 
are estimated by simulated annealing, and 𝐽𝐼 & 𝐽𝐹 are fixed a priori. 
Generating the 𝑆 matrix: 
The 𝑆 matrix, a switch matrix in logic space, was computed in a three step 
process. First, an 𝑛 × 𝑛  value logit matrix 𝐿𝑖𝑛𝑖𝑡 , in continuous space, was 
generated with an upper bound (UB) of 20 and lower bound (LB) of -20. In the 
second step, the 𝐿𝑖𝑛𝑖𝑡  matrix elements were converted by expit to a set of 
probabilities (𝐸). In the final step, the values of 𝐸 were then converted to a switch 
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matrix (𝑆) of on-off events (i.e. 0 or 1) by logical comparison of 𝐸  against a 
uniform random set (𝑈). 
Following pseudocode provides these details.  
let 𝐿𝑖𝑛𝑖𝑡  𝐿𝐵 + 𝑟𝑎𝑛𝑑(𝑛, 𝑛) ∘ (𝑈𝐵 − 𝐿𝐵)  # Generated initial values  
𝐿  𝑆𝑖𝑚𝑢𝑙𝑎𝑡 𝑑 𝑎𝑛𝑛 𝑎𝑙𝑖𝑛𝑔(𝐿𝑖𝑛𝑖𝑡) # Generate an optimised 𝐿 by simulated annealing 
let 𝐸  
1
(1+𝑒−𝐿)
 # Generate an expit set using an expit function 
let 𝑈  𝑟𝑎𝑛𝑑(𝑛, 𝑛) # Generate uniform random set 
let 𝑆   𝑧 𝑟𝑜𝑠(𝑛, 𝑛)  # Initialisation matrix 
𝑆(𝐸 ≥  𝑈)    1 # Condition to convert to logical set 
 
It is to be noted that the 𝑆 matrix can be generated using some other simpler 
methods, for instance in MATLAB by random integers generation (i.e. 
𝑟𝑎𝑛𝑑𝑖(2, 𝑛, 𝑛) − 1 ). But such an approach will lose information from 
neighbouring elements.  
Generating the 𝐾 matrix: 
An 𝑛 × 𝑛  initial value matrix for 𝐾 , in continuous space, was generated 
using a random number generating function with an upper bound (UB) of 1 and 
lower bound (LB) of 0.1. This matrix was then optimised using simulated 
annealing. 
Generating the 𝐹 matrix: 
An 𝑛 × 𝑛 initial value matrix 𝐹 was generated with every element equal to 
1. A single element (initially) was perturbed, with a location generated by 
simulated annealing and a value with an upper bound (UB) of 1000 and lower 
bound (LB) of 0.001. This provided a single atypical scenario. The 𝐹 matrix was 
then optimised using simulated annealing. So this matrix would (for most 
elements) be an identity for the Hadamard product calculation. An example 𝐹 
matrix for one of the atypical scenarios is provided below where all the elements 
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The location and the value of the factor that perturbs the flux (in this 
instance the element at 4th row and 2nd column of 𝐹 ) was optimised using 
simulated annealing. 
Implementation of simulated annealing: 
The  hyper set of matrices was presented as a single search matrix 𝑋  of 
dimension 6 × (𝑛 × 𝑛)  ( i.e.  𝑋  [𝐿𝑖𝑛𝑖𝑡; 𝐾; 𝐹; 𝐽𝐼; 𝐽𝐹; 𝐽𝑡] )  where 𝐽𝐼  and 𝐽𝐹  fixed a 
priori, and the values of 𝐽𝑡  were either fixed (to 0 for non-transient terminal 
states) or adapted from 𝐾  (for transient terminal states). Therefore simulated 
annealing optimises 3 × (𝑛 × 𝑛) elements of 𝑋 so that it searches for switches, 
rate constants and factors to modify fluxes for atypical scenarios. In the simple 
5-state model the upper bound of the dimensionality of the search space is 3 ×
(5 × 5)   75 parameters.  
Each iteration of the search included eight steps:  
(1) generate three sets of parameter matrices (𝐿, 𝐾 & 𝐹), 
(2) convert the logit elements (𝐿) to logic elements (𝑆), 
(3) compute the mass transfer rate constant matrix (𝑀) from 𝐽 matrix, 
(4) fix anomalies, i.e. always on/off and transient terminal states 
(5) set 𝐹  1, and compute the flux matrix (𝐽) (Equation 4.8), 
(6) compute the steady state concentrations for typical scenario using the 
simplified eigenvalue decomposition solution, 
(7) create one or two non-one elements for F and use to scale the fluxes, 
(8) repeat from step 4 for atypical1 scenario, 
(9) repeat from step 4 for atypical2 scenario, 
(10) compute the OBJ from the reference values using Equation 4.9. 
 
𝑂𝐵𝐽(𝑋)  ∑∑(
𝑟 𝑓 𝑟 𝑛𝑐  𝑣𝑎𝑙𝑢 𝑖𝑗 − 𝑝𝑟 𝑑𝑖𝑐𝑡 𝑑 𝑣𝑎𝑙𝑢 𝑖𝑗







Equation 4.9 Sum of squared relative difference: i=1, 2 represent solution 
from two target states and j=1, 2 &3 represent three scenarios  
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Overall the algorithm searches for the optimal 𝑋  (i.e. ?̂?) that minimises 
𝑂𝐵𝐽. This can be denoted by… 
?̂?, 𝑂𝐵𝐽̂ , 𝑝𝑟 𝑑𝑖𝑐𝑡 𝑑 𝑣𝑎𝑙𝑢 ̂ 𝑖𝑗  𝑎𝑟𝑔𝑚𝑖𝑛
𝐾,𝑆&𝑇
(𝑂𝐵𝐽(𝑋)̂ )  
Normalised reference values: 
Normalised reference values used for the 5-state model are provided in 
Table 4.1. These values are adapted from the metabolite data that shown in Table 
4.2. To reduce the run time per simulation in every iteration these values were 
normalised by the highest value among all concentrations (see section 4.3.2.1). 
Table 4.1 Reference values that used test the search process for 5-state 
model 
Scenario Target state-1 Target state-2 
Typical 0.0710 0.0323 
Atypical1 0.1180 0.0924 
Atypical2 1.0000 0.0197 
4.3.1.5. Evaluating the stability of the search process 
Finally the stability of the developed search method was evaluated to 
determine the consistency of the search over the difference in the initial 
parameter values. This was performed by replicating the search runs five times. 
4.3.2. Application of the search method to the azathioprine system 
4.3.2.1. Lumping of the original azathioprine model 
The original 30 state azathioprine model was simplified to an 18-state 
model by (heuristically) lumping the two sets of composites of the target 
metabolites into two nodes, i.e. to 6-MMP and 6-TGN, and combining the four 
states outside of the cell into one node (see Figure 4.7). In addition, the system 
was further simplified to follow first-order processes, thereby replacing the 
parameters 𝑉𝑚 𝑥 and 𝐾𝑀 with a single first-order term. Note the overall aim of 
this work is to find alternative structures and at this stage was not concerned 
with the values of the parameters but rather the relative rates of flux. 
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This simplification reduced the parameter space from 900 (for 30 states) to 
324 (for 18 states) without affecting the model’s performance.  See chapter 2 for 
a description of 6-MMP and 6-TGN states. 
 The reference concentrations for 6-TGN and 6-MMP in three scenarios 
were selected as per Table A3.4 in Appendix 3 (note they are different values 
than presented in Table 2.1 from Chapter 2). To reduce the simulation run time 
per iteration these concentrations are normalised by the highest concentration 
out of all scenarios (i.e. 6-MMP concentration in atypical2 scenario).  
Table 4.2 Reference concentrations of 6-MMP and 6-TGN in three clinical 
scenarios 
 MMP concentrations TGN concentrations 
Scenario Non-normalised Normalised Non-normalised Normalised 
Typical 656 0.0710 299 0.0323 
Atypical1 1092 0.1180 854 0.0924 
Atypical2 9233 1.0000 182 0.0197 
 
The simplified model was then considered to be the starting place for the search. 
Although not used in this search, the 𝑆𝑏  matrix (base switch matrix) was 
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The relevant model schematic is shown in the simplified schematic (i.e. 18-state 


































































































































































































Figure 4.7 Azathioprine original (30-states) and simplified model (18-
states) 
Chapter 4: Searching for alternative QSP model structures 
115  
 
4.3.2.2. Searching across the 18 state AZA model 
The search method was implemented for the simplified 18-state model. 
Here, in order to achieve target concentrations for atypical scenarios two 
different perturbation schemes were tested: (a) one edge perturbation and (b) 
two edge perturbations. The number of perturbations reflect atypical scenarios 
governed by polymorphism in one or two enzymes in the pathway. As 
mentioned before each atypical scenario could have the same or different edge 
perturbations. 
4.4. Results 
The results are presented for the 5-state model (in section 4.4.1) and then 
for the 18-state azathioprine model (in section 4.4.2). 
4.4.1. Development of search method 
4.4.1.1. Steady state solution for the simple 5-state model  
ODE solution: 
The 5-state model (of 5 nodes and 9 edges) with an input of continuous 
infusion was solved by ODEs until all nodes representing steady state 
concentrations. The run time for a single solution was 0.374481 seconds. The 
main issue found with ODE method was determining the time to reach steady 
state, particularly in the state that has low turnover. Which makes this method 
impractical for use during the search. 
Eigenvalue decomposition solution: 
Approximating the full time course of changes in the concentrations of the 
model states with an eigenvalue decomposition solution provided a quick 
algebraic solution. The concentration time profiles obtained by this solution were 
superimposed with the ODE solution (see Figure 4.8). A single run time took 
0.021553 seconds. But the issue with determining the time to steady state 
concentrations is still not solved with this method.  
 




Figure 4.8 Steady state concentrations of individual states. The profile of 
the overlaid open red circles from eigenvalue decomposition solution matches 
with that of the continuous black line from ODE solution. Some inaccuracies 
in the non-steady state concentrations are not important to consider as the 
overall interest is in steady state concentrations. 
Steady state solution: 
The steady state solution (Equation 4.6) provided a quick and exact solution 
for the steady state concentrations. The method does not need to determine the 
time to reach steady state. The run time for a single solution was 0.017796 
seconds. The difference between the steady concentrations of all 5 states obtained 
from ODE and simplified steady state methods was at the level of integration 
error (see Table 4.3). 
Table 4.3 Comparison between ODE and steady state eigenvalue 
decomposition solutions 
State ODE  Steady state eigenvalue decomposition  Difference 
1 1.00 1.00 4.71e-08 
2 0.25 0.25 1.87e-07 
3 0.37 0.37 3.58e-07 
4 0.25 0.25 1.57e-08 
5 0.12 0.12 1.57e-08 
4.4.1.2. Setting up simulated annealing for the search, and defining the 
objective function of the stability of the search method 
The algorithm searched the 5-state model while eliminating the abnormal 
structures. The search provided alternative structures and parameter values that 
most closely matched the arbitrary target concentrations.  
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The stability of the search algorithm was tested by replicating the search 
runs five times from different initial conditions and with a different seed. All 
runs yielded similar (3 of which were identical) structures and OBJ (see Figure 
4.9 and Table 4.4). The different structures occur under similar OBJ values may 
indicate that the model (e.g. run 2) found a local minimum or the minimum OBJ 
might be the same but there are multiple structures that yield the same solution 
(due to structural identifiability issues).  
It is seen, not unexpectedly, that the simple trial 5-state model does not 


















































































Figure 4.9 Five closely related structures that provided by the stability 
analysis of the search method. 





Table 4.4 Model outputs provided by the stability runs 
Scenarios 
Run-1 Run-2 Run-3 Run-4 Run-5 Reference 
6-TGN 6-MMP 6-TGN 6-MMP 6-TGN 6-MMP 6-TGN 6-MMP 6-TGN 6-MMP 6-TGN 6-MMP 
Typical 0.1078 0.0631 0.1185 0.0542 0.1125 0.0606 0.1124 0.0598 0.0964 0.0630 0.0710 0.0323 
Atypical1 0.1045 0.0611 0.0938 0.1233 0.1090 0.0587 0.1048 0.0741 0.1429 0.0934 0.1180 0.0924 
Atypical2 0.2340 0.0142 0.2105 0.0166 0.2082 0.0206 0.2157 0.0232 0.2046 0.0163 1.0000 0.0197 
OBJ 1.9681 1.7114 1.8751 1.7611 1.7412  
Runtime (seconds) 96 85 87 95 95  
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4.4.2. Application of the search method to the azathioprine system 
The search method was successfully implemented for the 18-state 
azathioprine model (for set of values shown in Table 4.2). Out of the two different 
perturbation schemes (i.e. one or two edge perturbation) for atypical scenarios 
the search found sufficiently accurate solutions for the two edge perturbation 
scheme (Table 4.5).  
Table 4.5 Predictions of the two model structures for the 18-state model 
that resulted from different perturbation schemes during the search process 
  Perturbation scheme 
 Reference 1-edge  2-edge  
6-TGN 
Typical 0.0710 0.0905 0.0690 
Atypical1 0.1180 0.1012 0.1148 
Atypcial2 1.0000 0.3000 1.0634 
6-MMP 
Typical 0.0323 0.0301 0.0350 
Atypical1 0.0924 0.0839 0.0863 
Atypcial2 0.0197 0.0222 0.0199 
OBJ 0.6152 0.0168 
Runtime (in seconds) 3982 5000 
 
In this work a sufficiently accurate solution is regarded as a model 
prediction that is within 10% of the reference values. Over all the search method 
found 4 model structures and parameter values that could predict 6-TGN and 6-
MMP concentrations for all scenarios (Table 4.6). These alternative model 
structures provided additional arrows. The additional edges (i.e. alternative 
pathways and perturbations) were overlaid on the 18-state model (see Figure 
4.11, Figure 4.12, Figure 4.13 and Figure 4.14). 
For atypical1 scenario each set of structures showed additional edges 
between different types of nodes. For atypical2 scenario in all four sets of 
structures arrows were mapped towards 6-MMP. This common pattern appears 
to be suggesting of the missing mechanism for the metabolite shunting. 




















































































Figure 4.10 Original 18 state model for azathioprine metabolism





Edges that don t have perturbation
Edges perturbed in atypical1 






















































































Figure 4.11 First alternative structure provided by the search 






















































































Edges that don t have perturbation
Edges perturbed in atypical1 
Edges perturbed in atypical2 
 
Figure 4.12 Second alternative structure provided by the search 

























































































Edges that don t have perturbation
Edges perturbed in atypical1 
Edges perturbed in atypical2 
 
Figure 4.13 Third alternative structure provided by the search 
























































































Edges that don t have perturbation
Edges perturbed in atypical1 
Edges perturbed in atypical2 
 
Figure 4.14 Fourth alternative structure provided by the search 






Table 4.6 Model predictions for the 4 alternative structures for azathioprine model that provided by the search method  
Scenarios 
Set-1 Set-2 Set-3 Set-4 Reference 
6-TGN 6-MMP 6-TGN 6-MMP 6-TGN 6-MMP 6-TGN 6-MMP 6-TGN 6-MMP 
Typical 0.0690 0.0350 0.0672 0.0284 0.0765 0.0325 0.0781 0.0352 0.0710 0.0323 
Atypical1 0.1148 0.0863 0.1082 0.0934 0.1063 0.0980 0.1161 0.0948 0.1180 0.0924 
Atypical2 1.0634 0.0199 0.9979 0.0203 0.9328 0.0203 1.0342 0.0189 1.0000 0.0197 
OBJ 0.0168 0.0253 0.0248 0.0220  




In this work a method to search across QSP model structures was 
developed using a simple 5-state model. This method was then successfully 
implemented for the 18-state azathioprine model. 
Development of search method: 
Development of the methodology was conducted in 5 parts: (1) Defining a 
node and edge model, (2) Deriving a steady state solution for the system, (3) 
Defining the flux parameters using logic and continuous variables, (4) Setting up 
simulated annealing for the search, and (5) Evaluating the stability of the search 
process. Each part provided the fundamental building block for the next part, 
and ensured the application of the method is generalizable to other model 
structures. 
Most models in the QSP framework, including the one in this work, are 
implemented using ODE based mathematical formalism. With ODE solutions a 
search across the structure incurs a significant computational burden. An 
eigenvalue decomposition approach can overcome the issue of computation cost 
but only in the case of linear stationary systems. In this work the system was 
reconstructed as a set of linear fluxes and then solved for steady state which 
significantly reduced computational burden. Nonlinear systems would pose a 
significant issue if non-steady state solutions were required. In this case an 
inductive linearisation method would be helpful to solve the system.150 Since 
only the steady state solution is required, a simplified version of this method 
(obtained by solving at 𝑡  ∞). 
A binary logic was used to switch the edges by turning the edges on or off 
(active/inactive). This approach allowed to generate various structures with 
varying connections between the nodes. In essence this is equivalent to turning 
on or off nodes, as a node with no inputs is essentially off. The active edges were 
then assigned to a continuous set of values (between 0.1-1) to accommodate rate 
constants to the fluxes to determine the input and output from the nodes and 
therefore provide a solution for steady state.  




The search resulted in appearance of various structural anomalies (e.g. 
islands, transient terminal states, trivial solutions) that could affect the stability 
(or credibility) of the search. In this work these anomalies were identified in test 
runs and hence the overall notation was updated to accommodate these effects.  
The solutions proposed here were either based on a priori constraints or a 
posteriori transient constraints.  The former relates to the use of always-on or 
always-off switches for the edges that overrode the search logic values and was 
used to eliminate island states and trivial solutions. The latter caused by transient 
terminal states (solved by a posteriori constraints) were identified during the 
search process. An alternative to the always-on or always-off scenario is to utilise 
a base model (termed 𝑆𝑏), in which the base model has a minimal logic structure 
that is never simplified further. This fix in essence reduces the dimensionality of 
the system, and, in theory will also help to minimise, but may not completely 
eliminate, identifiability issues. 
It is noted that Saez-Rodriguez et al. implemented a method to search for 
alternative model structures to recognise off target effects of various drugs on 
cellular networks in normal and transformed human hepatocytes.144 Their 
models used logic based models for which the method turns the nodes of the 
model on or off using Boolean functions. Several tutorials in the QSP framework 
have referred to this work as a method of exploring knowledge gaps.1, 52, 54, 56, 57, 
144 Contrasting to that, in this work the search for alternative structures involved 
switching the edges and then assigning continuous (constrained) numerical flux 
values to the active edges. This can yield a special case where a node is turned 
off since all edges that provide its input flux are inactive. Since data on the 
presence of nodes, in other words azathioprine metabolites, is well 
documented109, 112, 151, 152, switching nodes on and off is not a biologically 
plausible solution. 
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Search performance for the 5-state model:  
The method was explored using a simpler 5-state model in order to provide 
some idea as to the characteristics of the search approach. The model outputs 
from these runs showed that they are close to each other but do not match with 
the reference values (Table 4.4). This indicated, not surprisingly, that a 5-state 
model would not work effectively to solve the problem with azathiorpine. 
Results for the stability of the search method provided two inferences: (1) similar 
objective function values that resulted from the five runs indicates that the 
method is stable, and this brings the potential for extendibility of the method to 
any other (larger) models, and (2) different model structures (and fluxes) 
provided similar objective function values which suggests that the model has 
identifiability issues. Importantly it is evident that the search method is not 
affected by such issue. 
Inference from the 18-state azathioprine model search: 
The search method was implemented to a reduced 18-state azathioprine 
model where the two sets of composite target metabolites were lumped into two 
states, 6-TGN and 6-MMP. The search was explored with different perturbation 
schemes where either one or two edges were changed simultaneously. The two 
edge perturbation provided acceptable predictions of the reference 
concentrations indicating more than one pathway must be involved to generate 
the atypical scenarios (Table 4.5). 
The implemented search method with the 2-edge perturbation yielded 4 
alternative structures that provided target metabolite concentrations within 10% 
of the reference values (Table 4.6). These results were consistent across runs (i.e. 
similar OBJ and outputs) despite the model structures being different. The 
similarity of the OBJ suggests that the search across high dimensional spaces 
might lead to local minima. Issue with local minima are not generally expected 
with simulated annealing, but ultimately dimensionality will always be an issue. 
In addition, it is clear that there are several different structures that yield the 
same (or at least a very similar) OBJ solution. This suggests that the logic matrix 




(S) is not identifiable for this input-output data.  In addition, as not able to be 
seen structurally it is also reasonable to assume that the flux matrix (K) is also 
not identifiable.  Pinpointing the cause of such structural identifiability issues is 
practically challenging. 
The suggested four sets of alternative structures for the azathioprine model 
(reported in the figures of section 4.4.2) identified two trends. These can be 
visualised by overlaying the alternative pathways for atypical scenarios on the 
originally developed 30-state model (see Figure 4.15). Trend (1) the structures 
showed the need for the existence of a flow in the direction of metabolic reaction 
towards the production of 6-MMP (i.e. 6-MeTIMP or 6-MeTIDP or 6-MeTITP or 
6-MMP or 6-MMPR) from its lower region (i.e. from 6-MP or 6-TX or 6-MPR or 
6-TIMP or 6-TIDP or 6-TITP). This suggests there could be a missing feed 
forward mechanism (shown by a blue arrow in Figure 4.15). Trend (2) suggested 
an edge in the direction opposite to the flow of the metabolic reaction towards 6-
MMP from its right hand region (i.e. 6-TXMP or 6-MeTGTP or 6-MeTGDP or 6-
MeTGMP or 6-MeTGR or 6-MeTG or 6-TG or 6-TGR). This gives an impression 
that there might be a feedback mechanism to produce excess 6-MMP (shown by 
an orange arrow in Figure 4.15). 
These observations propose hypotheses that, there should be at least one 
pathway as a feedforward or feedback process in the metabolism of 
azathioprine. This aspect is not in the current boundaries of the knowledge of 
azathioprine metabolism, but it could investigated further in specifically 
designed in-vitro experiments. This finding showed the power of the QSP 
framework to provide alternative hypotheses.  
In the process of development of the search method it was assumed that 
the fluxes in the system were governed by first-order rate process in place of the 
usual enzyme kinetic parameters (𝑉𝑚 𝑥  and 𝐾𝑀 ). This approach may not be 
mechanistically appealing for describing enzymatic kinetics of metabolic 
pathways. This simplification was made to accommodate the eigenvalue 
decomposition solution. Since the goal was to explore alternative model 
Chapter 4: Searching for alternative QSP model structures 
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structures, and not the parameter values, this approach should not adversely 















































































































Figure 4.15 Trends of the missing pathways (orange and blue arrows) 
for the atypical scenarios suggested by the alternative structures. This 
separates the nodes in the model, apart from the composites of 6-TGN and 6-
MMP, into two regions, one on the right hand side (circled in thick orange 
line) and the other below (in thick blue line) to 6-MMP. 
 
This work illustrated a case where a QSP model was an incomplete 
representation of a system. Systems modelling approaches are in their 
developmental stage and are anticipated to empower drug development and 
pharmacotherapy. While discussions on success stories of QSP look appealing, 
sharing the experiences and challenges with the approach and implementation 
will add more value to the new field. The methodology presented in this chapter 
highlighted identification of the weakness of a developed model, with respect to 
gaps in the underpinning knowledge, and provided plausible future directions 




to overcome it. The method developed to search for alternative structure for an 
incomplete model could be generalizable to any other simple or complex QSP 
model. 
4.6. Conclusion 
A simulated annealing based algorithm was developed to revise the model 
structure and parameter values simultaneously in multidimensional space. The 
search provided four alternative structures for the systems model for 
azathioprine metabolism. The method can be extended to other QSP models. 
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Chapter 5:  Deterministic identifiability of 
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QSP models may need scale reduction in order to minimise issues with 
multidimensionality, and focus on specific modular components. The reduced 
models need to be tested for identifiability issues. Structural identifiability of PK 
and PKPD models has been discussed in several publications but there are very 
few on deterministic identifiability. This chapter introduces an additional theory 
to sub divide deterministic identifiability with the help of some simple PK and 
PKPD models. It is to be noted that, due to these theoretical components, in 
contrast to previous chapters this chapter has different section headings – i.e. 
introduction, theory, examples, results, discussion and conclusion. 
5.1. Introduction 
Identifiability is an important component of pharmacokinetic-
pharmacodynamic (PKPD) model development. An identifiability analysis can 
provide the basis for understanding the limits of model structure and 
parameterisation and will therefore inform model choice. Identifiability is a well-
recognised field in the disciplines of engineering, agricultural and computer 
sciences. As per literature research on identifiability in the area of PKPD 
modelling dates back to at least 35 years [e.g. Cobelli et al. 153], but the theoretical 
concepts have not been extensively applied in practise. In addition, the majority 
of studies have historically focused on fixed effects models 154-162, with only 
recent interest in the identifiability of nonlinear mixed effects models 163-168. The 
recent growth of systems pharmacology modelling, with a focus on 
multidimensional mechanistic models, further signals the need for a robust 
theoretical and practical framework for conducting identifiability analysis in 
pharmacometrics. 
Structural identifiability (SI), also known as theoretical or a priori 
identifiability, refers to the uniqueness of the parameter values in a model given 
a perfect input output data. The model is considered to be globally structurally 
identifiable if there is a unique set of parameters for the model. Whereas the 
model is said to be locally structurally identifiable if there are a finite set of 
parameter values that solve for perfect output data. Finally a model is considered 




not structurally identifiable if there are infinite sets of parameter values that 
provide the same output. As an example, a statistically nonlinear model with 
two or more states (e.g. an input compartment and observation compartment in 
a 1-compartment pharmacokinetic model) will, due to flip-flop kinetics, yield a 
model that is locally identifiable if observations are only available from the 
disposition compartment. In this case, such a model will have a finite set of 
parameter values that provide an identical output. However, if all compartments 
are observed, then the model is globally identifiable. 
There are two main methods for SI analysis; those that use algebraic 
methods and those that use numerical methods. Typical examples of algebraic 
methods include; the Laplace transformation approach 154, the principles of 
observability, controllability and connectivity 169, the use of a Taylor series 157, 
the similarity transformation approach 170, the augmented system approach 171 
and a differential algebra approach 172. Various numerical methods have also 
been described, including methods based on the information matrix 166, 173. Other 
methods include the applied Exact Arithmetic Rank (EAR) approach 174, 
methods based on the combination of a posterior likelihood approach and Exact 
Arithmetic Rank 175, and an applied Laplace transformation mixed effects 
extension, which is a semi numeric approach 165. It should be noted that most 
numerical methods cannot assess global identifiability since it is, in theory, 
impossible to assess all values of the parameters. Hence these methods tend to 
provide solutions for the local identifiability problem. 
Deterministic identifiability (DI), also known as practical identifiability or 
a posteriori identifiability, is concerned with the precision of the parameter 
estimates in an otherwise structurally (at least locally) identifiable model. In the 
setting of imperfect input-output data, the standard errors of some model 
parameters may be large enough to render the model as not deterministically 
identifiable. There are a large number of publications exploring deterministic 
identifiability, often in the framework of the optimal design of experiments (see 
Mentré et al. 176 for the derivation and Duffull et al. 177 for further details). It 
should be noted that some researchers (Godfrey 157) have used the term 




deterministic identifiability analysis to mean structural identifiability. 
Nevertheless, in this work the term deterministic identifiability analysis is used 
as defined above. 
This chapter intended to extend the concept of deterministic identifiably 
with two subcategories called external deterministic identifiably (EDI) and 
internal deterministic identifiably (IDI). The initial part will outline the 
underpinning theory followed by illustration of EDI and IDI using three 
examples. 
5.2. Theory 
5.2.1. External Deterministic identifiability 
EDI refers to models that may or may not DI as a result of the study design. 
The term ‘external’ is used as this level of identifiability is external to the model 
and relates to factors controlled by the investigator, such as (for example) dose, 
sampling times, number of subjects. For simplicity in this work only sampling 
times were considered but the concepts expressed here may be generalised to 
any design setting. When considering sampling times only, the risk of non-EDI 
problem can be defined by the relationship between the number of unique 
observations [d n t d a  𝑢𝑛𝑖𝑞𝑢 (𝑛)] and the number of parameters (𝑝) in the 
model. It is to be noted that the term unique observations refers to the 
observations that excludes the replicates (and therefore not independent) and 
hence refers to observations that are collected under different experimental 
conditions (e.g. dose levels, or sampling times). For a fixed effects model, if 
𝑢𝑛𝑖𝑞𝑢 (𝑛) < 𝑝 the study is said to be under-determined and the model will not 
be externally deterministically identifiable. This can occur despite the model 
being either globally or locally structurally identifiable. If 𝑢𝑛𝑖𝑞𝑢 (𝑛)  𝑝 then 
the model is said to be exactly determined. However, since the variance of an 
additive residual error may also be estimated, then this definition can be 
expanded to 𝑢𝑛𝑖𝑞𝑢 (𝑛)  𝑝 + 1. Of course this does not mean that the model 
parameters will be precisely estimated under a given design, simply that it is, in 
theory, possible to estimate the parameters under these conditions. This work 




proposes that 𝑢𝑛𝑖𝑞𝑢 (𝑛)  >  𝑝 + 1 can produce an externally deterministically 
identifiable model and under this condition it is simply a matter of finding a 
design that provides the necessarily precise parameter estimates. 
5.2.2. Internal Deterministic identifiability 
IDI refers to the deterministic identifiability of a model that is not 
specifically related to the study design but rather relates to an ‘internal’ aspect 
of the model. For all models that are structurally identifiable and are presumed 
to be deterministically identifiable, by virtue of the design (i.e. the design is 
considered externally deterministically identifiable), this work proposes that 
there may be a subset of models that are still not deterministically identifiable. 
To make the distinction with EDI, non-internal deterministic identifiability is 
defined as the existence of a set of parameter values for an otherwise externally 
deterministically identifiable model that leads to imprecise estimates of model 
parameters. This can be expressed as 
∃?⃗? : 𝑆𝐸(?⃗? , ?⃗? 𝑫) > 𝜓,       
Equation 5.1 Condition for non-internal deterministic identifiability 
where, 𝜃  is a 𝑝 × 1 vector of parameter values (𝜃  [𝜃1, … , 𝜃𝑝]T), [ ]
𝑇   is the 
transpose, 𝑆𝐸 denotes the asymptotic standard error of the parameter estimates, 
𝜉 𝐷 is an 𝑛 × 1 vector of D-optimum design variables and 𝜓 represents the level 
of imprecision that is important to the investigator. In this circumstance, the 
investigator may conduct an appropriately conceived experiment but be unable 
to estimate precisely the parameter values of interest. For the purposes of this 
research, a relative standard error (RSE) 100 % was defined as the upper limit of 
acceptable imprecision. This definition is arbitrary and any value can be chosen 
by the investigator. 
Equati n 5 1 can be re-written to formulate this as a minimax design that 
involves two sequential steps of minimisation and maximisation. In the first step 
(shown in Equation 5.2) the design vector, 𝜉 , is chosen to maximise the 
determinant of the Fisher information matrix (i.e. a D-optimum design, denoted 




as 𝜉 𝐷). In the second step (shown in the Equation 5.3) parameter values, 𝜃 , are 
then chosen that minimizes the determinant of the Fisher information matrix (i.e. 
finds the worst set of parameter values, the parameter set is denoted as 𝜃 𝐷
′
, the 
prime is used to denote that the parameter set minimizes the determinant of the 
information matrix). This process repeated iteratively until a stable set of 
parameter values is identified such that the set of parameter values yields the 
most imprecise parameter estimates. This is shown in a single iteration here: 
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, 𝑓𝑜𝑟 𝑖  1…𝑝 
and    𝑠𝑢𝑝({𝑐1, 𝑐2, … , 𝑐𝑝}) > 𝜓. 
𝐼 is defined as the Fisher information matrix and || signifies its 
determinant and 𝑐𝑖 is the relative standard error. The information matrix is 
constructed as a function of the Jacobian matrix (𝐉), a matrix of first partial 
derivatives of the response over all parameter values and design points. 
For a fixed effects model, 
𝐼(𝜃 , 𝜉 𝑛)  𝐉
𝑇  ∑ 1 𝐉  
Equation 5.4 Fisher information matrix for fixed effects model 
and for a mixed effects model (assuming a first-order Taylor series 
approximation with resulting independence of fixed and random effects 
components), 
𝐼(𝜃 , 𝜉 𝑛)  𝐉
𝑇  V 1 𝐉 , V  𝐉 Ω 𝐉𝑇  + ∑ 1  
Equation 5.5 Fisher information matrix mixed effects model 




The information matrix is therefore constructed as 
𝐼(𝜃 , 𝜉 𝑛) ≈ [
𝑀𝐵 0
0 𝑀𝑉
] , 𝑀𝐵  2𝐉
𝑇  V 𝟏𝐉, 









Here 𝑀𝐵 and 𝑀𝑉 are the information sub-matrices for the fixed and random 
effects, respectively, and 𝜆  is vector of the variances of all random effects 
parameters (between subject variances and residual variances, in this case 
elements of Σ (variance of the residual effects) and Ω (variance of the between-
subject effects)). The random effects parameters and Jacobian matrices are 
defined as: 
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In this notation, ∑ and Ω are diagonal matrices of dimension 𝑛  and 𝑝 of 
residual variance ( 𝜎2 ) and between subject variance ( 𝜔2 ) parameters, 
respectively, and 𝑓(𝜃 , 𝜉 )  is a prediction of the response from the nonlinear 
function of the structural model for a particular input. 
Since the minimax function (in Equation 5.2 and Equation 5.3) will be 
prohibitively burdensome, in this work D-optimal maximisation step was 
replaced with a supersaturated design. Such design is defined here as one in which 
the number of observations greatly exceeds the number of parameters to be 
estimated by at least a factor of 10; such that  𝑢𝑛𝑖𝑞𝑢 (𝑛) > 10𝑝. Note this differs 
from other uses of the term supersaturated which is often applied to models and 
defined where the number of parameters greatly exceeds the number of 
observations. 




5.2.3. Examples to illustrate IDI in PK and PKPD models 
Three examples are presented to illustrate internal deterministic 
identifiability. The first example shows an obvious case of non IDI using a first-
order input-output PK model (Oral 1 compartment PK model [also known as the 
Bateman-model]). This model is standard in PK and is known to be structurally 
locally identifiable. The second example extends the IDI analysis to a model that 
is structurally globally identifiable. In this case a parent-metabolite model (PM-
model) was considered with iv-bolus input of the parent, first-order complete 
metabolism of the parent to the metabolite and first-order elimination of the 
metabolite. Finally, the concept is explored using a motivating PKPD model as 
an example. This example is characterised by a 1-compartment intravenous-
bolus PK model connected to an Emax model via a turnover link (IVBTO-model). 
A supersaturated design of 96 samples was used for each response variable. 
The design was based on a geometric series from time zero to at least 4 times the 
maximum half-life. Each study was assumed to be conducted on 100 subjects 
and the dose administered was 1000 mg. For the Bateman-model and PM-models 
the initial set of parameter values were arbitrary and for IVBTO-model the 
parameters were adapted from published data 178. Between subject variability for 
all models was set to 30% CV and random unexplained variability was 10% for 
proportional error and a variance of 1 mg/mL for the additive error. Random 
parameter vector variates were generated that covered a plausible profile of the 
response, within pre-defined boundaries. The relative asymptotic standard error 
(RSE) values for each of the generated random variates of the model were 
computed. 
The sets of parameter values with high RSE values (>  𝜓( 1); i.e. a relative 
standard error (RSE) > 100%) were additionally evaluated at the D-optimal 
design using POPT®. This reduces the iterative minimax design to a 2 stage 
process. Any model with a set of parameter values with RSE values greater than 
100% under the optimal design was designated to be not IDI. 
  




5.2.3.1. Oral 1 compartment PK-model 
This model describes plasma drug concentration-time data after 
extravascular administration that follows first-order kinetics. A typical 
schematic is shown in Figure 5.1. 
 
Figure 5.1 Schematic for oral 1 compartment model 
The integrated solution to the model is provided by Equation 5.6. 
𝑐(𝑡)  
𝐹 ∙ 𝐷 ∙ 𝑘𝑎
𝑉 ∙ (𝑘𝑎 − 𝑘)
(   ∙𝑡 −     ∙𝑡)   
Equation 5.6 Mathematical model for one compartment PK-model 
Here, 𝑐(𝑡) is the concentration of the drug in central compartment at time, 
𝐹 is the bioavailable fraction, 𝐷 is the dose administered, 𝑘𝑎 is the absorption 
rate constant, 𝑉 is volume, 𝑘 is the elimination rate constant which is calculated 
as 𝐶𝐿/𝑉. Observations are available only from the central compartment. 
This model predicts the drug concentration change in the systemic 
circulation. With observations from the central compartment only the model is 
noted to be structurally locally identifiable for fixed value of 𝐹 in that there are a 
discrete number of parameter sets that provide identical predictions (also termed 
flip-flop). It is also noted that the model has a mathematical singularity when the 
rate constants approach the same value (𝑘𝑎 − 𝑘   Δ → 0). It is worth noting that 
the ODE solution does not contain this singularity. 
As the first-order rate constant of input (𝑘𝑎 ) approaches the value for 
output (𝑘 ; 𝐶𝐿/𝑉), or vice versa, the RSE values for 𝑘𝑎 , 𝑉  and their between-
subject variance tend to infinity. This is shown in Figure 5.2, that there exists a 
set of parameter values that cause inflation of the RSE. Therefore it indicates that 
the model is not deterministically identifiable. In this case, since the model is 














Figure 5.2 Inflated RSE as (𝑲𝒂 − 𝒌) tends to zero 
This trivial example highlights that a simple model that is structurally 
(locally) identifiable, externally deterministically identifiable may not be 
internally identifiable for certain sets of parameter values.  In this example it is 
seen that when Δ  = 0.003645 (/h) the RSE for 𝑘𝑎 equals 100%. 
5.2.3.2. PM-model 
This model describes the PK of parent and its metabolite when 100% of 
metabolism takes place from parent to metabolite. The schematic is shown in 
Figure 5.3. 
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Equations for the model are: 
𝑃(𝑡)   
𝐷
𝑉𝑃
(   𝑃𝑀𝑡)  and  
Equation 5.7 Mathematical model for parent concentration 
𝑀(𝑡)   
𝐷 𝑘𝑃𝑀
𝑉𝑀(𝑘𝑃𝑀 − 𝑘𝑀0)
(   𝑀0𝑡 −    𝑃𝑀𝑡)  
Equation 5.8 Mathematical model for metabolite concentration 
𝑃(𝑡)  and  𝑀(𝑡)  are the concentrations of the parent and metabolite, 
respectively, in the systemic circulation at time 𝑡. 𝐷 is the dose administered, 
𝐶𝐿𝑃𝑀 and  𝐶𝐿𝑀0 are clearance parameters of parent to metabolite and for 
metabolite, respectively; 𝑉𝑃 and  𝑉𝑀 are volume parameters for parent and 
metabolite, respectively; 𝑘𝑃𝑀 is the rate constant for metabolism from parent to 
metabolite and is calculated as 
𝐶𝐿𝑃𝑀
𝑉𝑃
, 𝑘𝑀0 is the elimination rate constant of the 
metabolite and is calculated from 
𝐶𝐿𝑀0
𝑉𝑀
. Observations are available for both parent 
and metabolite. 
This model is structurally (globally) identifiable. The model equation for 
computing metabolite concentration (Equation 5.8) is the same as that of the 
Bateman model (Equation 5.6) in the case of the metabolite. Without any 
ambiguity, the same type of singularity will occur for this model (in this case, 
Δ   𝑘𝑃𝑀 − 𝑘𝑀0). 
Different values of 𝐶𝐿𝑃𝑀 , 𝐶𝐿𝑀0 , 𝑉𝑃𝑀  and 𝑉𝑀0  were selected to cover a 
reasonable range of parameter values as well as yield calculated rate constant 
values that would approach but not result in a singularity. It is seen that there is 
no circumstance in which a set of parameter values results in a %RSE of greater 
than 100% (see Figure 5.4). In addition, no set of parameter values evaluated in 
the search yielded a %RSE greater than 100%. It is concluded therefore that this 
model therefore does not possess non-IDI characteristics. 





Figure 5.4 Profiles of RSE values against the 𝒌𝑷𝑴 − 𝒌𝑴𝟎  values for 
(a) 𝑪𝑳𝑷𝑴, (b) 𝑽𝑷, (c) 𝑪𝑳𝑴𝟎, (d) 𝑽𝑴, (𝐞) 𝝎𝑪𝑳𝑷𝑴 , (f) 𝝎𝑽𝑷 , (g)𝝎𝑪𝑳𝑴𝟎  and (h) 𝝎𝑽𝑴  showing PM-
model is IDI 
5.2.3.3. IVBTO-model 
The IVBTO model is commonly used to link drug response with 
concentration at different time points 179, 180. The schematic is shown in Figure 
5.5. 





Figure 5.5 Schematic for IVBTO model 
Equations for the model are: 
𝑐(𝑡)   
𝐷
𝑉
(   𝑡)  and  




 𝑅𝑖𝑛 (1 −
𝐼𝑚 𝑥  𝑐(𝑡)
𝐼𝐶50 + 𝑐(𝑡)
) − 𝑘𝑜𝑢𝑡 𝑟  
Equation 5.10 Turnover model 
Similar to the notation used in the previous models, 𝑘 is calculated from 
𝐶𝐿/𝑉, and 𝑐(𝑡) is the concentration at time 𝑡. The pharmacodynamic response 
variable (𝑟) is given by an ordinary differential equation with constant input 
(𝑅𝑖𝑛) and an inhibitory Emax model with 𝐼𝑚𝑎𝑥 as the maximum inhibitory effect 
of the drug (0 < 𝐼𝑚𝑎𝑥 < 1), 𝐼𝐶50 is the concentration of the drug at which half 
the maximum inhibition takes place and 𝑘𝑜𝑢𝑡 is the first-order elimination rate 
constant for 𝑟. The initial conditions, also noted as baseline response (𝐵𝐿), for 𝑟 
are 𝑟(0)  𝑅𝑖𝑛/𝑘𝑜𝑢𝑡 . Observations are available for both concentration and 
effect. Note that this model was found to be structurally globally identifiable as 
per evaluation using DAISY 172 and structurally identifiable using popt_i (free to 
download from www.pharmacometrics.co.nz) (analysis not shown). Note that the 
numerical methods used in popt_i can only distinguish between local and 
structural identifiability and not between global and local identifiability. 
A reference set of parameters were adapted from Sharma et al. 178 and were 
27 L/h, 90 L, 1, 0.1 mg/L, 0.3 h-1, 30 for 𝐶𝐿, 𝑉, 𝐼𝑚𝑎𝑥, 𝐼𝐶50, 𝑘𝑜𝑢𝑡 and 𝐵𝐿. Under this 
𝑫𝒐𝒔𝒆 
𝑪 
𝒌   
𝑪𝑳
𝑽









set of parameter values the model was internally deterministically identifiable 
and all parameter values had RSE values below 100% (see Table 5.1). In order to 
assess for internal deterministic identifiability, sets of random variates were 
generated for the selected parameter values. Plausible experiment boundary 
values on the parameters were chosen to ensure that, for instance, the 
elimination did not become so prolonged that it could not reasonably be 
determined within the constraints of the experiment. The lower and upper 
boundaries for the reference parameter values were 10 - 50 L/h, 45 - 135 L, 0.5 - 
1, 0.01 - 10 mg/L, 0.03 - 3 h-1, 15 – 45 for 𝐶𝐿 , 𝑉 , 𝐼𝑚 𝑥 , 𝐼𝐶50 , 𝑘𝑜𝑢𝑡  and 𝐵𝐿 , 
respectively. Random sets of variates were generated and tested for RSE using a 
supersaturated design. A selection of those sets of parameter values that gave 
high RSE values were then subject to an optimal design where the number of 
observations exceeded the number of parameters by 4 fold in order to determine 
whether the model retained IDI issues. In addition, an adaptive random search 
method was used to identify the worst case set of parameter values. The search 
was designed to sample from a normal density (truncated at the boundary 
values) centred on the reference parameter values with wide dispersion. 
Deviates were tested for their RSE values, the parameter set that provided the 
highest RSE values was determined the worst set. The density was then re-
centred on the worst set of parameter values and the dispersion constricted every 
τ simulations (where in this study τ = 1000), ultimately leading to a single trace 
for each parameter (see Figure 5.6). 





Figure 5.6 Adaptive random search results for IVBTO model 
It was observed that there were several sets of random variates for which 
the model was not IDI. For example, the inflated RSE values of 𝜔𝐼𝐶50 for the 
arbitrary (A) sets is shown in Table 5.1. For both non-IDI and IDI cases the PK 
and PKPD responses are observed to have plausible profiles (see Figure 5.7). The 
worst case set was given by the parameter vector: 50 L/h, 45.92 L, 0.5, 9.99 
mg/mL, 0.03 h-1, 15 for CL, V, Imax, IC50, kout and BL, respectively. 
Overall there exist some set of parameters for which this model would be 
considered not deterministically identifiable and hence since the model would 
normally be expected to be deterministically identifiable it is said to possess non-
IDI characteristics. 
  




Table 5.1 Sets of fixed effects and between subject variance (𝑩𝑺𝑽) parameters and their %RSE values for IVBTO model. The 
reference set (R) has RSE values below 100%, but for the arbitrary sets (A1, A2, A3 and A4) % RSE values of 𝑩𝑺𝑽𝑰𝑪𝟓𝟎 (shown in 
bold) are greater than 100% rendering the model not IDI. 


















𝐶𝐿 27 3.3 13.3 3.5 4.00 3.2 1.35 3.3 1.00 3.2 
𝑉 90 3.2 135 3.2 13.9 3.2 75.0 3.2 16.0 3.2 
𝐼𝑚 𝑥 1 3.2 0.5 3.5 0.5 16.0 1.0 3.8 0.3 7.7 
𝐼𝐶50 0.1 7.5 0.052 10.7 2.1 34.8 0.4 9.6 0.5 32.8 
𝑘𝑜𝑢𝑡 0.3 3.6 0.517 4.8 0.05 12.3 0.39 6.3 0.05 13.7 
𝐵𝐿 30 3.2 16.0 3.2 397.1 3.2 4.0 3.4 89.8 3.2 
𝐵𝑆𝑉𝐶𝐿 0.1 15.0 0.1 16.0 0.1 14.5 0.1 15.3 0.1 14.5 
𝐵𝑆𝑉𝑉 0.1 14.5 0.1 14.8 0.1 14.3 0.1 14.5 0.1 14.3 
𝐵𝑆𝑉𝐼𝑚𝑎𝑥  0.1 14.5 0.1 16.5 0.1 53.1 0.1 17.7 0.1 26.6 
𝐵𝑆𝑉𝐼𝐶50 0.1 69.5 0.1 133.8 0.1 400.5 0.1 110.6 0.1 293.7 
𝐵𝑆𝑉 𝑜𝑢𝑡 0.1 17.6 0.1 29.9 0.1 57.4 0.1 48.2 0.1 55.3 
 




R A(1) A(2) 
Figure 5.7 PK (concentration (in mg) vs Time (in hrs)) and PD (Drug response vs Time (in hrs)) profiles of 
the sets of parameters for reference (R) for which IVBTO model is IDI and arbitrary (A(1), A(2), A(3), 
A(4)) sets of parameters for rendering the model not IDI 






In this work deterministic identifiability defines the precision with which a 
set of parameter values can be estimated given imperfect input-output data. For 
structurally identifiable models this type of identifiability is generally 
considered to be a function of the experimental design in the sense that a design 
exists for which the parameters can be estimated with appropriate precision. 
However, this work showed that even for structurally identifiable models with 
either a supersaturated design (i.e. a design where 𝑢𝑛𝑖𝑞𝑢 (𝑛)  >>  𝑝 + 1), or an 
optimal design, there sometimes exists sets of parameter values for which the 
precision is unacceptably poor. We defined this as internal deterministic 
identifiability as it is a function of the parameter values of the model and not of 
the design and hence is not controllable by the investigator. 
This works showed using two examples for a model that is either locally 
structurally identifiable (the oral 1 compartment PK model) or globally 
structurally identifiable (the IVBTO model) that there exist sets of parameter 
values that yield unacceptably low precision of parameter estimation. It is also 
seen that in another globally structurally identifiable model that a set of 
parameter values were not found that yielded issues with estimation precision. 
It is therefore, not obvious as to what features of a model are likely to render the 
model not-IDI. It is to be noted that the value of imprecision was chosen 
arbitrarily as a relative percent standard error of 100% to define a set of 
parameter values as non-IDI. This value could be chosen to be more conservative 
or otherwise. This does not affect the generality of the findings presented here. 
In some circumstances it was noted that IDI could be explained by a logical 
process such as the presence of a mathematical singularity as in the oral 1 
compartment PK model example. In this example it was noted that the values of 
rate constants that render the denominator in the model close to zero results in 
inflated RSE values of 𝑘𝑎 and 𝑉. This has been noted before and is indeed the 
reason for the introduction of the ‘DOST’ model 181, a simplified version of the 
Bateman model, which is often used to circumvent the issues with singularity 




seen in the oral 1 compartment PK model. However, the same logic cannot 
necessarily be applied to similar models. In this work the PM-model is an 
example of such a case. It seems likely that other locally identifiable models that 
have singularities, e.g. any multi-disposition compartment PK models, are likely 
to share IDI issues. Nevertheless, there might not be an obvious logic for the 
existence of the non-IDI situation. This is illustrated with the IVBTO model 
where some sets of parameter values render imprecise estimation of the 
parameters. This is a combination of a simple intravenous bolus one-
compartment PK model and an 𝐸𝑚 𝑥 model with turnover link. This model was 
selected due its simplicity, and because it is the basis of many PKPD models. 
It is worth noting that for all practical purposes if the maximum number of 
allowable subjects or a maximum allowable dose or repeated doses with 
maximum allowable total dose yield high RSE values then essentially the model 
possesses a non-IDI characteristic. This can be used to provide a distinction of 
EDI from IDI. If the boundaries on the design space render the model to have 
high RSE values over all parameter sets then the model is not externally 
deterministically identifiable. However if the boundaries do not cause inflated 
RSE values for most vectors of parameter values but do for a subset then the 
model is on the whole externally deterministically identifiable but possesses 
some non-internally deterministically identifiable characteristics. A reasonable 
convention by the investigator to adopt a previously used design that has 
performed well in similar circumstances may not, therefore, translate well to all 
new circumstances and this may not be obvious a priori. Often this can be 
overcome by increasing the number of subjects, however in the case of the Oral 
1-compartment PK-model as 𝑘𝑎 approaches 𝑘, the minimum number of subjects 
needed for precise estimation of all parameters tends to infinity (see Figure 5.8). 
In this case the maximum number of subjects needs to be considered a design 
boundary and at the point that the number of subjects exceeds the maximum of 
the study design would then represent the point at which the model would be 
said to possess issues with IDI. 





While this work appears to cast doubt about the credibility of models that 
are non-IDI (which could be many), it should be noted that this concept is 
applied to the level of the model and values of the parameter vector. Hence in 
many modelling scenarios an IDI issue may not of itself cause a problem. The 
observation that some parameters are poorly estimated is often a cause of 
frustration for modellers and is often considered to be caused by a limitation 
placed upon the design due to strong clinical constraints. However, it was noted 
in this work that even under very weak constraints (e.g. that sampling continues 
for at least 4 elimination half-lives) there are some values of the parameter vector 
that are just difficult to work with and it seems that some parameters may need 
to be fixed in order to allow convergence of local optimisation tools. Moving to 
global optimisation tools and using a hyperprior may well circumvent the IDI 
issue altogether. 
Figure 5.8 The profile of the minimum number of subjects needed for 
RSE<100% against 𝒌𝒂 − 𝒌 values for an Oral 1-Compartment PK model 





For structurally globally identifiable models, there are sets of parameter 
values that render the precision of parameter estimates to be unacceptably poor 
despite the design being optimal. Under these circumstances it is proposed, with 
this work, that the respective model be considered as not-internally 
deterministically identifiable. There does not appear to be an obvious logic that 
can predict the presence of non-internal deterministic identifiability. Any 
optimal design software can be used to assess for the presence of IDI (for 
example: Nyberg et al. 182). The presence of non-IDI does not indicate that the 
modelling process should be abandoned but is rather that a different structural 
model may need to be employed or that some parameters may need to be fixed. 
It should be noted that this is not something that the investigator can control for 
a priori.































Chapter 6: Discussion and future aspects 
159  
 
This chapter provides synopsis of the thesis, discussion on research 
findings and future aspects in terms of their contribution for the development of 
systems pharmacology framework. 
6.1. Synopsis of the thesis 
The initial aim of the thesis was to understand azathioprine metabolism 
using a quantitative systems pharmacology (QSP) approach. The project 
outcomes were expected to quantify biomarkers for azathioprine’s efficacy in 
order to develop dosing guidelines or a dosing tool for use in a clinical setting. 
During the model development it became clear that there are several gaps in the 
current knowledge of the metabolic pathways of azathioprine that underpin the 
model. This resulted in a change in the focus to address these challenges. 
The work presented in this thesis is divided into 3 parts considering the 
nature of the individual projects. Part-I described a systematic approach to 
develop a QSP model using azathioprine as case example. Part-II involved 
development of two methodologies (1) to address model completeness, an 
assessment of the potential for missing structures, and (2) to search for 
alternative structures, given the model was determined to be incomplete. Part-
III introduced a new methodological concept related to deterministic 
identifiability and highlighted issues that may arise with parameter estimation 
under some parameter sets for specific model structures. 
6.2. Discussion of the research findings 
6.2.1. Development of a systems based model for azathioprine metabolism 
In part-I of this thesis a QSP model for azathioprine metabolism was 
developed to address the clinical challenges, particularly with metabolite 
shunting that has been linked to hepatotoxicity. This involved a bottom up 
approach, and was underpinned by a proposed six stage work flow that was 
adapted from a publication by Gadkar et al.1 Information related to purine and 
thiopurine metabolism was extracted from several sources (i.e. literature, data 
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bases and experts’ opinion). This information was incorporated into the model, 
and ensured that it has covered every known detail of the metabolic pathway.  
The developed 30 state model, as anticipated, provided good predictions 
of the typical setting for both extra- and intra-cellular metabolite behaviour. 
However, when tested for highly plausible hypotheses for how atypical 
scenarios could arise the model could not capture the reference observations. 
This finding hindered the execution of the next stages in the process of the 
clinical implementation, in particular: simplification of the QSP model, 
resolution of identifiability issues, identifying and implementation of control 
mechanisms for dose adaptation. However deficiency of the model to represent 
the data raised the issue as to whether the values of the parameter vector 
adversely affected the model’s performance or whether the model was an 
incomplete representation of the system despite based on existing knowledge 
(i.e. no values of the parameter vector would resolve the problem). These 
questions provided scope for a new research opportunity to solve the issues with 
model deficiency. 
6.2.2. Model completeness analysis 
In this work a complete model refers to a model structure for which there 
exists at least a single set of parameter values that represents all of the reference 
data.  
The concept of existence simply requires a set of parameters to be identified 
that can represent the data. The corollary (non-existence) is a more complicated 
claim and requires a proof that no sets of parameters could exist. Such a proof is 
beyond the scope of the work presented here and therefore model completeness 
analysis was assessed using a global search algorithm. Chapter-3 outlines the 
development of such search. It was assumed that the model structure is correct, 
but activities for the intracellular enzyme activities and transporters were 
wrongly specified and hence an alternative parameter values could exist that 
fully captures the reference data. The algorithm searches across the parameter 
values, and the perturbation factors for abnormal enzyme activities. 
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The results from the global search for the azathioprine model showed that 
the model could predict both typical and atypical2 scenario but not atypical1. 
With this the model was determined to be incomplete (within the range of the 
search), and therefore the model structure is in correct. With this finding the 
question turned out to be is there a model structure that reflects the reference data? 
There are some other methods that can revise the model parameter values 
that can produce the distribution of the observations.52, 56, 57 But this method does 
not fit to serve the needs of this work where the model predictions should to be 
central tendencies of metabolite concentrations instead of a probability 
distributions. Therefore the global search method was developed. One of the 
advantages of using this method is that it is not affected by structure 
identifiability issues. 
6.2.3. Search for the complete or alternative structures of the model 
Chapter 4 concerned with providing solutions for an incomplete model. In 
this chapter a search algorithm was developed to revise model structures and 
parameter values to predict reference values.  
This is straightforward to implement for the QSP model here as the model 
compartments and connection (or movement) between them are naturally 
defined by nodes (vertices) and edges (fluxes), respectively. The search process 
is then a matter of turning on or off some of the fluxes in a model structure so 
that connectivity between the nodes will be altered. 
A simplified eigenvalue decomposition provided a quick algebraic solution 
for the steady state concentrations, and this was combined with a simulated 
annealing based search method. The search was governed by a two parts 
approach where at the first part applies a binary logic to switch the edges on or 
off and alter the connections between the nodes, and the second part determines 
a flux value for the active edges. These two parts were searched simultaneously. 
This method was proven to be stable, unaffected by identifiability issues (due to 
structures or parameter values) and it was possible to eliminate abnormal model 
Chapter 6: Discussion and future aspects 
 162 
 
structures that may destabilise the search process. These qualities, therefore, 
suggest the method may be applicable to any linear complex QSP model. 
There is an existing method published by Rodriguez et al. that modifies 
structures of logic models by switching the nodes in cellular network.144 But no 
such method has been noted that can alter the structure of a flux model. This is 
achieved by the search algorithm that developed in this work.  
The search provided four alternative structures for azathioprine model that 
suggested missing feedback or feed forward mechanisms in the metabolic 
pathway. This methodology showed that QSP models can fail to reflect the 
behaviour of the system due to knowledge gaps, and suggested alternative 
hypotheses that can potentially solve the issues. 
6.2.4. Deterministic identifiability of population PK and PKPD models 
QSP models are commonly affected by identifiability issues due to 
multidimensionality. This issue can be circumvented by scale reduction methods 
(see section 1.2.4.2 (1)), where the number of model compartments can be 
reduced by aggregating the uninformative/insensitive states/parameters. 
However the reduced model might have imprecise parameter estimates (that 
possess high standard errors). In chapter-5 (under part-III) of the thesis discussed 
about circumstances that lead to deterministic identifiability issues. 
Deterministic identifiability is concerned with the influence of study design 
on the precision of the parameter estimates in a structurally (at least locally) 
identifiable model given imperfect input-output data. This work further 
classified deterministic identifiability into two sub-types (1) external 
deterministic identifiability and (2) internal deterministic identifiability. External 
deterministic identifiability was defined as relating to the deterministic 
identifiability of models conditioned on the study design controlled by the 
investigator (i.e. external to the model). In a simple case, a design where the 
number of unique observations (n) is less than the number of parameters (p) in 
the model will be deterministically unidentifiable despite being structurally 
identifiable. By contrast, internal deterministic identifiability describes the 
Chapter 6: Discussion and future aspects 
163  
 
situation in which a specific set of parameters yield unreasonably imprecise 
parameter estimates, despite the model being structurally identifiable and the 
design fulfilling the needs of external deterministic identifiability.  Here external 
deterministic identifiability can be considered to be any unconstrained optimal 
design where unique (n) >> p. In this setting a situation is determined not to be 
internally deterministically identifiable if there exists a set of parameter values 
for which the relative standard errors of parameter estimates will be above an 
arbitrary threshold limit and where the design is optimal or near optimal. Here 
the level of imprecision that is important to the investigator. For the purposes of 
this research, it was defined that a relative standard error (RSE) 100 % to be the 
upper limit of acceptable imprecision.  
This study explored the presence of internal deterministic identifiability 
issues in a common set of PK and PKPD models. 
There was clear evidence that the Oral 1 compartment PK-model was not-
internally deterministically identifiable. It is seen in this trivial example that as 
the first-order rate constant of input (𝑘𝑎) approaches the value for output (𝑘; 
𝐶𝐿/𝑉) that the RSE values of 𝑘𝑎, 𝑉 and their between-subject variance tends to 
infinity. Whereas for the parent-metabolite model, there is no such observation 
and the model was internally deterministically identifiable. In the case of an i.v. 
bolus pharmacokinetic model linked to a pharmacodynamic turnover model 
there existed several sets of parameter values that provided high RSE for the 
between-subject variance for 𝐼𝐶50 for the optimal design. 
6.3. Future aspects 
This work was anticipated to provide an approach for adaptive dose 
adjustments for different clinical settings of azathioprine therapy. However, this 
plan did not eventuate due to issues noted during model evaluation, and hence 
was focussed to solve the issues. It is noted, however, that the issues identified 
in this thesis have only been partially resolved and an adaptive dose strategy has 
not been identified. 
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In Chapter 3, a new methodological concept called model completeness was 
proposed. The methodology was introduced for the purpose of solving the issues 
with the azathioprine model. However, it is believed that completeness issues 
could exist with other models too, and the tool could provide a way to identify 
inadequacies of model structures during QSP model development. In order to 
confirm the existence of a set of parameter values that solves for the reference 
problem, some additional investigation is needed. One of the options could be 
to validate the parameter values with the other data sets for which the values 
were already known. 
Chapter 4 proposed a search method for alternative model structures. This 
approach appears to be new for flux models, although there are some examples 
for logic models. It is proposed that this approach can be used to explore 
knowledge gaps in QSP models and provide alternative hypotheses for mass-
balance or mass-action schema. In this work the method was only initially 
proposed with only limited exploration of its properties. In particular, the 
method was developed for the steady state solution of a linear system. Its 
properties need further exploration when extended to non-steady state and non-
stationary or non-linear systems. Such as linearization of the non-linear systems 
using existing methods, and implement the search method to assess the 
functionality of the search method.150 
As per Chapter 5, precise estimation of the model parameters under 
optimal design may not always be possible. This work provided an awareness 
that there could be some exceptional cases where parameters are “difficult to 
work with”. The examples shown in this work were chosen for exploration 
purposes, and to confirm that internal deterministic identifiability issues exist in 
commonly used models. More exploration is required to understand what type 
of models or characteristics of models may cause these issues to arise. This could 
guide the investigator about when this issue could be influential in their model 
development.  




In this thesis, some explorative mathematical approaches were used to 
evaluate knowledge gaps, and introduce and report issues with deterministic 
identifiability in pharmacometrics. 
This work was not able to answer the question about the cause of various 
atypical scenarios with azathioprine and therefore was not able to propose a 
model based adaptive strategy.  Despite this, a number of methodological issues 
that may occur with QSP models were identified and potential solutions were 
developed and proposed. It is hoped that these methods will provide other 
investigators with the tools to identify and resolve issues in their QSP model 
development programmes. 
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2.1. Archived data for the biochemical pathway of azathioprine metabolism 
 






Fig-6(#1), Table-1, 2 &3 (#2), Fig-2 
(#3). Just wonder if the Km and Kcat 








Table-2&3 (#4) based on invitro 
experiments in human liver cytosol. 
Should ponder on using the Vmax & 











Table-2&3 (#4) based on invitro 
experiments in human liver cytosol. 
Should ponder on using the Vmax & 
Km values from these invitro 
experiments 
  







6-MP_IC SLC (transporter) 
Table-1 and Fig-7 (#5), Fig-5D & 6 (#6) 
and Fig-1, 5 & 6(#7) There is no 
primary literature about the SLC 
(SoLute Carrier) on red blood cells. 
But as per a secondary literature (#8) 
bone marrow cells need 
Hypoxanthine for salvage pathway. 
This is an indication of SLC presence 
on RBC - this is based on the fact that 
Hypoxanthine is translocated into 
cells by these transporters. 
SLC28 is called 
concentrative 
nucleoside transporter 
(CNT) that cotransports 
Nucleosides/bases 
with Na+ ion that 
wholly depend upon 
the electrochemical ion 
gradient, not 
concentration gradient. 




(ENT) that transports 
Nucleosides/bases that 
wholly depend upon 
concentration gradient 
(#20 & #21). 







Table-1 and Fig-7 (#5), Fig-5D & 6 (#6) 
and Fig-1,5&6(#7) There is no primary 
literature about the SLC (SoLute 
Carrier) on red blood cells. But as per 
a secondary literature (#8) bone 
marrow cells need Hypoxanthine for 
salvage pathway. This is an indicative 
of SLC presence on RBC - this is based 
on the fact that Hypoxanthine is 
translocated into cells by these 
transporters. 
  
6 6-MP_IC 6-TX_IC AOX1/XDH 
 Highlighted info in Fig-4 (#9). This is 
based on animal data. However it is 
still not clear about the key enzymes 
involved in RBC for this step. 
Therefore the parameter values are 
arbitrary. Additionally it is reported 
that XO availability in bone marrow is 
almost nil (#18). Clear evidence is not 
found on the availability of XDH. 
Additionally 8-OH-6-
MP also found in this 
process (#9: Figure-4, 
lower right). This is 
considered to be 
catalysed by AO. This is 
reported as biphasic 
reaction (uses two Vmax 
and Km values) 
7 6-TX_IC 6-TUA_IC XDH 
Highlighted info in Fig-4 (#9). It is still 
not clear about the key enzymes 
involved in RBC for this step. 
Therefore the parameter values are 
arbitrary.  
This is reported as 
Michalis-Menten 
reaction  
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8 6-MP_IC 6-TIMP HGPRT 
Fig-3c&d (#10), Table-7&8 (#11). 
Should ponder on using the Vmax & 
Km values from these invitro 
experiments. 
HGPRT deficiency is 
usually due to altered 
Vmax but as per #12 
there may cases where 
patients altered Km 
(increased) values  
9 6-MP_IC 6-MMP TPMT 
Table-1 (#13), Table-1 (#14). Should 
ponder on using the Vmax & Km 
values from these invitro experiments. 
  
10 6-TIMP 6-TXMP IMPDH 
Highlighted info in page-4 (#15), 
page-1(#16) & page-4(#17). Activities 
based on the conversion of IMP to 
XMP. These are arbitrary and not 
translated for the TIMP to TXMP 
conversion. Perhaps more research 
might have been done for 
mycofenolate mofetil as its activity 
underpinned by the inhibition of 
IMPDH. 
  
11 6-TXMP 6-TGMP GMPS 
No articles found that estimated the 
enzyme activity for this step. However 
secondary references provide 
mechanism for endogenous 
conversion of XMP to GMP (#19). 
Researchers seemed to translate this 
endogenous path to TXMP due to 
structural similarity with XMP. 
GMPS converts XMP to 
GMP with 
stoichiometric 
hydrolysis of ATP to 
AMP and inorganic 
pyrophosphate, and L-
glutamine to L-
glutamic acid. This 
process requires the 
presence of Mg++.  
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12 6-TGMP 6-TGDP NMPK 
No primary article found. However 
endogenous pathway (Fig-9.4 in #22) 
strongly supports the step. TGMP to 
TGDP conversion closely related to 
the conversion of GMP to GDP. Fig-
2&4 (#23). 
  
13 6-TGDP 6-TGTP NDPK 
Conversion is confirmed from Fig-2&4 
(#23). Authors from #24 confirmed the 
NDPK activity for the conversion, 
based on the conversion of dADP to 
dATP (dGTP is the phosphate donor), 
and the levels of TGDP and TGTP 
from the table-4. Additionally, #32 
showed (Fig-7) apoptosis induction 
required co-stimulation with CD28 
and was mediated by specific 
blockade of Rac1 activation through 
binding of azathioprine-generated 6-
thioguanine triphosphate (6-Thio-
GTP) to Rac1 instead of GTP. 
NDPK noted to exist in 
A & B forms. Reference 
#23, #24 & #25 reported 
the TGN levels are less 




possibility of loss of 
TGN with the old 
analysis methods which 
uses hydrolysis process. 
Also the frequent 
freeze-thaw cycles may 
cause the loss TGMP or 
TGTP. 
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14 6-TGDP 6-TdGDP RND 
TdGRibonucleotides presence from 
table -3 (#26) and RND/RNR role in 
the conversion of endogenous GDP to 
dGDP (#27) shows the existence of 
this step. No primary reference is 
found that quantify the enzyme 
activity for this conversion. However 
the DNA-TG levels in blood cells (#28 
& #29) confirm the step. 
  
15 6-TdGDP 6-TdGTP NDPK 
As per unique ID-13 NDPK involves 
in phosphorylation of nucleoside 
diphosphate, and as per unique ID-14 
the formation of the triphosphate is 
confirmed. Additionally the invitro 
assay in #30 supports that DNA 
polymerase utilise 6-TdGTP instead of 
dGTP (1st and 2nd headings from 
results in #30). This is considered to be 
the reason for the delayed cytotoxic 
effects of 6-MP (#31). 
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16 6-TGTP 6-TGMP NUDT15 
It is proved by #33 (Fig-2 & Fig-4c,4d) 
that DNA-TG/TGN ratio would 
increase as result of reduced NUDT15 
activity. Additionally results from #33 
shows that wild-type NUDT15 
efficiently converted the thiopurine 
active metabolite TGTP to the 
monophosphate thioguanosine 
nucleotide TGMP, with an apparent 
catalytic efficiency (Vmax/Km, ratio 
of maximal velocity to Michaelis 
constant) of 107.9 ± 0.2. In contrast, the 
four variant NUDT15 proteins 
showed 74.4 to 100% loss of enzymatic 
activity, with Vmax/Km of 23.6 ± 0.9, 
27.7 ± 1.1 and 14.9 ± 1.1  (Fig-1b) 
  
17 6-TdGTP 6-TdMP NUDT15 
Results from #34 confirm that wild-
type NUDT15 efficiently converted 
the thiopurine active metabolite 
TdGTP to TdGMP (Suppl Fig-2). 
  
18 6-TGMP 6-TGR Nucleotidase (NT5C2) 
No primary reference is available. As 
per fig-1 (reactions indicated by red 
arrows) from #34 shows the 
involvement of this enzyme to convert 
nucleotide to nucleoside. Hence this 
can be generalised to this step. 
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19 6-TGR 6-TG PNP 
No primary reference is available. 
Based on the endogenous function of 
the enzyme (figure-1) from #35 the 
this step can be generalised to be 
involved by PNP 
  
20 6-TG 6-TGMP HGPRT 
HGPRT activity in a PK study for TG 
(#36) relied on the conversion of 
Hypoxanthine to Inosine mono 
phosphate. No primary reference is 
found. 
  
21 6-TG 6-TX Guanase 
Guanase activity in #37 relied on the 
conversion of allopurinol to Xanthine. 
No primary reference is found. 
  
22 6-TG 6-MeTG TPMT 
Fig-1 (#38) suggests this step. 
Additionally row-10 in table-1 (#44) 
shows the Vmax and Km values for 
the TPMT activity when TG is the 
substrate 
Vmax and Km values 
are highly varying with 
the same concentrations 
of TG from different 
manufacturers 
23 6-TIMP 6-MeTIMP TPMT 
Occurrence of this step is confirmed in 
#40, see Vmax and Km values (Table-
1) 
  
24 6-MeTIMP 6-MeTIDP NMPK 
Endogenous role is reported in #43 
(table-1 & 3). Figure-4 from #23 
suggests this step 
  
25 6-MeTIDP 6-MeTITP NDPK 
Endogenous role is reported in #43 
(table-1 & 3). Figure-4 from #23 
suggests this step 
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26 6-MeTIMP 6-MeMPR Nucleotidase (NT5C2) 
No primary reference is available. As 
per fig-1 (reactions indicated by red 
arrows) from #34 shows the 
involvement of this enzyme to convert 
nucleotide to nucleoside. Hence this 
can be generalised to this step. 
  
27 6-MeMPR 6-MeTIMP Nucleoside kinase 
No clear evidence/reference found to 
support this step. However as per #34 
(Figure-1, 3rd step in the schematic) 
the endogenous path exists. In such 
case In AZA path there 3 more 
locations where such path could exist. 
((i) 6-MPR to 6-TIMP (ii) 6-MeTGMP 
to 6-MeTGR (iii) 6-TGP to 6-TGMP. 
see schematic for the proposed model) 
  
28 6-MeMPR 6-MMP PNP 
No primary reference is available. 
Based on the endogenous function of 
the enzyme (figure-1) from #35 the 
this step can be generalised to be 
involved by PNP 
  
29 6-TIMP 6-TIDP NMPK 
Endogenous role is reported in #43 
(table-1 & 3). Figure-4 from #23 
suggests this step 
  
30 6-TIDP 6-TITP NDPK 
Endogenous role is reported in #43 
(table-1 & 3). Figure-4 from #23 
suggests this step 
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31 6-TITP 6-TIMP ITPASE 
Column-3 in table-2 (#45) shows the 
Vmax and Km values for the ITPAse 
activity of different genotypes when 6-
TITP is the substrate 
  
32 6-TITP 6-MeTITP TPMT 
Row-15 in table-1 (#44) shows the 
Vmax and Km values for the TPMT 
activity when 6-TITP is the substrate 
  
33 6-TIMP 6-MPR Nucleotidase (NT5C2) 
No primary reference is available. As 
per fig-1 (reactions indicated by red 
arrows) from #34 shows the 
involvement of this enzyme to convert 
nucleotide to nucleoside. Hence this 
can be generalised to this step. 
  
34 6-MPR 6-MP PNP 
No primary reference is available. 
Based on the endogenous function of 
the enzyme (figure-1) from #35 the 
this step can be generalised to be 
involved by PNP 
  
35 6-TGMP 6-MeTGMP TPMT 
Row-16 in table-1 (#44) shows the 
Vmax and Km values for the TPMT 
activity when 6-TGMP is the substrate 
  
36 6-MeTGMP 6-MeTGDP NMPK Figure-4 from #23 suggests this step   
37 6-MeTGDP 6-MeTGTP NDPK Figure-4 from #23 suggests this step   
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38 6-MeTGMP 6-MeTGR Nucleotidase (NT5C2) 
No primary reference is available. As 
per fig-1 (reactions indicated by red 
arrows) from #34 shows the 
involvement of this enzyme to convert 
nucleotide to nucleoside. Hence this 
can be generalised to this step. 
  
39 6-MeTGR 6-MeTG PNP 
No primary reference is available. 
Based on the endogenous function of 
the enzyme (figure-1) from #35 the 
this step can be generalised to be 
involved by PNP 
  
40 6-MPR 6-MeMPR TPMT 
Row-13 in table-1 (#44) shows the 
Vmax and Km values for the TPMT 
activity when MPR is the substrate 
Row-14 in table-1 (#44) 
supports the possible 
conversion of TGR to 
MeTGR 
41 6-TIMP Efflux ABCC4&5 
Abstract and Figure-8 in #46 supports 
this efflux mechanism 
Additionally 6-MeTIMP 
also reported to be 
effluxed by ABCC4&5 
(Figure-8 in #46) 
42 6-TXMP Efflux ABCC5 
Abstract and Figure-8 in #46 supports 
this efflux mechanism 
  
43 6-TGMP Efflux ABCC4&5 
Abstract and Figure-8 in #46 supports 
this efflux mechanism 
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44 6-TGMP 6-TIMP GMP reductase 
As per #47 GMP reductase is present 
in Erythrocytes and involved in the 
conversion of GMP to IMP. However 
no studies concluded its role in 
thiopurine metabolism. 
  
45 6-MPR 6-TIMP Nucleoside kinase 
No clear evidence/reference found to 
support this step. However as per #34 
(Figure-1, 3rd step in the schematic) 
the endogenous path exists. 
  
46 6-MeTGMP 6-MeTGR Nucleoside kinase 
No clear evidence/reference found to 
support this step. However as per #34 
(Figure-1, 3rd step in the schematic) 
the endogenous path exists.  
  
47 6-TGP 6-TGMP Nucleoside kinase 
No clear evidence/reference found to 
support this step. However as per #34 
(Figure-1, 3rd step in the schematic) 
the endogenous path exists.  
  
48 AZA_ele Elimination 
As per #48, 50% of the radioactive 
dose being excreted in urine in 24 hrs. 
Out of the absorbed AZA 12% is 
known to be excreted through urine 
  
49 6-MP_EC_ele Elimination     
50 6-TUA_EC_ele Elimination     
51 6-TUA_IC_ele Elimination     
52 6-TITP_IC Elimination     
53 6-MMP_ele Elimination     
54 6-MTITP_ele Elimination     
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55 6-TGTP_ele Elimination     
56 6-TdGTP_ele Elimination     
57 6-MTGTP_ele Elimination     
58 6-TdGMP_ele Elimination     
59 6-MTG_ele Elimination     
60 AZA_abs Absorption     
*Note: The metabolites present outside and inside the RBC indicated as Extra_RBC and IC respectively 
Over all the pathway is concluded to have 60 steps (42 metabolic steps, 12 elimination steps, 5 efflux transfer (3 efflux and 2 carrier mediated 
transportation), and one step for absorption of azathioprine) 
 
References: 
1. Kaplowitz, N. J Pharmacol. Exp. Ther. 200, 479-486 (1977).  
2. Eklund et al. Mol. Pharmacol. 70, 747–754 (2006).   
3. Stocco, G.  J. Clin. Gastroenterol. 48, 43-51 (2014). 
4. Choughule, K. V. et al Drug Metab Dispos 42(8), 1334-40 (2014). 
5. Yao et al J Biol Chem. 286(11), 32552–32562 (2011). 
6. A.K. Fotoohi et al. Biochem. Biophys. Res. Commun. 343, 208–215 (2006). 
7. Conklin et al. J Dig Dis. 13, 82–93 (2012).  
8. Becher et al. Klin. Wschr. 56, 275-283 (1978).   
9. Kurowski et al. Cancer Chemotber Pharmacol 28, 7-14 (1991). 
10. Lennard et al. Br J clin Pharmac 36, 277-284 (1993).  
11. Preiss, J.et al J. Biol. Chem. 225, 759-770 (1957).   
12. Wilson et al, J. Clin. Invest. 71, 1331-1335 (1983).   
13. Jenneke et al. Ann Clin Biochem 40, 86–93 (2003).   
14. Deininger et al. Biochem. Pharmacol. 48, 2135-2138 (1994).  
15. Beringer, A. et al. J. Chromatogr. B 1044-1045, 194-199 (2017). 
Appendix 2: Appendices to Chapter 2 
 184 
 
16. Haglund, S et al. Br. J. Clin. Pharmacol. 65, 69-77 (2008).  
17. Haglund, S. et al. Ther. Drug Monit. 33, 200-208 (2011).  
18. Pritso et al Chem. Biol. Interact. 129, 195-208 (2000).  
19. Page et al. Int. J. Biochem. 16, 117-120 (1984).   
20. Baldwin et al. Mol. Med. Today 5, 216-224 (1999).  
21. A.K. Fotoohi et al. Biochemical Pharmacology 79, 1211–1220 (2010). 
22. Berg JM et al. Biochemistry. , 5th. edn 9-26 - 29-34 (Freeman, New York, 2002). 
23. Hofmann, U. et al. Anal. Chem. 84, 1294-1301 (2012).  
24. Karner, S. et al. Ther. Drug Monit. 32, 119-128 (2010).  
25. Shipkova et al. Clin. Chem. 49, 260-268 (2003).   
26. Tidd et al.Cancer Res. 34, 738-746 (1974).   
27. Torrents et al. Mol. Evol. 55, 138-152 (2002).   
28. Jacobsen et al. J. Chromatogr. B. 881– 882, 115– 118 (2012). 
29. Warren et al. Cancer Res. 55, 1670-1674 (1995).   
30. Ling et al. Mol. Pharmacol. 40, 508-514 (1991).   
31. Tidd et al. Cancer Res. 34, 738-746 (1974)   
32. Tiede, I. et al. J. Clin. Invest. 111, 1133-1145 (2003).  
33. Moriyama, T. et al. Pharmacogenet. Genomics 27, 236-239 (2017). 
34. Bogan etal. New J. Chem. 34, 845-853 (2010).  
35. Bzowska et al. Pharmacol. Ther. 88, 349-425 (2000).  
36. Van et al. Nucleosides Nucleotides Nucleic Acids 29, 284-290 (2010). 
37. Bemi, V. et al. Int. J. Cancer 82, 556-561 (1999).   
38. Kröplin et al. Eur. J. Clin. Pharmacol. 55, 285-291 (1999).  
39. Krenitsky et al. J. Biol. Chem. 244, 1263-1270 (1969).  
40. Krynetski et al. Mol. Pharmacol. 47, 1141-1147 (1995).  
41. Parker et al. Chem. Rev. 109, 2880-2893 (2009).   
42. Clarke et al. Cancer Res. 18, 445-456 (1958)   
43. Mourad et al. J. Biol. Chem. 241, 271-278 (1966).   
Appendix 2: Appendices to Chapter 2  
185  
 
44. Deininger et al. Biochem. Pharmacol. 48, 2135-2138 (1994). 
45. Bakker et al. Nucleosides Nucleotides Nucleic Acids 30, 839-849 (2011). 
46. Wielinga, P. R. et al. Mol. Pharmacol. 62, 1321-1331 (2002). 
47. http://liu.diva-portal.org/smash/get/diva2:403844/FULLTEXT01.pdf 
48. Elion, G. B. Proc R Soc Med 65(3), 257-60 1972.   
 
  
Appendix 2: Appendices to Chapter 2 
 186 
 
2.1.1. Pooled PK parameters 
1. AZA bioavailability ranged between 50-72%(secondary literature & may not be the human data: Aliment Pharmacol Ther 2000; 14: 1009-
1014) 
2. 6-MP bioavailability ranged between 5-37% (Secondary literature& may not be the human data: Aliment Pharmacol Ther 2000; 14: 1009-
1014) 
3 AZA_k10(h-1)    
     
 Ding (1980) 8 4.15 (h
-1) 
     
4 6-MP_k10(h-1)    
   (h
-1)  
 Data source n Value  
 Odlind et al (1986) 15 0.791  
 Bergan et al (1994) 30 1.332  
 Chan et al (1990) 5 0.407  
 Escousse (1998) 109 1.906  
 Weighted Average  1.65 (h
-1) 
     
5 6-TUA_k10(h-1)    
   (h
-1)  
 Data source n Value  
 Chan et al (1990) 6 0.204  
 Chan et al (1989) 5 0.192  
 Weighted Average  0.2 (h
-1) 
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2.1.2.  Enzyme activities 
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2.2. Matlab code used for the developed model 
%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%% 








Tf = 24; % dose intervals (hrs) 
NoD = 8*7; % change it to 1 to simulate 24hr profiles for EC_AZA, EC_6MP& EC_6TUA 
mg_Dose = 1.29*W; % oral azathioprine/6-MP dose (mg)%% dose is based on Goldenberg et 
al, Am J Gastroenterol 2004;99:1744–1748 
%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%% 
Y1=[]; T=[];% to be used as storage down below! 
    A0 = zeros(31,1); % initial values vector 
    A0(31) = mg_Dose*2.08; % oral dose of AZA equivalent to 6-MP  (change it to 100mg 
to simulate 24hr profiles for EC_AZA, EC_6MP& EC_6TUA) 
    dt = 12; % change it to 0.1 to simulate 24hr profiles for EC_AZA, EC_6MP& EC_6TUA 
    options = odeset('NonNegative',1:31,'AbsTol',1E-9); 
 
    for i=1:NoD 
        [time,A]=ode15s(@metabolize,[(i-1)*Tf:dt:Tf*i],A0,options,Tmax_AZA, Ka_AZA, 
Vd_AZA, v_AZA, cl_AZA, ... 
                K10_AZA,F_AZA_abs, F_AZA_6MP,F10_AZA,K_AZA_6MP,... 
                F_6MP_6TX, F10_6MP,CL_6MP, Vd_6MP, ... 
                v_6MP, cl_6MP, K10_6MP, K_6MPIC_6MPEC, K_6MPEC_6MPIC,... 
                Ke_6MMP,K10_6TUA, F10_6TUA, v_6TUA, v_6TX, Vm_6MP_XO_6TX,... 
                km_6MP_XO_6TX, Vm_6TX_XO_TUA, km_6TX_XO_TUA, keTUA,... 
                Vm_MPR_PNP_MP, Vm_MP_TPMT_MMP, Vm_MP_HGPRT_TIMP, ... 
                Vm_TIMP_NT5C2_MPR, Vm_TIMP_TPMT_MTIMP,... 
                Vm_TIMP_IMPDH_TXMP, Vm_TGMP_TPMT_MTGMP, Vm_TIMP_NMPK_TIDP,... 
                Vm_TIDP_NDPK_TITP, Vm_MMPR_PNP_MMP,... 
                Vm_MTIMP_NT5C2_MMPR, Vm_MTIMP_NMPK_MTIDP, Vm_MTIDP_NDPK_MTITP,... 
                Vm_TXMP_GMPS_TGMP, Vm_TGMP_NT5C2_TGR,... 
                Vm_TGMP_NMPK_TGDP, Vm_TGR_PNP_TG, Vm_TG_TPMT_MTG, ... 
                Vm_TGDP_NDPK_TGTP, Vm_MTGR_PNP_MTG,... 
                Vm_MTGMP_NT5C2_MTGR, Vm_MTGMP_NMPK_MTGDP,... 
                Vm_MTGDP_NDPK_MTGTP, Vm_TG_HGPRT_TGMP, Vm_TGTP_NUDT_TGMP,... 
                km_TGTP_NUDT_TGMP, Vm_TdGTP_NUDT_TdGMP, km_TdGTP_NUDT_TdGMP,... 
                Vm_TGDP_RND_TdGDP, km_TGDP_RND_TdGDP, Vm_TdGDP_NDPK_TdGTP, ... 
                km_TdGDP_NDPK_TdGTP, keTdGTP, km_MPR_PNP_MP, km_MP_TPMT_MMP,... 
                km_MP_HGPRT_TIMP, km_TIMP_TPMT_MTIMP, ... 
                km_TIMP_IMPDH_TXMP, km_TGMP_TPMT_MTGMP, km_TIMP_NMPK_TIDP,... 
                km_TIDP_NDPK_TITP, keTITP, km_MMPR_PNP_MMP,... 
                km_MTIMP_NT5C2_MMPR, km_MTIMP_NMPK_MTIDP,km_MTIDP_NDPK_MTITP, keMTITP, 
... 
                km_TXMP_GMPS_TGMP, km_TGMP_NT5C2_TGR, km_TGMP_NMPK_TGDP, ... 
                km_TGR_PNP_TG, km_TG_TPMT_MTG, km_TGDP_NDPK_TGTP, keTGTP,... 
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                km_MTGR_PNP_MTG, km_MTGMP_NT5C2_MTGR, Vm_MMPR_NK_MTIMP, 
km_MMPR_NK_MTIMP,Vm_MPR_NK_TIMP, 
km_MPR_NK_TIMP,Vm_MTGR_NK_MTGMP,km_MTGR_NK_MTGMP,Vm_TGR_NK_TGMP,km_TGR_NK_TGMP,... 
                km_MTGMP_NMPK_MTGDP, km_MTGDP_NDPK_MTGTP, keMTGTP, km_TG_HGPRT_TGMP,... 
                km_TIMP_NT5C2_MPR,Vm_6TX_XDH_TUA, km_6TX_XDH_TUA, Vm_MP_AOX_6TX,... 
                km_MP_AOX_6TX, Vm_MPR_TPMT_MMPR, km_MPR_TPMT_MMPR, ... 
                Vm_TITP_ITPASE_TIMP, km_TITP_ITPASE_TIMP,... 
                Vm_TIMP_ABCC, km_TIMP_ABCC, Vm_TITP_TPMT_MTITP, km_TITP_TPMT_MTITP,... 
                Vm_TXMP_ABCC1, km_TXMP_ABCC1, Vm_TGMP_ABCC2, km_TGMP_ABCC2,... 
                Vm_TG_GUANASE_TX, km_TG_GUANASE_TX, Vm_TGMP_GMPR_TIMP, 
km_TGMP_GMPR_TIMP, keTdGMP, keMTG); 
        A0(1:30)=A(end,1:30); 
        Y1=[Y1;A]; 
        T=[T;time]; 
    end 
        xlswrite('Y2',Y1); 
        xlswrite('T1',T); 
        Figures; 
 
%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%% 
             ParameterValues - call parameter values 
%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%% 
Extra RBC 
%nomenclature: parameter_substrate e.g. ka_aza = absorption rate constant for 
azathioprine Vmax_substrate_to_xc (x={i, e}) e.g. Vmax_6mp_6mmp_ec km_substrate_to ... 
FF=1; 
W = 70; % typical patient's weight (kg) 
Tmax_AZA = 0.75; % (hrs) from: Chan et al (1987) Pharmacotherapy 7(5):165-177 
Ka_AZA = 3*log(2)/Tmax_AZA; % approximation to ka of AZA. 
% CL_AZA = 8.12; % (L/h/kg) - from: El Yazigi & Abdel Wahab (1993) J Clin Pharmacol 
33:552-526 
CL_AZA = 3.88; %3.88 pooled estimate from literaure! <<============== 
Vd_AZA = 0.81; % (L/kg) from Goodman Gilman 
v_AZA = 10*Vd_AZA*W; 
cl_AZA = CL_AZA*W; 
K10_AZA = log(2)/(1/6); %cl_AZA/v_AZA; 
 
F_AZA_abs=0.54; % fraction of AZA absorbed from: Elion (1972) Proc Roy Soc Med 65:257-
260 
F_AZA_6MP=0.68*FF; % fraction of AZA --> 6MP [from mass-balance 
calculations]{multiplied by FF as Steve asked on 7 OCT 14} 
F10_AZA=1-F_AZA_6MP; % fraction of AZA that goes out!! 
K_AZA_6MP = 0.50; % conversion rate of AZA to 6MP in plasma [Closer value to literature 
value] 
 
F_6MP_6TX=20/37; %changed from 15% to 20% [from mass balance and Elion 1972] 
F10_6MP=1.3/37;%0.013/37; %fraction excreted renally from Elion 1972 
CL_6MP = 5.62; %(L/hr.kg) pooled estimate from literaure! <<=============== 
Vd_6MP = 3.46;% based on pooled estimate from literaure 
v_6MP = Vd_6MP*W; 
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cl_6MP = CL_6MP*W; 
K10_6MP = cl_6MP/v_6MP; % calculated from pooled estimate from literaure! 
<<=============== 
 
K_6MPIC_6MPEC = 0.0001; % Transport rate of 6MP from IC to EC [guess] 
K_6MPEC_6MPIC = 0.75; % Transport rate of 6MP from EC to IC [guess] 
 
Ke_6MMP = 0.693/120; %(Guess value) 
K10_6TUA = 0.2;% matches with this estimate 0.693/3.5 
F10_6TUA = 8.7/14.06; %fraction excreted renally [mass-balance] 
v_6TUA = 0.02*v_6MP; % guess! 
v_6TX = 10*v_6MP; % guess! 
XO Activity 
Vm_6MP_XO_6TX=5;% Guess  (M-Menton Vmax) 





keTUA=0.693/24; % made up 
TPMT Activity 
Vm_MP_TPMT_MMP=1 ;  
km_MP_TPMT_MMP=25 ;  
Vm_TIMP_TPMT_MTIMP=1 ; 
km_TIMP_TPMT_MTIMP=25 ; % Guess value 
Vm_TGMP_TPMT_MTGMP=1 ;  






km_TITP_TPMT_MTITP=50 ; % TPMT activity 
HGPRT Activity 
Vm_MP_HGPRT_TIMP=2 ;  
km_MP_HGPRT_TIMP=25 ; 
Vm_TG_HGPRT_TGMP=1 ;% Guess value for HGPRT 
km_TG_HGPRT_TGMP=50 ;% Guess value for HGPRT 
IMPDH Activity 
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Vm_TIMP_IMPDH_TXMP=5 ;  
km_TIMP_IMPDH_TXMP=10;  
GMPS Activity 
Vm_TXMP_GMPS_TGMP=1 ;  
km_TXMP_GMPS_TGMP=200;  
Nucleotidase Activity 
Vm_TIMP_NT5C2_MPR=5; %CHANGE THIS !!! 
km_TIMP_NT5C2_MPR=25 ;% Guess value 
Vm_MTIMP_NT5C2_MMPR=3 ; %CHANGE THIS !!! 
km_MTIMP_NT5C2_MMPR=100 ; 
Vm_TGMP_NT5C2_TGR=1; %% Re TGN 
km_TGMP_NT5C2_TGR=2 ;  
Vm_MTGMP_NT5C2_MTGR=1; 
km_MTGMP_NT5C2_MTGR=100 ;% Guess 











km_TIMP_NMPK_TIDP=10 ; %Guess value, very low since Nucleotides  are major metabolites. 
Vm_MTIMP_NMPK_MTIDP=1; 
km_MTIMP_NMPK_MTIDP=10;%Guess value, very low since Nucleotides  are major metabolites. 
Vm_TGMP_NMPK_TGDP=5; %% Re TGN 
km_TGMP_NMPK_TGDP=10 ;% Guess value, very low since TGN are major metabolites. 
Vm_MTGMP_NMPK_MTGDP=1; 
km_MTGMP_NMPK_MTGDP=10 ;% Guess 
NDPK Activity 
Vm_TIDP_NDPK_TITP=1; 
km_TIDP_NDPK_TITP=50 ; %Guess value, very low since Nucleotides  are major metabolites. 
Vm_MTIDP_NDPK_MTITP=1; 
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km_MTIDP_NDPK_MTITP=10 ;%Guess value, very low since Nucleotides  are major 
metabolites. 
Vm_TGDP_NDPK_TGTP=1; %% Re TGN 
km_TGDP_NDPK_TGTP=10 ;% Guess value, very low since TGN are major metabolites. 
Vm_MTGDP_NDPK_MTGTP=1; 
km_MTGDP_NDPK_MTGTP=10 ;% Guess 
Vm_TdGDP_NDPK_TdGTP=1;% from VTGTP (VIJAY) 
km_TdGDP_NDPK_TdGTP=10 ;% from kmTGTP (VIJAY) 
PNP Activity 
Vm_MPR_PNP_MP=1 ; %CHANGE THIS !!! 
km_MPR_PNP_MP=10 ; % Guess value most of MPR is converted to MP IC.. 
Vm_MMPR_PNP_MMP=5 ; 
km_MMPR_PNP_MMP=5 ; % Guess value most of MMPR is converted to MMP IC.. 
Vm_TGR_PNP_TG=1; 
km_TGR_PNP_TG=2 ;% Guess value, very low since TGN are major metabolites. 
Vm_MTGR_PNP_MTG=1; 
km_MTGR_PNP_MTG=5 ; %Guess value 
NUDT Activity 
Vm_TGTP_NUDT_TGMP=2;% Guess value  
km_TGTP_NUDT_TGMP=10 ;% in uM from Nucleic Acids Research, 2010, Vol. 38, No. 14 
(VIJAY) 
Vm_TdGTP_NUDT_TdGMP=2;% Guess value  




km_TITP_ITPASE_TIMP=25 ;% ITPASE km to be checked?? 
AOX Activity 
Vm_MP_AOX_6TX=5; 
km_MP_AOX_6TX=10 ;% Guess value=XO 
XDH Activity 
Vm_6TX_XDH_TUA=1;% Guess value 
km_6TX_XDH_TUA=20 ;% Guess value=XO 
RND Activity 
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Vm_TGDP_RND_TdGDP=2;% from VTGDP  









km_TIMP_ABCC=120 ; % not much compound leaves RBC 
Vm_TXMP_ABCC1=0.693; 
km_TXMP_ABCC1=120; % not much compound leaves RBC 
Vm_TGMP_ABCC2=0.693; 
km_TGMP_ABCC2=120; % not much compound leaves RBC 
Elimination rate constants 
keTdGTP=0.693/120;% from keTGTP (VIJAY) 
keTITP=0.693/120; % Guess value, half life of TGN is approximately 5 days. 
keMTITP=0.693/120; % Guess value, half life of TGN is approximately 5 days. 
keTGTP=0.693/120; % Guess value, half life of TGN is approximately 5 days. 





                               ODEs- call metabolize 
%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%% 
function dAdt = metabolize(~,A,Tmax_AZA, Ka_AZA, Vd_AZA, v_AZA, cl_AZA, ... 
                K10_AZA,F_AZA_abs, F_AZA_6MP,F10_AZA,K_AZA_6MP,... 
                F_6MP_6TX, F10_6MP,CL_6MP, Vd_6MP, ... 
                v_6MP, cl_6MP, K10_6MP, K_6MPIC_6MPEC, K_6MPEC_6MPIC,... 
                Ke_6MMP,K10_6TUA, F10_6TUA, v_6TUA, v_6TX, Vm_6MP_XO_6TX,... 
                km_6MP_XO_6TX, Vm_6TX_XO_TUA, km_6TX_XO_TUA, keTUA,... 
                Vm_MPR_PNP_MP, Vm_MP_TPMT_MMP, Vm_MP_HGPRT_TIMP, ... 
                Vm_TIMP_NT5C2_MPR, Vm_TIMP_TPMT_MTIMP,... 
                Vm_TIMP_IMPDH_TXMP, Vm_TGMP_TPMT_MTGMP, Vm_TIMP_NMPK_TIDP,... 
                Vm_TIDP_NDPK_TITP, Vm_MMPR_PNP_MMP,... 
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                Vm_MTIMP_NT5C2_MMPR, Vm_MTIMP_NMPK_MTIDP, Vm_MTIDP_NDPK_MTITP,... 
                Vm_TXMP_GMPS_TGMP, Vm_TGMP_NT5C2_TGR,... 
                Vm_TGMP_NMPK_TGDP, Vm_TGR_PNP_TG, Vm_TG_TPMT_MTG, ... 
                Vm_TGDP_NDPK_TGTP, Vm_MTGR_PNP_MTG,... 
                Vm_MTGMP_NT5C2_MTGR, Vm_MTGMP_NMPK_MTGDP,... 
                Vm_MTGDP_NDPK_MTGTP, Vm_TG_HGPRT_TGMP, Vm_TGTP_NUDT_TGMP,... 
                km_TGTP_NUDT_TGMP, Vm_TdGTP_NUDT_TdGMP, km_TdGTP_NUDT_TdGMP,... 
                Vm_TGDP_RND_TdGDP, km_TGDP_RND_TdGDP, Vm_TdGDP_NDPK_TdGTP, ... 
                km_TdGDP_NDPK_TdGTP, keTdGTP, km_MPR_PNP_MP, km_MP_TPMT_MMP,... 
                km_MP_HGPRT_TIMP, km_TIMP_TPMT_MTIMP, ... 
                km_TIMP_IMPDH_TXMP, km_TGMP_TPMT_MTGMP, km_TIMP_NMPK_TIDP,... 
                km_TIDP_NDPK_TITP, keTITP, km_MMPR_PNP_MMP,... 
                km_MTIMP_NT5C2_MMPR, km_MTIMP_NMPK_MTIDP,km_MTIDP_NDPK_MTITP, keMTITP, 
... 
                km_TXMP_GMPS_TGMP, km_TGMP_NT5C2_TGR, km_TGMP_NMPK_TGDP, ... 
                km_TGR_PNP_TG, km_TG_TPMT_MTG, km_TGDP_NDPK_TGTP, keTGTP,... 
                km_MTGR_PNP_MTG, km_MTGMP_NT5C2_MTGR, Vm_MMPR_NK_MTIMP, 
km_MMPR_NK_MTIMP,Vm_MPR_NK_TIMP, 
km_MPR_NK_TIMP,Vm_MTGR_NK_MTGMP,km_MTGR_NK_MTGMP,Vm_TGR_NK_TGMP,km_TGR_NK_TGMP,... 
                km_MTGMP_NMPK_MTGDP, km_MTGDP_NDPK_MTGTP, keMTGTP, km_TG_HGPRT_TGMP,... 
                km_TIMP_NT5C2_MPR,Vm_6TX_XDH_TUA, km_6TX_XDH_TUA, Vm_MP_AOX_6TX,... 
                km_MP_AOX_6TX, Vm_MPR_TPMT_MMPR, km_MPR_TPMT_MMPR, ... 
                Vm_TITP_ITPASE_TIMP, km_TITP_ITPASE_TIMP,... 
                Vm_TIMP_ABCC, km_TIMP_ABCC, Vm_TITP_TPMT_MTITP, km_TITP_TPMT_MTITP,... 
                Vm_TXMP_ABCC1, km_TXMP_ABCC1, Vm_TGMP_ABCC2, km_TGMP_ABCC2,... 
                Vm_TG_GUANASE_TX, km_TG_GUANASE_TX, Vm_TGMP_GMPR_TIMP, 
km_TGMP_GMPR_TIMP, keTdGMP, keMTG) 
 
% flux transfer 
J_T_31_30 = F_AZA_abs*Ka_AZA*A(31); 
J_T_4_1 = K_6MPIC_6MPEC*A(4); 
J_T_1_4 = (1-F_6MP_6TX)*K_6MPEC_6MPIC*A(1); 
J_T_7 = Vm_TIMP_ABCC*A(7)/(km_TIMP_ABCC+A(7)); 
J_T_16 = Vm_TXMP_ABCC1*A(16)/(km_TXMP_ABCC1+A(16)); 
J_T_17 = Vm_TGMP_ABCC2*A(17)/(km_TGMP_ABCC2+A(17)); 
 
% flux elimination 
J_E_30 = F10_AZA*K10_AZA*A(30); 
J_E_1 = F10_6MP*K10_6MP*A(1); 
J_E_3 = F10_6TUA*K10_6TUA*A(3); 
J_E_6 = keTUA*A(6); 
J_E_10 = keTITP*A(10); 
J_E_11 = Ke_6MMP*A(11); 
J_E_15 = keMTITP*A(15); 
J_E_19 = keTGTP*A(19); 
J_E_21 = keTdGTP*A(21); 
J_E_29 = keMTGTP*A(29); 
J_E_22 = keTdGMP*A(22); 
J_E_25 = keMTG*A(25); 
 
% flux metabolise 
J_M_30_1 = F_AZA_6MP*K_AZA_6MP*A(30); 
J_M_1_2 = F_6MP_6TX*Vm_6MP_XO_6TX*A(1)/(km_6MP_XO_6TX+A(1)); 
J_M_2_3 = Vm_6TX_XO_TUA*A(2)/(km_6TX_XO_TUA+A(2)); 
J_M_8_4 = Vm_MPR_PNP_MP*A(8)/(km_MPR_PNP_MP+A(8)); 
J_M_4_11 = Vm_MP_TPMT_MMP*A(4)/(km_MP_TPMT_MMP+A(4)); 
J_M_4_7 = Vm_MP_HGPRT_TIMP*A(4)/(km_MP_HGPRT_TIMP+A(4)); 
J_M_4_5 = Vm_MP_AOX_6TX*A(4)/(km_MP_AOX_6TX+A(4)) ; 
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J_M_5_6 = Vm_6TX_XDH_TUA*A(5)/(km_6TX_XDH_TUA+A(5)); 
J_M_7_8 = Vm_TIMP_NT5C2_MPR*A(7)/(km_TIMP_NT5C2_MPR+A(7)); 
J_M_8_7 = Vm_MPR_NK_TIMP*A(8)/(km_MPR_NK_TIMP+A(8)); 
J_M_8_13 = Vm_MPR_TPMT_MMPR*A(8)/(km_MPR_TPMT_MMPR+A(8)); 
J_M_17_7 = Vm_TGMP_GMPR_TIMP*A(17)/(km_TGMP_GMPR_TIMP+A(17)); 
J_M_10_7 = Vm_TITP_ITPASE_TIMP*A(10)/(km_TITP_ITPASE_TIMP+A(10)); 
J_M_7_12 = Vm_TIMP_TPMT_MTIMP*A(7)/(km_TIMP_TPMT_MTIMP+A(7)); 
J_M_7_16 = Vm_TIMP_IMPDH_TXMP*A(7)/(km_TIMP_IMPDH_TXMP+A(7)); 
J_M_7_9 = Vm_TIMP_NMPK_TIDP*A(7)/(km_TIMP_NMPK_TIDP+A(7)); 
J_M_9_10 = Vm_TIDP_NDPK_TITP*A(9)/(km_TIDP_NDPK_TITP+A(9)); 
J_M_10_15 = Vm_TITP_TPMT_MTITP*A(10)/(km_TITP_TPMT_MTITP+A(10)); 
J_M_13_11 = Vm_MMPR_PNP_MMP*A(13)/(km_MMPR_PNP_MMP+A(13)); 
J_M_12_13 = Vm_MTIMP_NT5C2_MMPR*A(12)/(km_MTIMP_NT5C2_MMPR+A(12)); 
J_M_13_12 = Vm_MMPR_NK_MTIMP*A(13)/(km_MMPR_NK_MTIMP+A(13)); 
J_M_12_14 = Vm_MTIMP_NMPK_MTIDP*A(12)/(km_MTIMP_NMPK_MTIDP+A(12)); 
J_M_23_17 = Vm_TGR_NK_TGMP*A(23)/(km_TGR_NK_TGMP+A(23)); 
J_M_14_15 = Vm_MTIDP_NDPK_MTITP*A(14)/(km_MTIDP_NDPK_MTITP+A(14)); 
J_M_16_17 = Vm_TXMP_GMPS_TGMP*A(16)/(km_TXMP_GMPS_TGMP+A(16)); 
J_M_17_27 = Vm_TGMP_TPMT_MTGMP*A(17)/(km_TGMP_TPMT_MTGMP+A(17)); 
J_M_24_17 = Vm_TG_HGPRT_TGMP*A(24)/(km_TG_HGPRT_TGMP+A(24)); 
J_M_17_23 = Vm_TGMP_NT5C2_TGR*A(17)/(km_TGMP_NT5C2_TGR+A(17)); 
J_M_17_18 = Vm_TGMP_NMPK_TGDP*A(17)/(km_TGMP_NMPK_TGDP+A(17)); 
J_M_23_24 = Vm_TGR_PNP_TG*A(23)/(km_TGR_PNP_TG+A(23)); 
J_M_24_25 = Vm_TG_TPMT_MTG*A(24)/(km_TG_TPMT_MTG+A(24)); 
J_M_24_5  = Vm_TG_GUANASE_TX*A(24)/(km_TG_GUANASE_TX+A(24)); 
J_M_18_19 = Vm_TGDP_NDPK_TGTP*A(18)/(km_TGDP_NDPK_TGTP+A(18)); 
J_M_26_25 = Vm_MTGR_PNP_MTG*A(26)/(km_MTGR_PNP_MTG+A(26)); 
J_M_27_26 = Vm_MTGMP_NT5C2_MTGR*A(27)/(km_MTGMP_NT5C2_MTGR+A(27)); 
J_M_26_27 = Vm_MTGR_NK_MTGMP*A(26)/(km_MTGR_NK_MTGMP+A(26)); 
J_M_27_28 = Vm_MTGMP_NMPK_MTGDP*A(27)/(km_MTGMP_NMPK_MTGDP+A(27)); 
J_M_28_29 = Vm_MTGDP_NDPK_MTGTP*A(28)/(km_MTGDP_NDPK_MTGTP+A(28)); 
J_M_19_17 = Vm_TGTP_NUDT_TGMP*A(19)/(km_TGTP_NUDT_TGMP+A(19)); 
J_M_18_20 = Vm_TGDP_RND_TdGDP*A(18)/(km_TGDP_RND_TdGDP+A(18)); 
J_M_20_21 = Vm_TdGDP_NDPK_TdGTP*A(20)/(km_TdGDP_NDPK_TdGTP+A(20)); 
J_M_21_22 = Vm_TdGTP_NUDT_TdGMP*A(21)/(km_TdGTP_NUDT_TdGMP+A(21)); 
 
% flux equations EC 
dAdt(30) = J_T_31_30 -J_M_30_1 -J_E_30; 
dAdt(1) = J_M_30_1 +J_T_4_1 -J_M_1_2  -J_T_1_4 -J_E_1 ;                       % 6-MP EC 
dAdt(2) = J_M_1_2 -J_M_2_3; 
dAdt(3) = J_M_2_3 -J_E_3;                                                     % 6-TUA 
EC 
dAdt(31) = -J_T_31_30; 
 
% flux equations IC 
dAdt(4) = J_T_1_4 +J_M_8_4 -J_T_4_1 -J_M_4_11 -J_M_4_7 -J_M_4_5;              % MP IC 
dAdt(5) = J_M_4_5 + J_M_24_5 -J_M_5_6;                                        % 6-TX 
dAdt(6) = J_M_5_6 -J_E_6;                                                     % 6-TUA 
dAdt(7) = J_M_4_7  +J_M_10_7 +J_M_17_7 +J_M_8_7 -J_M_7_8 -J_M_7_12 -J_M_7_9-J_M_7_16 -
J_T_7;    % TIMP 
dAdt(8) = J_M_7_8 -J_M_8_4 -J_M_8_13- J_M_8_7;                                 % MeMPR 
IC 
dAdt(9) = J_M_7_9 -J_M_9_10 ;                                                  % TIDP 
dAdt(10) = J_M_9_10 -J_M_10_7 -J_M_10_15 -J_E_10;                              % TITP 
dAdt(11) = J_M_4_11 +J_M_13_11 -J_E_11 ;                                       % 6 MMP 
dAdt(12) = J_M_7_12 + J_M_13_12 -J_M_12_13 -J_M_12_14;                         % MTIMP 
dAdt(13) = J_M_12_13 +J_M_8_13 - J_M_13_12 -J_M_13_11 ;                        % MMPR 
dAdt(14) = J_M_12_14 -J_M_14_15;                                               % MTIDP 
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dAdt(15) = J_M_14_15 +J_M_10_15 -J_E_15;                                       % MTITP 
dAdt(16) = J_M_7_16 -J_M_16_17 -J_T_16;                                        % TXMP 
dAdt(17) = J_M_16_17 +J_M_24_17 +J_M_19_17 +J_M_23_17-J_M_17_7 -J_M_17_23 -J_M_17_18 -
J_T_17-J_M_17_27 ;              % TGMP 
dAdt(18) = J_M_17_18 -J_M_18_19-J_M_18_20;                                     % TGDP 
dAdt(19) = J_M_18_19 -J_M_19_17 -J_E_19;                                       % TGTP 
dAdt(20) = J_M_18_20 -J_M_20_21;                                               % TdGDP 
dAdt(21) = J_M_20_21-J_M_21_22 -J_E_21 ; 
dAdt(22) = J_M_21_22-J_E_22; 
dAdt(23) = J_M_17_23 -J_M_23_17 -J_M_23_24; 
dAdt(24) = J_M_23_24 - J_M_24_17 -J_M_24_25 - J_M_24_5;                         % TGR 
dAdt(25) = J_M_24_25 +J_M_26_25-J_E_25;                                         % TG 
dAdt(26) = J_M_27_26 - J_M_26_27-J_M_26_25; 
dAdt(27) = J_M_17_27 + J_M_26_27 -J_M_27_26 -J_M_27_28; 
dAdt(28) = J_M_27_28 -J_M_28_29; 
dAdt(29) = J_M_28_29 -J_E_29;                                                   % MTGTP 
 
dAdt=[dAdt(1);dAdt(2);dAdt(3);dAdt(4);dAdt(5);dAdt(6);... 
    dAdt(7);dAdt(8);dAdt(9);dAdt(10);dAdt(11);dAdt(12);dAdt(13);... 
    dAdt(14);dAdt(15);dAdt(16);dAdt(17);dAdt(18);dAdt(19);dAdt(20);... 
    dAdt(21);dAdt(22);dAdt(23);dAdt(24);dAdt(25);dAdt(26);dAdt(27);... 
    dAdt(28);dAdt(29);dAdt(30);dAdt(31)]; 
end 
%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%% 
%%%%%%%%%%%%%%%%%%%       Figures for AZA dosing       %%%%%%%%%%%%%%%%%%% 
%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%% 
 
    figure(1)% Figure for Extra RBC 
    subplot(221) 
    plot(T,Y1(:,30)/v_AZA,'LineWidth',2,'color','black') % AZA_EC 
    title('AZA','Fontsize',14) 
    ylabel('mg/L' ,'Fontsize',14) 
    % grid on 
    xlim([0 600]) 
    set(gca,'FontSize',14,'LineWidth',2,'Box','off') 
    hold on 
 
    subplot(222)% for overlays better fit multiply by 0.75!! 
    plot(T,0.7*Y1(:,1)/(v_6MP),'LineWidth',2,'color','black')% 6-MP_EC 
    title('6-MP','Fontsize',14) 
    % ylabel('mg/L') 
    % grid on 
    xlim([0 600]) 
    set(gca,'FontSize',14,'LineWidth',2,'Box','off') 
    hold on 
 
    subplot(223) % for overlays better fit multiply by 0.7!! 
    plot(T,0.7*Y1(:,2)/v_6TX,'LineWidth',2,'color','black')%6-TX_EC 
    title('6-TX','Fontsize',14) 
    xlabel('Time (hours)','Fontsize',14) 
    xlim([0 600]) 
    ylabel('mg/L','Fontsize',14) 
    % grid on 
    set(gca,'FontSize',14,'LineWidth',2,'Box','off') 
    hold on 
 
    subplot(224) % for overlays better fit multiply by 0.7!! 
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    plot(T,0.7*Y1(:,3)/v_6TUA,'LineWidth',2,'color','black')%6-TUA_EC 
    title('6-TUA','Fontsize',14) 
    xlabel('Time (hours)','Fontsize',14) 
    xlim([0 600]) 
    ylabel('mg/L','Fontsize',14) 
    % grid on 
    set(gca,'FontSize',14,'LineWidth',2,'Box','off') 
 
    hold off 
 
    print('Fig_EC_AZA', '-dpng', '-r500'); 
 
 
    MMP=Y1(:,11)+Y1(:,12)+Y1(:,13)+Y1(:,14)+Y1(:,15); 
    TGN=Y1(:,17)+Y1(:,18)+Y1(:,19)+Y1(:,20)+Y1(:,21)+Y1(:,22); 
    kk=8/5*1e-4; 
    dd=1/7; 
 
    % Figure for Intra RBC 
    figure(2)% figures to create: 6-MP, 6-MMP, 6TGR, 6TGMP, 6TGDP, 6TGTP 
 
      subplot(6,3,1) 
%     subplot(431) 
    plot(dd*T/24,kk*Y1(:,4),'LineWidth',1,'color','black'); 
    title('6-MP','Fontsize',10) 
    %             ylabel('(pmol/10^8 RBCs)', 'Fontsize',12) 
%     xlim([0 8]) 
    set(gca,'FontSize',10,'LineWidth',1.5,'Box','off') 
    hold on 
 
      subplot(6,3,2) 
%     subplot(432) 
    plot(dd*T/24,kk*Y1(:,13),'LineWidth',1,'color','black'); 
    title('6-MPR','Fontsize',10) 
%     xlim([0 8]) 
    set(gca,'FontSize',10,'LineWidth',1.5,'Box','off') 
    hold on 
 
      subplot(6,3,3) 
%     subplot(433) 
    plot(dd*T/24,kk*Y1(:,5),'LineWidth',1,'color','black'); 
    title('6-TX','Fontsize',10) 
%     xlim([0 8]) 
    set(gca,'FontSize',10,'LineWidth',1.5,'Box','off') 
    hold on 
 
      subplot(6,3,4) 
%     subplot(434) 
    plot(dd*T/24,kk*MMP,'LineWidth',1,'color','black'); 
    title('6-MMP','Fontsize',10) 
    %             ylabel('(pmol/10^8 RBCs)', 'Fontsize',10) 
%     xlim([0 8]) 
    set(gca,'FontSize',10,'LineWidth',1.5,'Box','off') 
    hold on 
 
      subplot(6,3,5) 
%     subplot(435) 
    plot(dd*T/24,kk*Y1(:,7),'LineWidth',1,'color','black'); 
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    title('6-TIMP','Fontsize',10) 
%     xlim([0 8]) 
    set(gca,'FontSize',10,'LineWidth',1.5,'Box','off') 
    hold on 
 
      subplot(6,3,6) 
%     subplot(436) 
    plot(dd*T/24,kk*Y1(:,16),'LineWidth',1,'color','black'); 
    title('6-TXMP','Fontsize',10) 
%     xlim([0 8]) 
    set(gca,'FontSize',10,'LineWidth',1.5,'Box','off') 
    hold on 
 
      subplot(6,3,7) 
%     subplot(437) 
    plot(dd*T/24,kk*Y1(:,12),'LineWidth',1,'color','black'); 
    title('6-MTIMP','Fontsize',10) 
%     xlim([0 8]) 
    set(gca,'FontSize',10,'LineWidth',1.5,'Box','off') 
    %             ylabel('(pmol/10^8 RBCs)', 'Fontsize',12) 
    hold on 
 
      subplot(6,3,8) 
%     subplot(438) 
    plot(dd*T/24,kk*Y1(:,14),'LineWidth',1,'color','black'); 
    title('6-MTIDP','Fontsize',10) 
%     xlim([0 8]) 
    set(gca,'FontSize',10,'LineWidth',1.5,'Box','off') 
    hold on 
 
      subplot(6,3,9) 
%     subplot(439) 
    plot(dd*T/24,kk*Y1(:,15),'LineWidth',1,'color','black'); 
    title('6-MTITP','Fontsize',10) 
%     xlim([0 8]) 
    set(gca,'FontSize',10,'LineWidth',1.5,'Box','off') 
    hold on 
 
      subplot(6,3,10) 
%     subplot(4,3,10) 
    plot(dd*T/24,kk*Y1(:,27),'LineWidth',1,'color','black'); 
    title('6-MTGMP','Fontsize',10) 
%     xlabel('weeks','Fontsize',10) 
    %             ylabel('(pmol/10^8 RBCs)', 'Fontsize',10) 
%     xlim([0 8]) 
    set(gca,'FontSize',10,'LineWidth',1.5,'Box','off') 
    hold on 
 
      subplot(6,3,11) 
%     subplot(4,3,11) 
    plot(dd*T/24,kk*Y1(:,28),'LineWidth',1,'color','black'); 
    title('6-MTGDP','Fontsize',10) 
 
%     xlim([0 8]) 
    set(gca,'FontSize',10,'LineWidth',1.5,'Box','off') 
    hold on 
 
      subplot(6,3,12) 
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%     subplot(4,3,12) 
    plot(dd*T/24,kk*Y1(:,29),'LineWidth',1,'color','black') 
    title('6-MTGTP','Fontsize',10) 
%     xlabel('weeks','Fontsize',10) 
%     xlim([0 8]) 
    set(gca,'FontSize',10,'LineWidth',1.5,'Box','off') 
    hold off 
%     print('Fig_IC_AZA', '-dpng', '-r1000'); 
 
 
%     figure(3) 
      subplot(6,3,13) 
%        subplot(2,3,1)% Figure for TGNs 
    plot(dd*T/24,kk*Y1(:,17),'LineWidth',1,'color','black'); 
    title('TGMP','Fontsize',10) 
%      xlim([0 8]) 
    set(gca,'FontSize',10,'LineWidth',1.5,'Box','off') 
    hold on 
 
      subplot(6,3,14) 
%        subplot(2,3,2) 
    plot(dd*T/24,kk*Y1(:,18),'LineWidth',1,'color','black'); 
    title('TGDP','Fontsize',10) 
%      xlim([0 8]) 
    set(gca,'FontSize',10,'LineWidth',1.5,'Box','off') 
    hold on 
 
      subplot(6,3,15) 
%        subplot(2,3,3) 
    plot(dd*T/24,kk*Y1(:,19),'LineWidth',1,'color','black'); 
    title('TGTP','Fontsize',10) 
%      xlim([0 8]) 
    set(gca,'FontSize',10,'LineWidth',1.5,'Box','off') 
    hold on 
 
      subplot(6,3,16) 
%        subplot(2,3,4) 
    plot(dd*T/24,kk*Y1(:,20),'LineWidth',1,'color','black'); 
    title('TdGDP','Fontsize',10) 
     xlabel('weeks','Fontsize',10) 
%      xlim([0 8]) 
    set(gca,'FontSize',10,'LineWidth',1.5,'Box','off') 
    hold on 
 
      subplot(6,3,17) 
%        subplot(2,3,5) 
    plot(dd*T/24,kk*Y1(:,21),'LineWidth',1,'color','black'); 
    title('TdGTP','Fontsize',10) 
     xlabel('weeks','Fontsize',10) 
%      xlim([0 8]) 
    set(gca,'FontSize',10,'LineWidth',1.5,'Box','off') 
    hold on 
 
    subplot(6,3,18) 
%        subplot(2,3,6) 
    plot(dd*T/24,kk*TGN,'LineWidth',1,'color','black'); 
    title('6-TGN','Fontsize',10) 
   xlabel('weeks','Fontsize',10) 
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%     xlim([0 8]) 
    set(gca,'FontSize',10,'LineWidth',1.5,'Box','off') 
    hold off 
    print('Fig_ic_AZA', '-dpng', '-r1000'); 
2.3. List of metabolites  
# Acronym Metabolite Name 
1 AZA Azathioprine 
2 6-MP mercaptopurine 
3 6-TX 6-Thioxanthine 
4 6-TUA 6-Thiouric acid 
5 6-MMP 6-Methylmercaptopurine 
6 6-MMPR 6-Methlymercaptopurine ribose 
7 6-MPR 6-Mercaptopurine ribose 
8 6-TIMP 6-Thioinosine monophosphate 
9 6-TIDP 6-Thioinosine diphosphate 
10 6-TITP 6-Thioinosine triphosphate 
11 6-MeTIMP 6-Methlythioinosine monophosphate 
12 6-MeTIDP 6-Methlythioinosine diphosphate 
13 6-MeTITP 6-Methlythioinosine triphosphate 
14 6-TXMP 6-Thixanthosine phosphate 
15 6-TGMP 6-Thioguannosine monophosphate 
16 6-TGDP 6-Thioguannosine diphosphate 
17 6-TGTP 6-Thiodeoxyguanosine triphosphate 
18 6-TdGMP 6- Thio deoxy guanosine monophosphate 
19 6-TdGDP 6- Thio deoxy guanosine diphosphate 
20 6-TdGTP 6- Thio deoxy guanosine triphosphate 
21 6-MeTGMP 6-Methylthioguannosine monophosphate 
22 6-MeTGDP 6-Methylthioguannosine diphosphate 
23 6-MeTGTP 6-Methylthioguannosine triphosphate 
24 6-TG 6-Thioguannosine 
25 6-TGR 6-Thioguannosine ribose 
26 6-MeTG 6-Methylthioguannosine 
27 6-MeTGR 6-Methylthioguannosine ribose 
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2.4. List of enzymes and transporters 
# Acronym Name of the enzyme/transporter  
1 GSTA1  glutathione-S-transferase A1  
2 GSTA2  glutathione-S-transferase A2  
3 GSTM1  glutathione-S-transferase M1  
4 XO Xanthine oxidase 
5 TPMT Thiopurine methyltransferase 
6 HGPRT Hypoxanthine phosphoriboslytransferase 
7 NK Nucleoside kinase 
8 PNP Purine nucleoside phosphorylase 
9 - Nucleotidase 
10 NDPK Nucleotide di phosphokinase 
11 NMPK Nucleotide mono phosphokinase 
12 IMPDH Inosine monophosphate dehydrogenase 
13 GMPS Guanylate synthetase 
14 XDH Xanthine dehydrogenase 
15 AOX1 Aldehyde oxidase 





solute carrier family 28 , member 2;  
solute carrier family 28 , member 3,  
Solute carrier family 29 , member 1,  
solute carrier family 29 , member 2 
18 ABCC4, 
ABCC4 
Multidrug resistance-associated protein 4,  
Multidrug resistance-associated protein 5 
19 GMP reductase Guanosine mono phosphate reductase 
20 NUDT15 nucleoside diphosphate linked moiety X-type motif 15 
21 RND Ribonucleotide reductase 
22 - Guanase 
 
  





𝑇𝑚𝑎𝑥𝐴𝑍𝐴    0 75 Time to achieve maximum plasma 
concentration of azathioprine (h) 
𝑘𝑎𝐴𝑍𝐴    3 ∗ 𝑙𝑜𝑔(2)/𝑇𝑚𝑎𝑥𝐴𝑍𝐴 Absorption rate constant for azathioprine 
(/h) 
𝐶𝐿𝐴𝑍𝐴    3 88 Clearance of azathioprine(L/h) 
𝑉𝑑𝐴𝑍𝐴    0 81 Volume of distribution of azathioprine (L) 
𝑘𝐴𝑍𝐴    𝑙𝑜𝑔(2)/(1/6); Azathioprine’s volume of distribution (/h) 
𝐹𝐴𝑍𝐴𝑎𝑏𝑠  0 54 Fraction of azathioprine absorbed 
𝐹𝐴𝑍𝐴 6𝑀𝑃  0 68 ∗ 𝐹𝐹 Fraction of azathioprine metabolised to 5-
MP 
𝐹𝐴𝑍𝐴  1 − 𝐹𝐴𝑍𝐴 6𝑀𝑃 Fraction of azathioprine excreted  
𝑘𝐴𝑍𝐴 6𝑀𝑃    0 50 Rate of conversion from azathioprine to 6-
MP 
𝐹6𝑀𝑃 6𝑇𝑋  20/37 Fraction of azathioprine metabolised to 6-
thioxanthine 
𝐹6𝑀𝑃  1 3/37 Fraction of 6-MP eliminated 
𝐶𝐿6𝑀𝑃    5 62 Clearance of 6-MP (L/h) 
𝑉𝑑6𝑀𝑃    3 46 Volume of distribution of 6-MP (L) 
𝐾6𝑀𝑃𝐼𝐶 6𝑀𝑃𝐸𝐶    0 0001 Rate of transportation of 6-MP from 
intracellular space to extracellular space 
𝑘6𝑀𝑃𝐸𝐶 6𝑀𝑃𝐼𝐶    0 75 Rate of transportation of 6-MP from 
extracellular space to intracellular space 
𝑘6𝑇𝑈𝐴    0 2 Elimination rate constant for 6-TUA 
𝐹6𝑇𝑈𝐴    8 7/14 06 Fraction of 6-TUA excreted  
𝑉6𝑇𝑈𝐴    0 02 ∗ 𝑉6𝑀𝑃 Volume of distribution of 6-TUA (L) 
𝑉6𝑇𝑋    10 ∗ 𝑉6𝑀𝑃 Volume of distribution of 6-TX (L) 
XO activity 
𝑉𝑚𝑎𝑥{6𝑀𝑃→6𝑇𝑋}  5  
Appendix 2: Appendices to Chapter 2  
203  
 
𝐾𝑀{6𝑀𝑃→6𝑇𝑋}  10  
𝑉𝑚𝑎𝑥{6𝑇𝑋→6𝑇𝑈𝐴}  1  





𝑉𝑚𝑎𝑥{6𝑀𝑃→6𝑀𝑀𝑃}  1  
𝐾𝑀{6𝑀𝑃→6𝑀𝑀𝑃}  25  
𝑉𝑚𝑎𝑥{6𝑇𝐼𝑀𝑃→6𝑀𝑇𝐼𝑀𝑃}  1  
𝐾𝑀{6𝑇𝐼𝑀𝑃→6𝑀𝑇𝐼𝑀𝑃}  25  
𝑉𝑚𝑎𝑥{6𝑇𝐺𝑀𝑃→6𝑀𝑇𝐺𝑀𝑃}  1  
𝐾𝑀{6𝑇𝐺𝑀𝑃→6𝑀𝑇𝐺𝑀𝑃}  2  
𝑉𝑚𝑎𝑥{6𝑇𝐺→6𝑀𝑇𝐺}  2  
𝐾𝑀{6𝑇𝐺→6𝑀𝑇𝐺}  50  
𝑉𝑚𝑎𝑥{6𝑀𝑃𝑅→6𝑀𝑀𝑃𝑅}  15  
𝐾𝑀{6𝑀𝑃𝑅→6𝑀𝑀𝑃𝑅}  10  
𝑉𝑚𝑎𝑥{6𝑇𝐼𝑇𝑃→6𝑀𝑇𝐼𝑇𝑃}  1  
𝐾𝑀{6𝑇𝐼𝑇𝑃→6𝑀𝑇𝐼𝑇𝑃}  50  
HGPRT activity 
𝑉𝑚𝑎𝑥{6𝑀𝑃→6𝑀𝑇𝐼𝑀𝑃}  2  
𝐾𝑀{6𝑀𝑃→6𝑀𝑇𝐼𝑀𝑃}  25  
𝑉𝑚𝑎𝑥{6𝑇𝐺→6𝑇𝐺𝑀𝑃}  1  
𝐾𝑀{6𝑇𝐺→6𝑇𝐺𝑀𝑃}  50  
IMPDH activity 
𝑉𝑚𝑎𝑥{6𝑇𝐼𝑀𝑃→6𝑇𝑋𝑀𝑃}  5  
𝐾𝑀{6𝑇𝐼𝑀𝑃→6𝑇𝑋𝑀𝑃}  10  
GMPS activity 
𝑉𝑚𝑎𝑥{6𝑇𝑋𝑀𝑃→6𝑇𝐺𝑀𝑃}  1  
𝐾𝑀{6𝑇𝑋𝑀𝑃→6𝑇𝐺𝑀𝑃}  200  




𝑉𝑚𝑎𝑥{6𝑇𝐼𝑀𝑃→6𝑀𝑃𝑅}  5  
𝐾𝑀{6𝑇𝐼𝑀𝑃→6𝑀𝑃𝑅}  25  
𝑉𝑚𝑎𝑥{6𝑀𝑇𝐼𝑀𝑃→6𝑀𝑀𝑃𝑅}  3  
𝐾𝑀{6𝑀𝑇𝐼𝑀𝑃→6𝑀𝑀𝑃𝑅}  100  
𝑉𝑚𝑎𝑥{6𝑇𝐺𝑀𝑃→6𝑇𝐺𝑅}  1  
𝐾𝑀{6𝑇𝐺𝑀𝑃→6𝑇𝐺𝑅}  2  
𝑉𝑚𝑎𝑥{6𝑀𝑇𝐺𝑀𝑃→6𝑀𝑇𝐺𝑅}  1  
𝐾𝑀{6𝑀𝑇𝐺𝑀𝑃→6𝑀𝑇𝐺𝑅}  100  
Nucleoside kinase activity 
𝑉𝑚𝑎𝑥{6𝑀𝑀𝑃𝑅→6𝑀𝑇𝐼𝑀𝑃}  8  
𝐾𝑀{6𝑀𝑀𝑃𝑅→6𝑀𝑇𝐼𝑀𝑃}  10  
𝑉𝑚𝑎𝑥{6𝑀𝑃𝑅→6𝑇𝐼𝑀𝑃}  1  
𝐾𝑀{6𝑀𝑃𝑅→6𝑇𝐼𝑀𝑃}  5  
𝑉𝑚𝑎𝑥{6𝑀𝑇𝐺𝑅→6𝑀𝑇𝐺𝑀𝑃}  2  
𝐾𝑀{6𝑀𝑇𝐺𝑅→6𝑀𝑇𝐺𝑀𝑃}  10  
𝑉𝑚𝑎𝑥{6𝑇𝐺𝑅→6𝑇𝐺𝑀𝑃}  1  
𝐾𝑀{6𝑇𝐺𝑅→6𝑇𝐺𝑀𝑃}  100  
NMPK activity 
𝑉𝑚𝑎𝑥{6𝑇𝐼𝑀𝑃→6𝑇𝐼𝐷𝑃}  1  
𝐾𝑀{6𝑇𝐼𝑀𝑃→6𝑇𝐼𝐷𝑃}  10  
𝑉𝑚𝑎𝑥{6𝑀𝑇𝐼𝑀𝑃→6𝑀𝑇𝐼𝐷𝑃}  1  
𝐾𝑀{6𝑀𝑇𝐼𝑀𝑃→6𝑀𝑇𝐼𝐷𝑃}  10  
𝑉𝑚𝑎𝑥{6𝑇𝐺𝑀𝑃→6𝑇𝐺𝐷𝑃}  5  
𝐾𝑀{6𝑇𝐺𝑀𝑃→6𝑇𝐺𝐷𝑃}  10  
𝑉𝑚𝑎𝑥{6𝑀𝑇𝐺𝑀𝑃→6𝑀𝑇𝐺𝐷𝑃}  1  
𝐾𝑀{6𝑀𝑇𝐺𝑀𝑃→6𝑀𝑇𝐺𝐷𝑃}  10  
NDPK activity 
𝑉𝑚𝑎𝑥{6𝑇𝐼𝐷𝑃→6𝑇𝐼𝑇𝑃}  1  
𝐾𝑀{6𝑇𝐼𝐷𝑃→6𝑇𝐼𝑇𝑃}  50  
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𝑉𝑚𝑎𝑥{6𝑀𝑇𝐼𝐷𝑃→6𝑀𝑇𝐼𝑇𝑃}  1  
𝐾𝑀{6𝑀𝑇𝐼𝐷𝑃→6𝑀𝑇𝐼𝑇𝑃}  10  
𝑉𝑚𝑎𝑥{6𝑇𝐺𝐷𝑃→6𝑇𝐺𝑇𝑃}  1  
𝐾𝑀{6𝑇𝐺𝐷𝑃→6𝑇𝐺𝑇𝑃}  10  
𝑉𝑚𝑎𝑥{6𝑀𝑇𝐺𝐷𝑃→6𝑀𝑇𝐺𝑇𝑃}  1  
𝐾𝑀{6𝑀𝑇𝐺𝐷𝑃→6𝑀𝑇𝐺𝑇𝑃}  10  
𝑉𝑚𝑎𝑥{6𝑇𝑑𝐺𝐷𝑃→6𝑇𝑑𝐺𝑇𝑃}  1  
𝐾𝑀{6𝑇𝑑𝐺𝐷𝑃→6𝑇𝑑𝐺𝑇𝑃}  10  
PNP activity 
𝑉𝑚𝑎𝑥{6𝑀𝑃𝑅→6𝑀𝑃}  1  
𝐾𝑀{6𝑀𝑃𝑅→6𝑀𝑃}  10  
𝑉𝑚𝑎𝑥{6𝑀𝑀𝑃𝑅→6𝑀𝑀𝑃}  5  
𝐾𝑀{6𝑀𝑀𝑃𝑅→6𝑀𝑀𝑃}  5  
𝑉𝑚𝑎𝑥{6𝑇𝐺𝑅→6𝑇𝐺}  1  
𝐾𝑀{6𝑇𝐺𝑅→6𝑇𝐺}  2  
𝑉𝑚𝑎𝑥{6𝑀𝑇𝐺𝑅→6𝑀𝑇𝐺}  1  
𝐾𝑀{6𝑀𝑇𝐺𝑅→6𝑀𝑇𝐺}  5  
NUDT activity 
𝑉𝑚𝑎𝑥{6𝑇𝐺𝑇𝑃→6𝑇𝐺𝑀𝑃}  2  
𝐾𝑀{6𝑇𝐺𝑇𝑃→6𝑇𝐺𝑀𝑃}  10  
𝑉𝑚𝑎𝑥{6𝑇𝑑𝐺𝑇𝑃→6𝑇𝑑𝐺𝑀𝑃}  2  
𝐾𝑀{6𝑇𝑑𝐺𝑇𝑃→6𝑇𝑑𝐺𝑀𝑃}  10  
ITPase activity 
𝑉𝑚𝑎𝑥{6𝑇𝐼𝑇𝑃→6𝑇𝐼𝑀𝑃}  5  
𝐾𝑀{6𝑇𝐼𝑇𝑃→6𝑇𝐼𝑀𝑃}  25  
AOX activity 
𝑉𝑚𝑎𝑥{6𝑀𝑃→6𝑇𝑋}  5  
𝐾𝑀{6𝑀𝑃→6𝑇𝑋}  10  
 
 




𝑉𝑚𝑎𝑥{6𝑇𝑋→6𝑇𝑈𝐴}  1  
𝐾𝑀{6𝑇𝑋→6𝑇𝑈𝐴}  20  
RND activity 
𝑉𝑚𝑎𝑥{6𝑇𝐺𝐷𝑃→6𝑇𝑑𝐺𝐷𝑃}  2  
𝐾𝑀{6𝑇𝐺𝐷𝑃→6𝑇𝑑𝐺𝐷𝑃}  10  
Guanase activity 
𝑉𝑚𝑎𝑥{6𝑇𝐺→6𝑇𝑋}  1  
𝐾𝑀{6𝑇𝐺→6𝑇𝑋}  2  
GMP reductase activity 
𝑉𝑚𝑎𝑥{6𝑇𝐺𝑀𝑃→6𝑇𝐼𝑀𝑃}  1  
𝐾𝑀{6𝑇𝐺𝑀𝑃→6𝑇𝐼𝑀𝑃}  10  
Efflux transportation 
𝑉𝑚𝑎𝑥{6𝑇𝐼𝑀𝑃}  0 693  
𝐾𝑀{6𝑇𝐼𝑀𝑃}  120  
𝑉𝑚𝑎𝑥{6𝑇𝑋𝑀𝑃}  0 693  
𝐾𝑀{6𝑇𝑋𝑀𝑃}  120  
𝑉𝑚𝑎𝑥{6𝑇𝐺𝑀𝑃}  0 693  
𝐾𝑀{6𝑇𝐺𝑀𝑃}  120  
Elimination rate constants 
𝑘𝑇𝑑𝐺𝑇𝑃  0 693/120  
𝑘𝑇𝐼𝑇𝑃  0 693/120  
𝑘𝑀𝑇𝐼𝑇𝑃  0 693/120  
𝑘𝑇𝐺𝑇𝑃  0 693/120  
𝑘𝑀𝑇𝐺𝑇𝑃  0 693/120  
𝑘𝑇𝑑𝐺𝑀𝑃  0 693/120  
𝑘𝑀𝑇𝐺  0 693/120  
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This appendix provides the additional data that obtained from Canterbury 
hospital and computation of the mean concentrations, global search results for 
this data set, and search results for different types of OBJ. 
3.1. Mean concentrations for three scenarios calculated from Canterbury 
data 
Data collected from 51 patients was used to compute the mean 
concentrations for the metabolites in three different clinical scenarios.  
 
Type of data used: 
- Patients using azathioprine at least for 5 weeks 
- All doses are normalised to 100 mg 
- Missing doses are handled using last observation carried forward 
(LOCF) or next observation carried backwards (NOCB) criteria 
- Repeated measures from a patient are considered as independent 
 
Criterion to separate the data into typical and atypical-1&2: 
1. Typical  
a. 200 < TGN <450 
b. MMP < 5500 
2. Atypical-1  
a. TGN > 450 
b. MMP < 5500 
3. Atypical-2  
a. TGN <450 
b. MMP > 5500 
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Patient 6-TGN 6-MMP 
1 328.00 444.00 
2 299.00 811.00 
3 303.00 714.00 
4 324.00 496.00 
5 245.00 90.00 
6 291.00 290.00 
7 420.00 440.00 
8 292.00 199.00 
9 345.00 219.00 
10 356.00 561.60 
11 261.60 1760.00 
12 360.00 1026.74 
13 334.83 95.79 
14 213.01 251.26 
15 397.60 437.55 
16 330.00 552.10 
17 320.86 426.86 
18 375.65 167.70 
19 218.95 1055.31 
20 253.11 639.71 
21 320.67 696.90 
22 241.24 225.03 
23 410.72 383.59 
24 279.33 1454.44 
25 398.85 515.52 
26 211.23 271.54 
27 229.70 393.90 
28 206.67 196.67 
29 224.10 2769.81 
30 206.25 682.36 
31 274.74 2072.01 
Mean 299.10 656.11 
SD 64.90 610.22 
SE 11.66 109.60 
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Patient 6-TGN 6-MMP 
1 521.15 580.02 
2 473.87 139.65 
3 529.23 86.35 
4 464.79 113.45 
5 492.63 344.93 
6 615.31 557.79 
7 711.87 864.89 
8 764.12 1686.98 
9 1314.93 1528.38 
10 853.59 735.60 
11 1027.94 972.61 
12 1028.00 1072.00 
13 1114.00 906.00 
14 456.30 588.68 
15 908.76 1347.15 
16 2401.72 5962.36 
Mean 854.89 1092.93 
SD 491.61 1385.46 
SE 122.90 346.37 
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Table A 3.3 Patient data for the metabolite concentrations of atypical2 
scenario 
Patient 6-TGN 6-MMP 
1 90.48 3773.33 
2 150.86 2952.56 
3 66.94 5698.92 
4 108.93 18300.91 
5 168.92 7216.27 
6 67.00 5699.00 
7 144.50 8913.00 
8 294.00 15914.00 
9 206.70 9453.67 
10 220.64 8117.58 
11 240.65 9172.02 
12 280.24 9669.03 
13 245.60 7808.81 
14 266.35 11559.09 
15 217.80 14293.85 
16 248.93 15958.22 
17 183.32 7250.54 
18 140.03 7282.12 
19 169.33 9904.00 
20 135.33 5724.67 
Mean 182.33 9233.08 
SD 69.39 4139.18 
SE 15.52 925.55 
3.1.1. Summary of the computations 
Table A 3.4 Mean metabolite concentrations for the 3 clinical scenarios 
(Canterbury data) 
 6-MMP (±SE) 6-TGN (±SE) 
Typical* 656 (±109.5) 299 (±11.6) 
Atypical1** 1092 (±346.3) 854 (±122.9) 
Atypical2** 9233 (±925.5) 182 (±15.5) 
*N=31; **N=16; ***N=20 
N = number of observations used to compute SE
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3.2. Global search results for Canterbury data 
The algorithm was ran for five times, and the results are shown in Table A 3.5. These results show that the model is incomplete 
as the concentrations for the atypical scenarios are deviated from the reference values. This is similar to the observation with the 
reference concentrations that obtained from the publications (shown in Table 3.2 of Chapter 3). 
 
 
Table A 3.5 Results of the five repeated runs for the global search algorithm 
Scenarios 
Run-1 Run-2 Run-3 Run-4 Run-5 Reference 
6-TGN 6-MMP 6-TGN 6-MMP 6-TGN 6-MMP 6-TGN 6-MMP 6-TGN 6-MMP 6-TGN 6-MMP 
Typical 2834 331 2809 325 2914 325 2973 322 2820 325 2973 325 
Artypical1 2750 308 2732 309 2818 313 0 490 2728 314 2683 490 
Atypical2 10333 185 5321 185 3505 185 5737 185 10380 185 10380 185 
OBJ 0.4688 0.9296 1.0935 1.4549 0.4268  
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3.3. Global search results with different OBJ 
The global search algorithm was evaluated using different types of 
objective function:  
 
(i) Sum of absolute relative difference with respect to reference values 
(S_ARD_RV),  
𝑂𝐵𝐽  ∑∑𝑎𝑏𝑠 (
𝑟 𝑓 𝑟 𝑛𝑐  𝑣𝑎𝑙𝑢 𝑖𝑗 − 𝑝𝑟 𝑑𝑖𝑐𝑡 𝑑 𝑣𝑎𝑙𝑢  𝑖𝑗








(ii) Sum of absolute relative difference with respect to predicted values 
(S_ARD_PV),  
𝑂𝐵𝐽  ∑∑𝑎𝑏𝑠 (
𝑟 𝑓 𝑟 𝑛𝑐  𝑣𝑎𝑙𝑢 𝑖𝑗 − 𝑝𝑟 𝑑𝑖𝑐𝑡 𝑑 𝑣𝑎𝑙𝑢  𝑖𝑗








(iii) Sum of squared relative difference with respect to reference values 
(SS_ARD_RV),  
𝑂𝐵𝐽  ∑∑(
𝑟 𝑓 𝑟 𝑛𝑐  𝑣𝑎𝑙𝑢 𝑖𝑗 − 𝑝𝑟 𝑑𝑖𝑐𝑡 𝑑 𝑣𝑎𝑙𝑢  𝑖𝑗










(iv)  Sum of squared differences (SS_D), 








The results (shown in Table A3.6) showed that the different objective 
functions provided different values, but the predictions were almost similar. 
However, the predictions were deviated from the reference values. This 
indicates that the structure has limitations with respect to reflecting the systems 
behaviour under different clinical scenarios.














S_ARD_RV S_ARD_PV SS_ARD_RV SS_D Reference 
6-TGN 6-MMP 6-TGN 6-MMP 6-TGN 6-MMP 6-TGN 6-MMP 6-TGN 6-MMP 
Typical 2834 331 2853 506 2869 376 2896 347 2973 325 
Artypical1 2750 308 2762 489 2780 363 2790 334 2683 490 
Atypical2 10333 185 10379 185 10385 185 10377 184 10380 185 












1. Gadkar, K., Kirouac, D.C., Mager, D.E., van der Graaf, P.H. & Ramanujan, 
S. A six-stage workflow for robust application of systems pharmacology. 
CPT: Pharmacometrics & Systems Pharmacology 5, 235-249 (2016). 
 
2. Fleisher, B., Brown, A.N. & Ait-Oudhia, S. Application of 
pharmacometrics and quantitative systems pharmacology to cancer 
therapy: The example of luminal a breast cancer. Pharmacol. Res. 124, 20-
33 (2017). 
 
3. Hasegawa, C. & Duffull, S.B. Automated scale reduction of nonlinear QSP 
models with an illustrative application to a bone biology system. CPT 
Pharmacometrics. Syst Pharmacol.,  (2018). 
 
4. Wajima, T., Isbister, G.K. & Duffull, S.B. A comprehensive model for the 
humoral coagulation network in humans. Clin. Pharmacol. Ther. 86, 290-
298 (2009). 
 
5. Helmlinger, G. et al. Drug-disease modeling in the pharmaceutical 
industry - where mechanistic systems pharmacology and statistical 
pharmacometrics meet. Eur. J. Pharm. Sci. 109, S39-S46 (2017). 
 
6. Agoram, B. Evaluating systems pharmacology models is different from 
evaluating standard pharmacokinetic–pharmacodynamic models. CPT 
Pharmacometrics. Syst Pharmacol. 3, e101 (2014). 
 
7. Kirouac, D.C. How do we validate a QSP model? CPT Pharmacometrics. 
Syst Pharmacol., 7, 547–548 (2018). 
 
8. Visser, S.A., de Alwis, D.P., Kerbusch, T., Stone, J.A. & Allerheiligen, S.R. 
Implementation of quantitative and systems pharmacology in large 
pharma. CPT Pharmacometrics. Syst Pharmacol. 3, e142 (2014). 
 
9. Iyengar, R., Zhao, S., Chung, S.-W., Mager, D.E. & Gallo, J.M. Merging 
systems biology with pharmacodynamics. Sci. Transl. Med. 4(126), 126ps7 
(2012). 
 
10. Kell, D.B. & Goodacre, R. Metabolomics and systems pharmacology: why 
and how to model the human metabolic network for drug discovery. Drug 
Discov Today. 19, 171-182 (2014). 
 
11. Ribba, B. et al. Methodologies for quantitative systems pharmacology 
(QSP) models: design and estimation. CPT Pharmacometrics. Syst 





12. Friedrich, C.M. A model qualification method for mechanistic 
physiological QSP models to support model-informed drug 
development. CPT Pharmacometrics. Syst Pharmacol. 5, 43-53 (2016). 
 
13. Rogers, M., Lyster, P. & Okita, R. NIH spupport for the emergence of 
quantitative and systems pharmacology. CPT Pharmacometrics. Syst 
Pharmacol. 2, e37 (2013). 
 
14. Trame, M.N. et al. Perspective on the state of pharmacometrics and 
systems pharmacology integration. CPT Pharmacometrics. Syst Pharmacol. 
7, 617-620 (2018). 
 
15. Duffull, S.B. A Philosophical Framework for integrating systems 
pharmacology models into pharmacometrics. CPT Pharmacometrics. Syst 
Pharmacol. 5, 649-655 (2016). 
 
16. Vicini, P. & van der Graaf, P.H. systems pharmacology for drug discovery 
and development: paradigm shift or flash in the pan? Clin. Pharmacol. 
Ther. 93, 379-381 (2013). 
 
17. van der Graaf, P.H. & Benson, N. Systems pharmacology: bridging 
systems biology and pharmacokinetics-pharmacodynamics (PKPD) in 
drug discovery and development. Pharm. Res. 28, 1460-1464 (2011). 
 
18. Lee, W.H. & Fujiwara, M. Pharmacometrics of guinea-pig's gallbladder in 
vitro*. Taiwan Yi Xue Hui Za Zhi 70, 687-696 (1971). 
 
19. Wicha, S.G. & Kloft, C. Quantitative systems pharmacology in model-
informed drug development and therapeutic use. Current Opinion in 
Systems Biology 10, 19-25 (2018). 
 
20. Graaf, P.H. CPT: Pharmacometrics and Systems Pharmacology. CPT 
Pharmacometrics. Syst Pharmacol. 1, 8 (2012). 
 
21. Mager, D.E. & Kimko, H.H.C. Systems pharmacology and 
pharmacodynamics: an introduction. Systems Pharmacology and 
Pharmacodynamics eds. Mager, D.E. & Kimko, H.H.C.) 3-14 (Springer 
International Publishing, Cham, 2016). 
 
22. Levy, G. The development of pharmacodynamics as a pharmaceutical 
science: a personal perspective. Ann. Pharmacother. 40, 520-523 (2006). 
 
23. Jusko, W.J. & Ko, H.C. Physiologic indirect response models characterize 






24. Shebley, M. et al. Physiologically based pharmacokinetic model 
qualification and reporting procedures for regulatory submissions: a 
consortium perspective. Clin. Pharmacol. Ther. 104, 88-110 (2018). 
 
25. Rowland, M., Peck, C. & Tucker, G. Physiologically-based 
pharmacokinetics in drug development and regulatory science. Annu. 
Rev. Pharmacol. Toxicol. 51, 45-73 (2011). 
 
26. Rostami-Hodjegan, A. Reverse translation in PBPK and QSP: going 
backwards in order to go forward with confidence. Clin. Pharmacol. Ther. 
103, 224-232 (2018). 
 
27. Peterson, M.C. & Riggs, M.M. A physiologically based mathematical 
model of integrated calcium homeostasis and bone remodeling. Bone 46, 
49-63 (2010). 
 
28. Nestorov, I.A., Aarons, L.J., Arundel, P.A. & Rowland, M. Lumping of 
whole-body physiologically based pharmacokinetic models. J. 
Pharmacokinet. Biopharm. 26, 21-46 (1998). 
 
29. Nestorov, I. Whole-body physiologically based pharmacokinetic models. 
Expert Opin. Drug Metab. Toxicol. 3, 235-249 (2007). 
 
30. Nestorov, I. Whole body pharmacokinetic models. Clin. Pharmacokinet. 42, 
883-908 (2003). 
 
31. Kuepfer, L. et al. Applied Concepts in PBPK modeling: how to build a 
PBPK/PD model. CPT Pharmacometrics. Syst Pharmacol. 5, 516-531 (2016). 
 
32. Jones, H. & Rowland-Yeo, K. Basic concepts in physiologically based 
pharmacokinetic modeling in drug discovery and development. CPT 
Pharmacometrics. Syst Pharmacol. 2, e63 (2013). 
 
33. Jamei, M. et al. Population-based mechanistic prediction of oral drug 
absorption. AAPS J. 11, 225-237 (2009). 
 
34. Jamei, M., Dickinson, G.L. & Rostami-Hodjegan, A. A framework for 
assessing inter-individual variability in pharmacokinetics using virtual 
human populations and integrating general knowledge of physical 
chemistry, biology, anatomy, physiology and genetics: a tale of 'bottom-
up' vs 'top-down' recognition of covariates. Drug Metab. Pharmacokinet. 24, 
53-75 (2009). 
 
35. Espie, P., Tytgat, D., Sargentini-Maier, M.L., Poggesi, I. & Watelet, J.B. 






36. Darwich, A.S. et al. Evaluation of an in silico PBPK post-bariatric surgery 
model through simulating oral drug bioavailability of atorvastatin and 
cyclosporine. CPT Pharmacometrics. Syst Pharmacol. 2, e47 (2013). 
 
37. Cao, Y. & Jusko, W.J. Applications of minimal physiologically-based 
pharmacokinetic models. J. Pharmacokinet. Pharmacodyn. 39, 711-723 
(2012). 
 
38. Aarons, L. Physiologically based pharmacokinetic modelling: a sound 
mechanistic basis is needed. Br. J. Clin. Pharmacol. 60, 581-583 (2005). 
 
39. Wynn, M.L., Consul, N., Merajver, S.D. & Schnell, S. Logic-based models 
in systems biology: a predictive and parameter-free network analysis 
method(). Integr Biol (Camb) 4(11),1323-37 (2012). 
 
40. Balbas-Martinez, V. et al. A systems pharmacology model for 
inflammatory bowel disease. PLoS One 13, e0192949 (2018). 
 
41. Ruiz-Cerdá, M.L. et al. Towards patient stratification and treatment in the 
autoimmune disease lupus erythematosus using a systems pharmacology 
approach. Eur. J. Pharm. Sci. 94, 46-58 (2016). 
 
42. Fumiã, H.F. & Martins, M.L. Boolean network model for cancer pathways: 
predicting carcinogenesis and targeted therapy outcomes. PLoS One 8, 
e69008 (2013). 
 
43. Chudasama, V.L., Ovacik, M.A., Abernethy, D.R. & Mager, D.E. Logic-
based and cellular pharmacodynamic modeling of bortezomib responses 
in U266 human myeloma cells. J. Pharmacol. Exp. Ther. 354, 448-458 (2015). 
 
44. Le Novere, N. Quantitative and logic modelling of molecular and gene 
networks. Nature reviews. Genetics 16, 146-158 (2015). 
 
45. Morris, M.K., Saez-Rodriguez, J., Clarke, D.C., Sorger, P.K. & 
Lauffenburger, D.A. Training signaling pathway maps to biochemical 
data with constrained fuzzy logic: quantitative analysis of liver cell 
responses to inflammatory stimuli. PLoS Comput. Biol. 7, e1001099 (2011). 
 
46. Morris, M.K., Clarke, D.C., Osimiri, L.C. & Lauffenburger, D.A. 
Systematic analysis of quantitative logic model ensembles predicts drug 
combination effects on cell signaling networks. CPT Pharmacometrics. Syst 





47. Aldridge, B.B., Saez-Rodriguez, J., Muhlich, J.L., Sorger, P.K. & 
Lauffenburger, D.A. Fuzzy logic analysis of kinase pathway crosstalk in 
TNF/EGF/insulin-induced signaling. PLoS Comput. Biol. 5, e1000340 
(2009). 
 
48. Zhu, X., Shen, X., Qu, J., Straubinger, R.M. & Jusko, W.J. Multi-scale 
network model supported by proteomics for analysis of combined 
gemcitabine and birinapant effects in pancreatic cancer cells. CPT 
Pharmacometrics. Syst Pharmacol.,  (2018). 
 
49. Peterson, M.C. & Riggs, M.M. Predicting nonlinear changes in bone 
mineral density over time using a multiscale systems pharmacology 
model. CPT Pharmacometrics. Syst Pharmacol. 1, e14 (2012). 
 
50. Karelina, T., Voronova, V., Demin, O., Colice, G. & Agoram, B.M. A 
mathematical modeling approach to understanding the effect of anti‐
interleukin therapy on eosinophils. CPT Pharmacometrics. Syst Pharmacol. 
5, 608-616 (2016). 
 
51. Zhang, X.Y., Trame, M.N., Lesko, L.J. & Schmidt, S. Sobol sensitivity 
analysis: a tool to guide the development and evaluation of systems 
pharmacology models. CPT Pharmacometrics. Syst Pharmacol. 4, 69-79 
(2015). 
 
52. Allen, R.J., Rieger, T.R. & Musante, C.J. Efficient generation and selection 
of virtual populations in quantitative systems pharmacology models. CPT 
Pharmacometrics. Syst Pharmacol. 5, 140-146 (2016). 
 
53. Gadkar, K., Kirouac, D., Parrott, N. & Ramanujan, S. Quantitative systems 
pharmacology: a promising approach for translational pharmacology. 
Drug Discov Today Technol. 21-22, 57-65 (2016). 
 
54. Cheng, Y. et al. QSP toolbox: computational implementation of integrated 
workflow components for deploying multi-scale mechanistic models. 
AAPS J. 19, 1002-1016 (2017). 
 
55. Hallow, K.M. et al. A model-based approach to investigating the 
pathophysiological mechanisms of hypertension and response to 
antihypertensive therapies: extending the Guyton model. Am J Physiol 
Regul Integr Comp Physiol306, R647-R662 (2014). 
 
56. Rieger, T.R. et al. Improving the generation and selection of virtual 
populations in quantitative systems pharmacology models. Prog. Biophys. 





57. Schmidt, B.J., Casey, F.P., Paterson, T. & Chan, J.R. Alternate virtual 
populations elucidate the type I interferon signature predictive of the 
response to rituximab in rheumatoid arthritis. BMC Bioinformatics 14, 221 
(2013). 
 
58. Gulati, A., Faed, J.M., Isbister, G.K. & Duffull, S.B. Development and 
evaluation of a prototype of a novel clotting time test to monitor 
enoxaparin. Pharm. Res. 29, 225-235 (2012). 
 
59. Benson, N. et al. Systems pharmacology of the nerve growth factor 
pathway: use of a systems biology model for the identification of key drug 
targets using sensitivity analysis and the integration of physiology and 
pharmacology. Interface focus 3, 20120071-20120071 (2013). 
 
60. Shivva, V., Tucker, I.G. & Duffull, S.B. An in silico knockout mModel for 
gastrointestinal absorption using a systems pharmacology approach - 
development and application for ketones. PLoS One 11, e0163795 (2016). 
 
61. Meeuwisse, C.M. et al. Identification of CXCL13 as a marker for 
rheumatoid arthritis outcome using an in silico model of the rheumatic 
joint. Arthritis Rheum. 63, 1265-1273 (2011). 
 
62. Gulati, A., Isbister, G.K. & Duffull, S.B. Scale reduction of a systems 
coagulation model with an application to modeling pharmacokinetic-
pharmacodynamic data. CPT Pharmacometrics. Syst Pharmacol. 3, e90 
(2014). 
 
63. Snowden, T.J., van der Graaf, P.H. & Tindall, M.J. Model reduction in 
mathematical pharmacology : integration, reduction and linking of PBPK 
and systems biology models. J. Pharmacokinet. Pharmacodyn. 45, 537-555 
(2018). 
 
64. Relling, M.V. et al. Clinical pharmacogenetics implementation consortium 
guidelines for thiopurine methyltransferase genotype and thiopurine 
dosing. Clin. Pharmacol. Ther. 89, 387-391 (2011). 
 
65. Dubinsky, M.C. et al. Pharmacogenomics and metabolite measurement 
for 6-mercaptopurine therapy in inflammatory bowel disease. 
Gastroenterology 118, 705-713 (2000). 
 
66. Dubinsky, M.C. et al. 6-MP metabolite profiles provide a biochemical 
explanation for 6-MP resistance in patients with inflammatory bowel 






67. Gardiner, S.J., Gearry, R.B., Begg, E.J., Zhang, M. & Barclay, M.L. 
Thiopurine dose in intermediate and normal metabolizers of thiopurine 
methyltransferase may differ three-fold. Clin. Gastroenterol. Hepatol. 6, 654-
660 (2008). 
 
68. Weinshilboum, R.M. & Sladek, S.L. Mercaptopurine pharmacogenetics: 
monogenic inheritance of erythrocyte thiopurine methyltransferase 
activity. Am. J. Hum. Genet. 32, 651-662 (1980). 
 
69. Meijer, B., Mulder, C.J. & de Boer, N.K. NUDT15: a novel player in 
thiopurine metabolism. J. Gastrointestin. Liver Dis. 25, 261-262 (2016). 
 
70. Moriyama, T. et al. The effects of inherited NUDT15 polymorphisms on 
thiopurine active metabolites in Japanese children with acute 
lymphoblastic leukemia. Pharmacogenet. Genomics 27, 236-239 (2017). 
 
71. Moriyama, T. et al. NUDT15 polymorphisms alter thiopurine metabolism 
and hematopoietic toxicity. Nat. Genet. 48, 367-373 (2016). 
 
72. Yang, J.J. et al. Inherited NUDT15 Variant Is a Genetic determinant of 
mercaptopurine intolerance in children with acute lymphoblastic 
leukemia. J. Clin. Oncol. 33, 1235-1242 (2015). 
 
73. Yin, D. et al. Impact of NUDT15 polymorphisms on thiopurines-induced 
myelotoxicity and thiopurines tolerance dose. Oncotarget 8, 13575-13585 
(2017). 
 
74. Zhu, X. et al. NUDT15 polymorphisms are better than thiopurine S-
methyltransferase as predictor of risk for thiopurine-induced leukopenia 
in chinese patients with crohn's disease. Aliment. Pharmacol. Ther. 44, 967-
975 (2016). 
 
75. Zelinkova, Z. et al. Inosine triphosphate pyrophosphatase and thiopurine 
S-Methyltransferase genotypes relationship to azathioprine-induced 
myelosuppression. Clin. Gastroenterol. Hepatol. 4, 44-49 (2006). 
 
76. Nygaard, U., Toft, N. & Schmiegelow, K. Methylated metabolites of 6-
mercaptopurine are associated with hepatotoxicity. Clin. Pharmacol. Ther. 
75, 274-281 (2004). 
 
77. Shaye, O.A. et al. Hepatotoxicity of 6-mercaptopurine (6-MP) and 






78. Gardiner, S.J., Gearry, R.B., Burt, M.J., Ding, S.L. & Barclay, M.L. Severe 
hepatotoxicity with high 6-methylmercaptopurine nucleotide 
concentrations after thiopurine dose escalation due to low 6-thioguanine 
nucleotides. Eur. J. Gastroenterol. Hepatol. 20, 1238-1242 (2008). 
 
79. Kreijne, J.E. et al. Routinely established skewed thiopurine metabolism 
leads to a strikingly high rate of early therapeutic failure in patients with 
inflammatory bowel disease. Ther. Drug Monit. 37, 797-804 (2015). 
 
80. van Egmond, R., Chin, P., Zhang, M., Sies, C.W. & Barclay, M.L. High 
TPMT enzyme activity does not explain drug resistance due to 
preferential 6-methylmercaptopurine production in patients on 
thiopurine treatment. Aliment. Pharmacol. Ther. 35, 1181-1189 (2012). 
 
81. Sparrow, M.P. et al. Allopurinol safely and effectively optimizes 
tioguanine metabolites in inflammatory bowel disease patients not 
responding to azathioprine and mercaptopurine. Aliment. Pharmacol. Ther. 
22, 441-446 (2005). 
 
82. Seinen, M.L. et al. Allopurinol enhances the activity of hypoxanthine-
guanine phosphoribosyltransferase in inflammatory bowel disease 
patients during low-dose thiopurine therapy: preliminary data of an 
ongoing series. Nucleosides, nucleotides & nucleic acids 30, 1085-1090 (2011). 
 
83. Blaker, P.A. et al. Mechanism of allopurinol induced TPMT inhibition. 
Biochem. Pharmacol. 86, 539-547 (2013). 
 
84. Deswal, S. & Srivastava, A. Role of allopurinol in optimizing thiopurine 
therapy in patients with sutoimmune hepatitis: a review. J. Clin. Exp. 
Hepatol. 7, 55-62 (2017). 
 
85. Lennard, L., Lilleyman, J.S., Van Loon, J. & Weinshilboum, R.M. Genetic 
variation in response to 6-mercaptopurine for childhood acute 
lymphoblastic leukaemia. Lancet 336, 225-229 (1990). 
 
86. M., B., R., E. & P., C. Letter: TPMT – not all that glitters is gold; authors’ 
reply. Aliment. Pharmacol. Ther. 36, 209-210 (2012). 
 
87. Y., G.-L. & P., G.J. Letter: TPMT – not all that glitters is gold. Aliment. 
Pharmacol. Ther. 36, 208-209 (2012). 
 
88. Gardiner, S.J. et al. Allopurinol might improve response to azathioprine 
and 6-mercaptopurine by correcting an unfavorable metabolite ratio. J. 





89. Hoentjen, F. et al. Safety and effectiveness of long-term allopurinol-
thiopurine maintenance treatment in inflammatory bowel disease. 
Inflamm. Bowel Dis. 19, 363-369 (2013). 
 
90. Roberts, R.L., Gearry, R.B., Barclay, M.L. & Kennedy, M.A. IMPDH1 
promoter mutations in a patient exhibiting azathioprine resistance. 
Pharmacogenomics J. 7, 312-317 (2007). 
 
91. Adam de Beaumais, T. et al. Determinants of mercaptopurine toxicity in 
paediatric acute lymphoblastic leukemia maintenance therapy. Br. J. Clin. 
Pharmacol. 71, 575-584 (2011). 
 
92. Elion, G.B. & Hitchings, G.H. Azathioprine. Antineoplastic and 
Immunosuppressive Agents: Part II eds. Sartorelli, A.C. & Johns, D.G.) 404-
425 (Springer Berlin Heidelberg, Berlin, Heidelberg, 1975). 
 
93. Lennard, L. The clinical pharmacology of 6-mercaptopurine. Eur. J. Clin. 
Pharmacol. 43, 329-339 (1992). 
 
94. Moher, D. et al. Preferred reporting items for systematic review and meta-
analysis protocols (PRISMA-P) 2015 statement. Systematic reviews 4, 1 
(2015). 
 
95. Krenitsky, T.A., Neil, S.M., Elion, G.B. & Hitchings, G.H. A comparison of 
the specificities of xanthine oxidase and aldehyde oxidase. Arch. Biochem. 
Biophys. 150, 585-599 (1972). 
 
96. Hamilton, L. & Elion, G.B. The fate of 6-mercaptopurine in man. Ann. N. 
Y. Acad. Sci. 60, 304-314 (1954). 
 
97. Krenitsky, T.A., Papaioannou, R. & Elion, G.B. Human hypoxanthine 
phosphoribosyltransferase. I. Purification, properties, and specificity. J. 
Biol. Chem. 244, 1263-1270 (1969). 
 
98. Elion, G.B. The pharmacology of azathioprine. Ann. N. Y. Acad. Sci. 685, 
401-407 (1993). 
 
99. Elion, G.B. The purine path to chemotherapy. Science 244, 41-47 (1989). 
 
100. Elion, G.B. Significance of azathioprine metabolites. Proc. R. Soc. Med. 65, 
257-260 (1972). 
 
101. Clarke, D.A., Elion, G.B., Hitchings, G.H. & Stock, C.C. Structure-activity 






102. PharmGKB, S.U. Thiopurine pathway, pharmacokinetics-
pharmacodynamics. 2000 [cited 2017]Available from: 
https://www.pharmgkb.org/pathway/PA2040 
 
103. Alberta, W.R.G.U.o. Small molecule pathway database. 2009 [cited 
2017]Available from: http://smpdb.ca/view/SMP0000430# 
 
104. Thorn, C., Siripuram, V.K., email communication, Topic:Conglomerates of 
target metabolites, 6-TGN and 6-MMP, 09 September 2016 
 
105. Schwab, M., Siripuram, V.K., email communication, Topic:Is 6-MMP a 
substrate to IMPDH, 18 July 2017 
 
106. Hedstrom, L., Siripuram, V.K., email communication, Topic:IMPDH 
substrates in thiopurine metabolism, 04 August 2017 
 
107. Parker, W.B., Siripuram, V.K., email communication, Topic:HGPRT 
activity on 6-MeMP, 18 July 2017 
 
108. Duley, J., Siripuram, V.K., email communication, Topic:Evaluation of the 
current knowledge (archived) on azathioprine metabolism 11 December 2017 
 
109. Hofmann, U. et al. Simultaneous quantification of eleven thiopurine 
nucleotides by liquid chromatography-tandem mass spectrometry. Anal. 
Chem. 84, 1294-1301 (2012). 
 
110. Neurath, M.F. et al. 6-Thioguanosine diphosphate and triphosphate levels 
in red blood cells and response to azathioprine therapy in crohn’s disease. 
Clin. Gastroenterol. Hepatol. 3, 1007-1014 (2005). 
 
111. Wang, H. & Wang, Y. LC-MS/MS coupled with stable isotope dilution 
method for the quantification of 6-thioguanine and S(6)-
methylthioguanine in genomic DNA of human cancer cells treated with 
6-thioguanine. Anal. Chem. 82, 5797-5803 (2010). 
 
112. Jacobsen, J.H., Schmiegelow, K. & Nersting, J. Liquid chromatography-
tandem mass spectrometry quantification of 6-thioguanine in DNA using 
endogenous guanine as internal standard. J. Chromatogr. B Analyt. Technol. 
Biomed. Life Sci. 881-882, 115-118 (2012). 
 
113. Vikingsson, S., Andersson, D., Almer, S., Peterson, C. & Hindorf, U. Novel 
assay to improve therapeutic drug monitoring of thiopurines in 
inflammatory bowel disease. J Crohns Colitis. 8, 1702-1709 (2014). 
 
114. Page, T., Bakay, B. & Nyhan, W.L. Human GMP synthetase. Int. J. Biochem. 





115. Chan, G.L.C., Canafax, D.M. & Johnson, C.A. The therapeutic use of 
azathioprine in renal transplantation. Pharmacotherapy 7, 165-177 (1987). 
 
116. Chan, G.L.C., Erdmann, G.R., Gruber, S.A., Matas, A.J. & Canafax, D.M. 
Azathioprine metabolism: pharmacokinetics of 6-mercaptopurine, 6-
thiouric acid and 6-thioguanine nucleotides in renal transplant patients. J 
Clin Pharmacol. 30, 358-363 (1990). 
 
117. Chan, G.L. et al. Pharmacokinetics of 6-thiouric acid and 6-
mercaptopurine in renal allograft recipients after oral administration of 
azathioprine. Eur. J. Clin. Pharmacol. 36, 265-271 (1989). 
 
118. Ding, T.L. & Benet, L.Z. Determination of 6-mercaptopurine and 
azathioprine in plasma by high-performance liquid chromatography. J. 
Chromatogr. 163, 281-288 (1979). 
 
119. Escousse, A., Guedon, F., Mounie, J., Rifle, G., Mousson, C. & D'Athis, P. 
6-Mercaptopurine pharmacokinetics after use of azathioprine in renal 
transplant recipients with intermediate or high thiopurine methyl 
transferase activity phenotype. J. Pharm. Pharmacol. 50, 1261-1266 (1998). 
 
120. Gilissen, L.P., Derijks, L.J., Bos, L.P., Bus, P.J., Hooymans, P.M. & Engels, 
L.G. Therapeutic drug monitoring in patients with inflammatory bowel 
disease and established azathioprine therapy. Clin. Drug Investig. 24, 479-
486 (2004). 
 
121. Odlind, B., Hartvig, P., Lindstrom, B., Lonnerholm, G., Tufveson, G. & 
Grefberg, N. Serum azathioprine and 6-mercaptopurine levels and 
immunosuppressive activity after azathioprine in uremic patients. Int. J. 
Immunopharmacol. 8, 1-11 (1986). 
 
122. Van Os, E.C. et al. Simultaneous determination of azathioprine and 6-
mercaptopurine by high-performance liquid chromatography. J. 
Chromatogr. B Biomed. Appl. 679, 147-154 (1996). 
 
123. Derijks, L.J.J. et al. Pharmacokinetics of 6-mercaptopurine in patients with 
inflammatory bowel disease: Implications for therapy. Ther. Drug Monit. 
26, 311-318 (2004). 
 
124. Sanborn, W.J. Rational dosing of azathioprine and 6-mercaptopurine. Gut 
48, 591-592 (2001). 
 
125. Bostrom, B. & Erdmann, G. Cellular pharmacology of 6-mercaptopurine 






126. Hedstrom, L. IMP dehydrogenase: structure, mechanism, and inhibition. 
Chem. Rev. 109, 2903-2928 (2009). 
 
127. Cuffari, C., Hunt, S. & Bayless, T.M. Enhanced bioavailability of 
azathioprine compared to 6-mercaptopurine therapy in inflammatory 
bowel disease: correlation with treatment efficacy. Aliment. Pharmacol. 
Ther. 14, 1009-1014 (2000). 
 
128. Dubinsky, M.C. Azathioprine, 6-mercaptopurine in inflammatory bowel 
disease: pharmacology, efficacy, and safety. Clin. Gastroenterol. Hepatol. 2, 
731-743 (2004). 
 
129. Goldenberg, B.A., Rawsthorne, P. & Bernstein, C.N. The utility of 6-
thioguanine metabolite levels in managing patients with inflammatory 
bowel disease. Am. J. Gastroenterol. 99, 1744-1748 (2004). 
 
130. Panetta, J.C., Evans, W.E. & Cheok, M.H. Mechanistic mathematical 
modelling of mercaptopurine effects on cell cycle of human acute 
lymphoblastic leukaemia cells. Br. J. Cancer 94, 93-100 (2006). 
 
131. Jayachandran, D., Rundell, A.E., Hannemann, R.E., Vik, T.A. & 
Ramkrishna, D. Optimal chemotherapy for leukemia: a model-based 
strategy for individualized treatment. PLoS One 9, e109623 (2014). 
 
132. Jayachandran, D. et al. Model-based individualized treatment of 
chemotherapeutics: bayesian population modeling and dose 
optimization. PLoS One 10,  (2015). 
 
133. Lavrova, A.I., Postnikov, E.B., Zyubin, A.Y. & Babak, S.V. Ordinary 
differential equations and boolean networks in application to modelling 
of 6-mercaptopurine metabolism. R. Soc. Open Sci. 4, 160872 (2017). 
 
134. Ogungbenro, K. & Aarons, L. Physiologically based pharmacokinetic 
modelling of methotrexate and 6-mercaptopurine in adults and children. 
Part 1: methotrexate. J. Pharmacokinet. Pharmacodyn. 41, 159-171 (2014). 
 
135. Ogungbenro, K. & Aarons, L. Physiologically based pharmacokinetic 
modelling of methotrexate and 6-mercaptopurine in adults and children. 
Part 2: 6-mercaptopurine and its interaction with methotrexate. J. 
Pharmacokinet. Pharmacodyn. 41, 173-185 (2014). 
 
136. Ogungbenro, K. & Aarons, L. Physiologically based pharmacokinetic 
model for 6-mercpatopurine: exploring the role of genetic polymorphism 





137. Duley, J. & Florin, T. Thiopurine therapies - Problems, complexities, and 
progress with monitoring thioguanine nucleotides. Ther. Drug Monit. 
2005. pp. 647-654. 
 
138. Roberts, R.L., Gearry, R.B., Kennedy, M.A. & Barclay, M.L. Beyond TPMT: 
genetic influences on thiopurine drug responses in inflammatory bowel 
disease. Per. Med. 5, 233-248 (2008). 
 
139. Kaplowitz, N. Interaction of azathioprine and glutathione in the liver of 
the rat. J. Pharmacol. Exp. Ther. 200, 479-486 (1977). 
 
140. Eklund, B.I., Moberg, M., Bergquist, J. & Mannervik, B. Divergent 
activities of human glutathione transferases in the bioactivation of 
azathioprine. Mol. Pharmacol. 70, 747-754 (2006). 
 
141. Liu, H. et al. The impact of glutathione S–transferase genotype and 
phenotype on the adverse drug reactions to azathioprine in patients with 
inflammatory bowel diseases. J. Pharmacol. Sci. 129, 95-100 (2015). 
 
142. Bloomingdale, P., Nguyen, V.A., Niu, J. & Mager, D.E. Boolean network 
modeling in systems pharmacology. J. Pharmacokinet. Pharmacodyn. 45, 
159-180 (2018). 
 
143. Traynard, P., Tobalina, L., Eduati, F., Calzone, L. & Saez-Rodriguez, J. 
Logic modeling in quantitative systems pharmacology. CPT 
Pharmacometrics. Syst Pharmacol. 6, 499-511 (2017). 
 
144. Saez-Rodriguez, J., Alexopoulos, L.G., Zhang, M., Morris, M.K., 
Lauffenburger, D.A. & Sorger, P.K. Comparing signaling networks 
between normal and transformed hepatocytes using discrete logical 
models. Cancer Res. 71, 5400-5411 (2011). 
 
145. Goffe, W.L., Ferrier, G.D. & Rogers, J. Global optimization of statistical 
functions with simulated annealing. J. Econom. 60, 65-99 (1994). 
 
146. Kirkpatrick, S., Gelatt, C.D., Jr. & Vecchi, M.P. Optimization by simulated 
annealing. Science 220, 671-680 (1983). 
 
147. Gareth Hegarty, S.B.D. Solving systems of ordianry differential equations 
that arise in PKPD. Part I - linear systems with time-constant parameters. 
Dunedin, New Zealand: School of Pharmacy, University of Otago; 2012. 
Report No.: Technical Report #003/12. 
 
148. Hasegawa, C. & Duffull, S.B. Selection and qualification of simplified QSP 






149. Janzen, D.L.I., Jirstrand, M., Chappell, M.J. & Evans, N.D. Extending 
existing structural identifiability analysis methods to mixed-effects 
models. Math. Biosci. 295, 1-10 (2018). 
 
150. Hasegawa, C. & Duffull, S.B. Exploring inductive linearization for 
pharmacokinetic-pharmacodynamic systems of nonlinear ordinary 
differential equations. J. Pharmacokinet. Pharmacodyn. 45, 35-47 (2018). 
 
151. Kirchherr, H., Shipkova, M. & von Ahsen, N. Improved method for 
therapeutic drug monitoring of 6-thioguanine nucleotides and 6-
methylmercaptopurine in whole-blood by LC/MSMS using isotope-
labeled internal standards. Ther. Drug Monit. 35, 313-321 (2013). 
 
152. De Nicolo, A. et al. UPLC-MS/MS method for quantification of the 
azathioprine metabolites 6-mercaptoguanosine and 6-
methylmercaptopurine riboside in peripheral blood mononuclear cells. J. 
Pharm. Biomed. Anal. 98, 271-278 (2014). 
 
153. Cobelli, C. A priori identifiability analysis in pharmacokinetic experiment 
design. Kinetic Data Analysis: Design and Analysis of Enzyme and 
Pharmacokinetic Experiments (ed. Endrenyi, L.) 181-208 (Springer US, 
Boston, MA, 1981). 
 
154. Bellman, R. & Åström, K.J. On structural identifiability. Math. Biosci. 7, 
329-339 (1970). 
 
155. Evans, N., Godfrey, K., Chapman, M., Chappell, M., Aarons, L. & Duffull, 
S.B. An identifiability analysis of a parent–metabolite pharmacokinetic 
model for ivabradine. J. Pharmacokinet. Pharmacodyn. 28, 93-105 (2001). 
 
156. Godfrey, K.R. & Chapman, M.J. Identifiability and indistinguishability of 
linear compartmental models. Math Comput. Simu. 32, 273-295 (1990). 
 
157. Godfrey, K.R. & Fitch, W.R. The deterministic identifiability of nonlinear 
pharmacokinetic models. J. Pharmacokinet. Biopharm. 12, 177-191 (1984). 
 
158. Jacquez, J.A. Identifiability: the first step in parameter estimation. Fed. 
Proc. 46, 2477-2480 (1987). 
 
159. Merino, J.A., De Biasi, J., Plusquellec, Y. & Houin, G. Local identifiability 
for two and three-compartment pharmacokinetic models with time-lags. 





160. Yates, J.W.T. Structural identifiability of physiologically based 
pharmacokinetic models. J. Pharmacokinet. Pharmacodyn. 33, 421-439 
(2006). 
 
161. Yates, J.W.T., Jones, R.D.O., Walker, M. & Cheung, S.Y.A. Structural 
identifiability and indistinguishability of compartmental models. Expert 
Opin. Drug Metab. Toxicol. 5, 295-302 (2009). 
 
162. Jacquez, J.A. Identifiability and parameter estimation. J Parenter Enteral 
Nutr. 15, 55S-59S (1991). 
 
163. Cheung, S.Y., Majid, O., Yates, J.W. & Aarons, L. Structural identifiability 
analysis and reparameterisation (parameter reduction) of a 
cardiovascular feedback model. Eur. J. Pharm. Sci. 46, 259-271 (2012). 
 
164. Cheung, S.Y., Yates, J.W. & Aarons, L. The design and analysis of parallel 
experiments to produce structurally identifiable models. J. Pharmacokinet. 
Pharmacodyn. 40, 93-100 (2013). 
 
165. Janzen, D.L., Jirstrand, M., Chappell, M.J. & Evans, N.D. Three novel 
approaches to structural identifiability analysis in mixed-effects models. 
Comput. Methods Programs Biomed. (2016). 
 
166. Shivva, V., Korell, J., Tucker, I.G. & Duffull, S.B. An approach for 
identifiability of population pharmacokinetic–pharmacodynamic 
models. CPT Pharmacometrics. Syst Pharmacol. 2, 1-9 (2013). 
 
167. Shivva, V., Korell, J., Tucker, I.G. & Duffull, S.B. Parameterisation affects 
identifiability of population models. J. Pharmacokinet. Pharmacodyn. 41, 81-
86 (2014). 
 
168. Lavielle, M. & Aarons, L. What do we mean by identifiability in mixed 
effects models? J. Pharmacokinet. Pharmacodyn. 43, 111-122 (2016). 
 
169. Cobelli, C., Lepschy, A. & Jacur, G.R. Identifiability results on some 
constrained compartmental systems. Math. Biosci. 47, 173-195 (1979). 
 
170. Chappell, M.J., Godfrey, K.R. & Vajda, S. Global identifiability of the 
parameters of nonlinear systems with specified inputs: a comparison of 
methods. Math. Biosci. 102, 41-73 (1990). 
 
171. Janzén, D., Jirstrand, M., Evans, N.D. & Chappell, M. Structural 
identifiability in mixed-effects models: two different approaches. IFAC-





172. Bellu, G., Saccomani, M.P., Audoly, S. & D'Angio, L. DAISY: a new 
software tool to test global identifiability of biological and physiological 
systems. Comput. Methods Programs Biomed. 88, 52-61 (2007). 
 
173. Jacquez, J.A. & Greif, P. Numerical parameter identifiability and 
estimability: integrating identifiability, estimability, and optimal 
sampling design. Math. Biosci. 77, 201-227 (1985). 
 
174. Karlsson, J., Anguelova, M. & Jirstrand, M. An efficient method for 
structural identifiability analysis of large dynamic systems. IFAC 
proceedings volumes 45, 941-946 (2012). 
 
175. Raue, A. et al. Structural and practical identifiability analysis of partially 
observed dynamical models by exploiting the profile likelihood. 
Bioinformatics 25, 1923-1929 (2009). 
 
176. Mentré, F., Mallet, A. & Baccar, D. Optimal design in random-effects 
regression models. Biometrika 84, 429-442 (1997). 
 
177. Duffull, S.B., Waterhouse, T. & Eccleston, J. Some considerations on the 
design of population pharmacokinetic studies. J. Pharmacokinet. 
Pharmacodyn. 32, 441-457 (2005). 
 
178. Sharma, A. & Jusko, W.J. Characteristics of indirect pharmacodynamic 
models and applications to clinical drug responses. Br. J. Clin. Pharmacol. 
45, 229-239 (1998). 
 
179. Dayneka, N.L., Garg, V. & Jusko, W.J. Comparison of four basic models 
of indirect pharmacodynamic responses. J. Pharmacokinet. Biopharm. 21, 
457-478 (1993). 
 
180. Sharma, A. & Jusko, W.J. Characterization of four basic models of indirect 
pharmacodynamic responses. J. Pharmacokinet. Biopharm. 24, 611-635 
(1996). 
 
181. Dost, F.H. Grundlagen der Pharmakokinetik. G. Thieme, Stuttgart: 2. Gufl 
2, 38 - 47 (1968). 
 
182. Nyberg, J. et al. Methods and software tools for design evaluation in 
population pharmacokinetics-pharmacodynamics studies. Br. J. Clin. 
Pharmacol. 79, 6-17 (2015). 
 
 
 
